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Chapter 1 
In 2000, 69.000 cases of cancer were diagnosed in the Netherlands. Over 85% of human 
cancers are solid tumors and a common type of solid tumors is melanoma with 2418 new 
cases in 2000, while sarcomas are relatively rare with an incidence of 448 in soft tissues 
and 65 in bones and joints. Over 50% of these patients will eventually die of the disease (1). 
Soft-tissue sarcomas (STS) can occur in any anatomic region of the body because of the 
ubiquitous nature of connective tissue, but about half of the sarcomas develop in the 
extremities and the lower limb is approximately two to three times more affected than the 
upper limb (2,3). 
To eradicate tumors with chemotherapy, lethal concentration of anticancer drugs must 
reach the tumor cells. Inadequate drug delivery would lead to regrowth of tumors and 
possible development of resistant cells. There are several reasons why treatment of solid 
tumors with anticancer drugs is not sufficient. The first reason is the metabolism and 
clearance of drugs in the body, resulting in low drug concentrations at the tumor site. 
Secondly, heterogeneous tumor perfusion and increased interstitial fluid pressure (IFP) may 
limit the penetration of drugs into the tumor and impair drug accumulation in tumor cells 
distant from blood vessels. Last reason is the toxicity of most anticancer drugs for both 
tumor and normal cells. Hence, the dose of administrated drugs is limited by normal tissue 
tolerance (4-8). Methods for improving drug delivery and penetration in tumor tissues are 
therefore of great clinical interest.  
This thesis describes two strategies for improving solid tumor therapy. The first strategy is 
based on the addition of vasoactive drugs, like Tumor Necrosis Factor-α (TNF), 
Interleukin-2 (IL-2) and histamine to melphalan-based isolated limb perfusion (ILP). The 
second approach is based on vascular targeting with TNF in combination with 
chemotherapeutic drugs, encapsulated in Stealth® liposomes in a systemic treatment setting. 
 
Tumor Necrosis Factor-α 
In 1893 Coley observed that patients with concurrent bacterial infections sometimes 
developed spontaneous regression of tumors (9). In 1944 bacterial lipopolysaccharide 
(LPS) was demonstrated as the active factor that induced haemorrhagic necrosis of 
transplantable tumors in mice (10). It was not until 1975 that the serum factor TNF was 
found to be responsible for the haemorrhagic necrosis (11).  
Cytokine TNF is member of the TNF ligand superfamily and its family consists of nearly 
20 different homologues including TNF-β, CD27, CD30, CD40, Fas ligand, OX40, RANK 
and TRAIL (12,13). Monocytes/macrophages are the main producers of TNF, but other 
cells such as T-lymphocytes, natural killer (NK) cells, smooth muscle cells, endothelial 
cells and some tumor cells also produce TNF (14,15). The circulation half-life of TNF is 
15-30 min (16-18) and clearance predominantly takes place in the kidney, followed by the 
liver (14). TNF binds as a trimer of 17 kDa subunits to two distinct cell-surface receptors, 
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TNF-R1 (55 kDa) and TNF-R2 (75 kDa), present in great numbers on most cells. TNF-R1 
signals for cell survival and the death domain of the receptor induces cell death. TNF-R2 
lacks a death domain and primarily mediates cell survival signals (19-23). The proteolytic 
cleavage of membrane-bound TNF-receptors results in soluble TNF-receptors. These 
soluble TNF-receptors compete with membrane receptors for binding of free TNF and may 
therefore have physiologic importance in the regulation of TNF-activity (24). The primary 
role of TNF is the regulation of immune cells, but TNF is also known to be involved in 
disorders such as rheumatoid arthritis, asthma, septic shock, inflammatory bowel disease, 
haemorrhagic fever and cachexia (13,14,25-27).  
TNF showed antitumor activity in some murine and human tumors in vitro (28) and 
induced haemorrhagic necrosis in certain transplanted animal tumors. The majority of the 
antitumor effects are indirectly mediated through damage of the tumor associated 
vasculature (11,29-31). Low doses of TNF (0.01-1 ng) induced angiogenesis, whereas high 
doses (1-5 µg) caused inhibition of angiogenesis and can even induce destruction of newly 
formed bloodvessels (32). TNF-induced endothelial damage leads to release of von 
Willebrand factor (VWF) (33), followed by platelet aggregation and erythrostasis, which 
results in an impaired blood flow. Impaired blood flow leads to edema, vascular congestion, 
extravasation of erythrocytes, infiltration of polymorphonuclear neutrophils and 
haemorrhagic necrosis (29,31,34-37). 
Impressive antitumor activity observed in animal models raised high expectations for the 
results of clinical trials. However, systemic TNF therapy proved ineffective with a lack of 
objective tumor response and severe side effects (hypotension and organ failure). The 
maximum tolerated dose was 10-50 times lower than the estimated effective dose (38-42).  
 
Interleukin-2 
Since its identification by Morgan et al. in 1976 (43), T cell growth factor or IL-2 has been 
studied extensively as a molecule of central importance in the long-term culture of T 
lymphocytes. IL-2 is a 15 kDa glycoprotein produced by antigen-activated T lymphocytes 
that plays a varied and critical role in immuno-regulation. It activates other cells in the 
immune system such as NK cells and B-lymphocytes. IL-2 binds to the IL-2 receptor and 
this receptor has been demonstrated on all classes of lymphocytes, i.e. T-, B-, and NK- cells 
and their precursors and on macrophages/monocytes (44). IL-2R is composed of three 
different receptor subunits; alpha chain (α), common beta chain (βc) and common gamma 
chain (γc). It is clear that the IL-2R is expressed not only on hematopoietic cells, but also on 
non-hematopoietic cells. Different reports have indicated the presence of IL-2 receptors on 
cells in head and neck squamous cell carcinoma (45) and different human melanomas (46).  
IL-2, as a single agent, has been shown to have antitumor activity in animal models (47,48). 
Clinical studies have been carried out mainly in patients with renal cell cancer and 
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melanomas and trials with high-doses of IL-2 have achieved response rates approaching 
20% without significant differences according to route, schedule and dosage (49-52). 
Due to the rapid clearance of IL-2, high and frequent doses must be administered to achieve 
significant antitumor activity, leading to serious side effects, including fever, nausea, 
diarrhea, cardiac toxicity, hypotension, hepatic dysfunction, capillary leakage and in some 
instances death. Capillary leak syndrome is characterized by retention of extravascular 
fluid, severe hypotension, and multiple organ system dysfunction (44,49-54). 
Many authors have investigated the effects of combined immunotherapy with IL-2 and 
other cytokines like Interferon (IFN) and TNF, traditional cytotoxic antineoplastic drugs or 
lymphokine-activated killer cells (LAK cells). Response rates and survival benefits of 
current treatment options remain disappointing and future studies of newer agents or 
treatment protocols are needed (44,53,55-59). 
 
Histamine 
Histamine, or β-aminoethylimidazole, is one of the most important mediators involved in 
various physiological and pathological conditions, including neurotransmission, secretion 
of pituitary hormones, regulation of gastrointestinal functions and inflammatory reactions 
and histamine has been shown to influence the immune response. Histamine is synthesized 
by decarboxylation of histidine by L-histidine decarboxylase (HDC). Mast cells and 
basophils are the major sources of granule-stored histamine. Histamine is released when 
these cells degranulate in response to various immunologic and non-immunologic stimuli. 
Several myeloid and lymphoid cell types (dendritic cells and T-cells), which do not store 
histamine, show high HDC activity and are capable of producing high amounts of 
histamine. Histamine exerts its effects by activating histamine receptors (HR) of which 4 
subtypes (H1-R, H2-R, H3-R and H4-R) are found. H1-R and H2-R are expressed on many 
cell types, including nerve cells, vascular smooth muscle cells, endothelial cells, 
neutrophils, monocytes and T- and B- cells. H3-R is expressed on histaminergic neurons in 
the brain and on some peripheral tissues. H4-R is found mainly on neutrophils, eosinophils 
and T-helper cells, but also on mast cells (reviewed in (60-62)). 
The interest in histamine as a potential anti-neoplastic agent originated in the late 1970s 
from mouse studies in which passive induction of local anaphylaxis reduced the size of 
established, chemically induced fibrosarcomas (63). Most investigators have administered 
histamine systemically by subcutaneous or intravenous injection and some antitumor 
effects have been observed in fibrosarcoma (64), Leydig cell sarcoma (65), chemically 
induced gut tumor (66), colorectal carcinoma (67) and melanoma (68). The mechanisms for 
the antitumoral effects of histamine are largely unknown, but both H1 (64) and H2 (67,68) 
receptors have been suggested to mediate the protective effects.  
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Experimental data indicate that histamine in combination with IL-2 act synergistically to 
activate NK- and T-cells and restore their antineoplastic cytotoxic capabilities (69,70). 
Clinical studies with IL-2 plus histamine showed favorable clinical results in melanoma 
patients with liver metastases (71,72).  
 
Isolated limb perfusion 
The technique of isolated limb perfusion (ILP) was first described in 1958 by Creech et al. 
(73). Isolation of the blood circuit of a limb is achieved by clamping and canulation of the 
artery and vein, connection to an oxygenated extracorporeal circuit, ligating of collateral 
vessels and application of a tourniquet around the base of the limb to compress the 
remaining minor vessels. Once isolation is secured, drugs can be added to the perfusion 
circuit. Temperature of the limb and systemic leakage are monitored throughout the 
procedure. After 1-1.5 hours of perfusion, the limb is rinsed with an electrolyte solution, 
cannulas are removed and the vessels are repaired (74-76).  
The advantage of ILP is the high dose of cytostatic drug that can be delivered to the tumor-
bearing extremity. Cytostatic drug concentrations of 15-20 times higher than with systemic 
administration can be reached without systemic toxicity (77). With ILP using the standard 
drug melphalan (L-phenyl-alaninemustard), a mean complete remission rate of about 54% 
can be obtained in patients with advanced extremity melanoma (reviewed in (78)). Soft 
tissue sarcomas are large and bulky in contrast to relatively small melanomas and results 
have been quite poor (79,80). 
The successful application of TNF for the treatment of soft tissue sarcomas is seriously 
hampered by its severe toxicity. Lienard et al. were the first who pioneered the use of high-
dose TNF in combination with melphalan in the isolated limb perfusion setting and they 
reported impressive results (81). TNF-based ILP with melphalan has been reported in a 
European multicenter trial with response rates greater than 80% and limb salvage rates 
above 70% in advanced soft tissue sarcoma (76,82) and advanced extremity melanoma 
(81,83,84). These studies led to the approval of TNF by the European Medicine Evaluation 
Agency (EMEA) (85). Currently, TNF-based ILP has become the standard treatment for 
patients with multiple in transit melanoma metastases or non-resectable extremity 
sarcomas. 
In the clinical setting, the tumor vascular bed appears to be the selective target of TNF. The 
effects seen after TNF-based ILP are described as early endothelium activation, 
upregulation of adhesion molecules and invasion of polymorphonuclear cells, leading to 
coagulative necrosis with haemorrhagic necrosis (86-88). Angiographic studies revealed 
that 1 or 2 weeks after TNF-based ILP all tumor associated vessels had disappeared, 
indicating that TNF only targets tumor vasculature and not normal vessels (82,89,90).  
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Liposomal therapy 
Liposomes were discovered in 1965 (91) and ten years later their potential as vehicles for 
the delivery of cytotoxic drugs to tumors was explored (92-94). Early studies however, 
demonstrated rapid recognition and removal of liposomes from the circulation by the 
reticulo-endothelial system (RES). The primary organs associated with the RES are the 
liver, spleen and lung. A major breakthrough in prolonging circulation time was the coating 
of liposomes with polyethylene glycol (PEG), a synthetic hydrophilic polymer. The PEG 
headgroup serves as a barrier preventing interactions with plasma opsonins as a result of the 
concentration of highly hydrated groups that sterically inhibit hydrophobic and electrostatic 
interactions of a variety of blood components with the liposome surface. These PEG-coated 
liposomes are referred to as sterically stabilized or Stealth® liposomes (95-97). The use of 
Stealth® liposomes as drug carriers for chemotherapeutic agents offers a potential means of 
manipulating drug distribution to improve antitumor efficacy and reduce toxicity (96,98-
100). Because of their small size, long circulation time, and reduced interaction with 
formed elements of the blood, these liposomes tend to accumulate in tumors, presumably 
due to leakage through the often-compromised tumor vasculature. Furthermore, they can 
target the tumor with high selectivity by taking advantage of the enhanced permeability and 
retention effect (EPR) (5,96-99,101-105).  
A well known liposomal formulation is Doxil® (Stealth® liposomal doxorubicin). Doxil® is 
effective in the treatment of several tumor types, including advanced or metastatic soft 
tissue sarcoma (106), AIDS-related Kaposi's sarcoma (107), metastatic breast cancer (108) 
and epithelial ovarian cancer (109).  
We showed in previous studies that co-administration of Doxil® and low-dose TNF resulted 
in a pronounced tumor response in both rat and murine tumor models. The augmented 
accumulation of the chemotherapeutic drug found in tumor tissue presumably explains the 
enhanced tumor regression (110,111). A possible explanation for the augmented 
accumulation is that TNF likely increases the leakiness of the vasculature by increasing the 
gaps between the endothelial lining in the tumor (34,112).  
Stealth® liposomes offer an attractive tool for delivery of anticancer drugs to tumors. 
Combining the tumor localizing properties with appropriate vascular targeting may enable a 
further step of improvement. 
 
Aim of the thesis 
The aim of this thesis is to improve local and systemic chemotherapy by changing the 
pathophysiology of solid tumors. Several studies were performed to identify ways to further 
improve efficacy of existing local and systemic therapies, to elucidate mechanisms of TNF 
and test new therapies. 
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ILP with TNF and melphalan is associated with synergistic antitumor effects against 
melanoma, large soft tissue sarcoma and various other tumors in the clinical setting. We 
showed that the basis for the synergy is the enhancement of tumor-selective melphalan 
uptake and the complete destruction of the tumor vasculature. The enhanced tumor uptake 
of different cytotoxic agents prompted us to investigate a number of vasoactive drugs for 
similar effects. In chapter 2 the effects of IL-2 in a melphalan-based ILP in soft-tissue 
sarcoma bearing rats were investigated and in chapter 3 the combination therapy of 
histamine and melphalan is described. Based on the potential synergistic effects of IL-2 and 
histamine in the systemic setting we evaluated whether this combination could improve 
response rates in melphalan-based ILP (chapter 4).  
In chapter 5 we focused on early effects inflicted by TNF during and shortly after ILP, 
which could explain the improved tumor response when used in a melphalan-based ILP. 
The advantage of Doxil® liposomes over free doxorubicin is the prolonged circulation time, 
decreased toxicity and augmented tumor localization. In chapter 6 we examined the 
efficacy of Doxil® in a TNF-based ILP in sarcoma-bearing rats. 
In previous studies we showed that the addition of low-dose TNF to Doxil® treatment 
resulted in a pronounced tumor response in soft tissue sarcoma-bearing rats with most of 
the rats showing tumor regression and comparable results were seen in B16BL6 melanoma-
bearing mice. In chapter 7 we evaluated the antitumor activity and side effects of low dose 
TNF and liposomal cisplatin (SPI-077) in soft tissue- and osteosarcoma-bearing rats.  
In chapter 8 experiments are described whether the use of low-dose TNF in combination 
with Doxil® not only results in synergistic antitumor response in the highly vascularized 
soft-tissue sarcoma but also in the less vascularized osteosarcoma.  
In chapter 9 the B16BL6 mouse tumor model was used to investigate the biodistribution of 
Stealth® liposomes of different sizes in combination with low-dose TNF. Intravital 
observations are performed to evaluate tumor distribution of free and liposomal drugs in 
B16BL6 melanoma implanted in the mouse dorsal skin-fold chamber. In chapter 10 is 
investigated whether or not addition of low-dose TNF to Doxil® treatment would have a 
similar effect in two very different tumor systems in terms of tumor vasculature: the Lewis 
Lung Carcinoma and the B16BL6 melanoma model. 
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Abstract 
The cytokine interleukin-2 (IL-2) is a mediator of immune cell activation with some 
antitumor activity, mainly in renal cell cancer and melanoma. We have previously 
demonstrated that Tumor Necrosis Factor-alpha (TNF) has strong synergistic antitumor 
activity in combination with chemotherapeutics in the isolated limb perfusion (ILP) setting 
based on a TNF-mediated enhanced tumor-selective uptake of the chemotherapeutic drug 
followed by a selective destruction of the tumor vasculature. IL-2 can cause vascular 
leakage and edema and for this reason we examined the antitumor activity of a combined 
treatment with IL-2 and melphalan in our well-established ILP in soft tissue sarcoma-
bearing rats (BN175). ILP with either IL-2 or melphalan alone has no antitumor effect, but 
the combination of IL-2 and melphalan resulted in a strong synergistic tumor response, 
without any local or systemic toxicity. IL-2 significantly enhanced melphalan uptake in 
tumor tissue. No signs of significant vascular damage were detected to account for this 
observation, although the tumor sections of the IL-2 and IL-2 plus melphalan treated 
animals revealed scattered extravasation of erythrocytes compared to the untreated animals. 
Clear differences were seen in the localization of ED-1 cells, with an even distribution in 
the sham, IL-2 and melphalan treatments, while in the IL-2 plus melphalan treated tumors 
clustered ED-1 cells were found. Additionally, increased levels of TNF mRNA were found 
in tumors treated with IL-2 and IL-2 plus melphalan. These observations indicate a 
potentially important role for macrophages in the IL-2-based perfusion. The results in our 
study indicate that the novel combination of IL-2 and melphalan in ILP has synergistic 
antitumor activity and may be an alternative for ILP with TNF and melphalan. 
 
Introduction 
We have demonstrated that isolated limb perfusion with TNFα and melphalan is associated 
with excellent antitumor effects against melanoma (1), large soft tissue sarcomas (2,3) and 
various other tumors in the clinical setting (4-6). We have previously shown that the basis 
for the synergy is, on one hand a significant enhancement of tumor selective melphalan 
uptake and on the other hand the subsequent complete destruction of tumor vasculature 
(2,7). The enhanced uptake of different cytotoxic agents shown in various limb and liver 
tumor models in our laboratory prompted us to investigate a number of vasoactive 
substances for similar potential effects (7-12).  
One of these agents is the cytokine IL-2 that is known to cause significant changes in 
vascular permeability and to cause a vascular leakage syndrome when administered at high 
concentrations (13-15). IL-2 is a pleiotropic cytokine that is mainly known as a molecule of 
central importance in the long-term culture of T lymphocytes and as a mediator of immune 
cells (16). IL-2, as a single agent, has been shown to have antitumor activity in both animal 
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models (17,18) and some antitumor activity in mainly renal cell cancer or melanoma 
patients (19-21). 
Here we report on the evaluation of the effects of high concentrations of IL-2 in 
combination with melphalan in the ILP setting. 
 
Materials and methods 
Chemicals 
Human recombinant interleukin 2 (IL-2) was kindly provided by Chiron (Amsterdam, the 
Netherlands). The content of one vial of lyophilized IL-2 (1 mg per vial, specific activity 
18x106 IU/mg) was diluted in 1 ml sterile water for injections according to the 
manufacturer's instructions. Melphalan (Alkeran, 50 mg per vial, Wellcom, Beckenham, 
UK) was dissolved in 10 ml diluent solvent. Further dilutions were made in phosphate 
buffered saline to a concentration of 2 mg/ml. Fluorescein and fluorescein isothiocyanate 
conjugated to bovine serum albumin (FITC-BSA) were purchased from Sigma 
(Zwijndrecht, the Netherlands) and dissolved in phosphate buffered saline to a 
concentration of 10 mg/ml. 
 
Animals and tumor model 
Male inbred Brown Norway rats were used for the soft tissue sarcoma model (BN175). Rats 
were obtained from Harlan-CPB, (Austerlitz, the Netherlands), weighing 250-300 grams, 
and were fed a standard laboratory diet ad libitum (Hope Farms Woerden, the Netherlands). 
Small fragments (3 mm) of the syngeneic BN175 sarcoma were implanted subcutaneously 
in the right hind leg just above the ankle as previously described (8,10). Tumor growth was 
recorded by caliper measurement and tumor volume calculated using the formula 
0.4(A2xB) (where B represents the largest diameter and A the diameter perpendicular to B). 
Rats were sacrificed if tumor diameter exceeded 25 mm or at the end of the experiment. All 
animal studies were done in accordance with protocols approved by the committee on 
Animal Research of the Erasmus MC, Rotterdam, the Netherlands. 
 
Isolated limb perfusion 
The perfusion technique was performed as described previously (8,10). Perfusions were 
performed at a tumor diameter of 12-15 mm at least 7 days after implantation. During 
perfusion animals were anaesthetized with Hypnorm and Ketamine (Janssen 
Pharmaceutica, Tilburg, the Netherlands). The femoral vessels were approached through an 
incision parallel to the inguinal ligament after systemic heparin administration of 50 IU 
(Leo Pharmaceutical Products, Weesp, the Netherlands) to prevent coagulation in the 
collateral circulation and in the perfusion circuit. The femoral artery and vein were 
cannulated with silastic tubing (0.30 mm inner diameter, 0.64 mm outer diameter; 0.64 mm 
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inner diameter, 1.19 mm outer diameter, respectively; Dow Corning, Ann Arbor, MI). 
Collaterals were temporarily occluded by applying a tourniquet around the groin. An 
oxygenation reservoir filled with 5 ml Haemaccel (Behring Pharma, Amsterdam, the 
Netherlands) and a low-flow roller pump (Watson Marlow type 505 U, Falmouth, UK) 
were included into the circuit. Drugs, 50 µg IL-2 and/or 40 µg melphalan, were added to 
the Haemaccel reservoir. The roller pump circulated the perfusate at a flow rate of 2.4 
ml/min for 30 minutes. A washout with 5 ml oxygenated Haemaccel was performed at the 
end of the perfusion. During ILP and washout, the hind leg was kept at a constant 
temperature of 38-39°C by a warm-water mattress applied around the leg. The pH of the 
perfusate was monitored during ILP with a pH probe in the perfusion reservoir (pH meter 
HI 8424, Hanna Instruments, Inc, Ann Arbor, USA). 
 
Assessment of tumor response 
Tumor size was recorded by daily caliper measurements. The classification of tumor 
response was: progressive disease (PD) = increase of tumor volume (>25%); no change 
(NC) = tumor volume equal to volume during perfusion (in a range of -25% and + 25%); 
partial remission (PR) = decrease of tumor volume (-25% and -90%); complete remission 
(CR) = tumor volume less than 10% of initial volume (10). To test synergy of IL-2 and 
melphalan, the tumor response ratio is calculated by dividing the tumor volume at day 0 
with the volume at day 8. The ratio of IL-2 alone plus melphalan alone was compared with 
the ratio of IL-2 plus melphalan (Mann Whitney U test). 
 
In vitro response of endothelial and tumor cells to IL-2 
Cells isolated from the BN175 soft tissue sarcoma were maintained in cell culture in RPMI 
1640 supplemented with 10% fetal calf serum and 0.1% penicilline-streptomycine. Media 
and supplements were obtained from Life Technologies (Breda, the Netherlands). 
Human Umbilical Vein Endothelial Cells (HUVEC) were isolated from normal human 
umbilical cords by the method of Jaffe et. al. (22). Cells were cultured in fibronectin coated 
tissue culture flasks in culture medium (Human Endothelial-SFM (GIBCO-BRL, Life 
Technologies, Breda, the Netherlands), with 20% Newborn Calf Serum, 10% Human 
Serum (Cambrex, Verviers, Belgium), 20 ng/ml bFGF and 100 ng/ml EGF (Peprotech, 
London, UK). Passages 5-7 were used for the experiments. 
BN175 cells were added in 100 µl aliquots to 96-well flat-bottomed microtiter plates 
(Costar, Cambridge, MA, USA) at a final concentration of 1x104 cells per well and allowed 
to grow as a monolayer. HUVECs were plated in fibronectine coated 96-well plates at a 
final concentration of 6x103 cells per well. Cells were incubated at 37ºC in 5% CO2 for 72 
hours in the presence of various concentrations of IL-2 and melphalan with or without 
leukocytes in a total volume of 150 µl. 
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Growth of tumor cells was measured using the Sulphorhodamine-B (SRB) assay according 
to the method of Skehan (23). In short, cells were washed twice with phosphate buffered 
saline, incubated with 10% trichloric acetic acid (1 hour, 4ºC) and washed again. Cells were 
stained with 0.4% SRB (Sigma, Zwijndrecht, the Netherlands) for 15-30 min, washed with 
1% acetic acid and were allowed to dry. Protein bound SRB was dissolved in TRIS (10 
mM, pH 9.4). The optical density was read at 540 nm. Tumor growth was calculated using 
the formula: tumor growth = (test well/control) x 100 percent. The drug concentration 
reducing the absorbance to 50% of the control (IC50) was determined from the growth 
curves. The experiments were repeated at least 5 times. 
 
Preparation of leukocytes 
Venous blood from healthy adult volunteers was collected in Na-heparin tubes (Becton 
Dickinson, Alphen aan den Rijn, the Netherlands). After centrifuging for 20 min (1500 g, 
room temperature), total white blood cell fraction was collected and remaining red blood 
cells were lysed with lysis buffer (0.83% NH4Cl, 10 mM Hepes, pH = 7.0) for 30 min at 
room temperature. After centrifuging for 30 min (1500 rpm, room temperature), the 
leukocytes were dissolved in HUVEC medium at a concentration of 120.104 cells/ml.  
 
Measurement of melphalan in tissue 
At the end of the perfusion directly after the washout, the tumor and part of the hind limb 
muscle were excised. The tissues were immediately frozen in liquid nitrogen to stop 
metabolism of melphalan and stored at -80°C. Tumor and muscle tissues were 
homogenized in 2 ml acetonitrile (Pro 200 homogenizer, Pro Scientific, CT, USA) and 
centrifuged at 2500 g. Melphalan was measured in the supernatant by gas chromotography-
mass spectrometry (GC-MS). p-[Bis(2-chloroethyl)amino]-phenylacetic methyl ester was 
used as an internal standard. Samples were extracted over trifunctional C18 silica columns. 
After elution with methanol and evaporation, the compounds were derived with 
trifluoroacetic anhydride and diazomethane in ether. The stable derivates were separated on 
a methyl phenyl siloxane GC capillary column and measured selectively by single-ion 
monitoring GC-MS in the positive EI mode described earlier by Tjaden and de Bruijn (24). 
 
Vascular permeability 
During ILP 400 µl FITC BSA was added to the perfusate. After perfusion the tumor was 
excised and frozen in liquid nitrogen. Acetone-fixed frozen sections were fixed for 30 min 
with 4% formaldehyde. After washing with PBS, the slides were incubated for 1 hour with 
mouse-anti-rat-CD31PE (Becton Dickinson, Alphen aan den Rijn, the Netherlands) diluted 
1:50 in PBS with 5% rat serum. Thereafter, the sections were rinsed with PBS and 
counterstained with 300 µg/ml Hoechst (Molecular Probes, Leiden, the Netherlands) and 
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mounted with mounting medium containing polyvinyl alcohol (Mowiol 4-88, Fluka, 
Zwijndrecht, the Netherlands). The sections were examined on a Leica DM-RXA and 
photographed using a Sony 3CCD DXC 950 camera. 
 
HUVEC permeability assays 
To study the effect of IL-2 on transendothelial monolayer permeability a transwell device 
(Costar, Cambridge, MA, USA) consisting of an upper chamber with a polycarbonate 
membrane (6.5 mm diameter, 0.4 µm pore size), placed inside a 24-well plate (lower 
chamber) was used. Confluent HUVECs were trypsinized and 1.2x104 cells were seeded on 
the fibronectin coated upper chamber. In the lower compartment 1 ml of HUVEC medium 
was added. Two days after seeding, non-adhering cells were removed and the medium was 
replaced with 250 µl of 10 µg/ml IL-2 together with 50 µl FITC-BSA or fluorescein (1 
mg/ml). The medium in the lower chamber was replaced with 700 µl of HUVEC medium. 
At 0.25, 0.5, 1, 2, 4, 8 and 24 hours, 50 µl medium of the lower chamber was taken and 
fluorescence activity was measured under excitation at 490 nm and emission at 530 nm. A 
standard curve was prepared with known concentrations of FITC-BSA or fluorescein. 
Induction of permeability was indicated by a higher concentration of FITC-BSA or 
fluorescein in the lower chamber of the transwell, relative to untreated controls. 
 
HE staining 
Directly after ILP tumors were excised, stored in formalin and embedded in paraffin. The 4 
µm sections were stained with hematoxylin and eosin using standard procedures. Three or 
four different tumors in each experimental group were subjected to blind evaluation. At 
least 6 slides were examined from each tumor. The sections were examined on a Leica DM-
RXA and photographed using a Sony 3CCD DXC 950 camera. 
 
Apoptosis Assays: TUNEL/CD31PE double staining 
Apoptotic cell death was detected using the technique of 3'hydroxy end labeling. A 
commercially available end-labeling kit (In Situ Cell Death detection Kit, Fluorescein 
labeled, Roche, Almere, the Netherlands) was used. Tumor tissues were also stained for 
endothelial cells to differentiate between apoptosis of the endothelium and apoptosis of 
tumor cells. Aceton-fixed frozen sections were fixed in 4% paraformaldehyde for 30 
minutes and incubated for 1 hour with mouse-anti-rat CD31PE (Becton Dickinson) diluted 
1:50 in PBS with 5% rat serum. After washing with PBS the sections were again fixed in 
4% paraformaldehyde for 10 minutes and incubated in 0.1% Triton X-100 in 0.1% sodium 
citrate for 2 minutes on ice to allow permeabilization. The slides were incubated with the 
TUNEL mixture for 60 min at 37°C. After incubation, the slides were rinsed three times in 
PBS and counterstained with 300 µg/ml Hoechst (Molecular Probes) for 10 min. After 
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washing with PBS the slides were mounted with mounting medium containing polyvinyl 
alcohol (Mowiol 4-88, Fluka). The slides were examined on a Leica DM-RXA and 
photographed using a Sony 3CCD DXC 950 camera. 
 
Immunohistochemistry 
After ILP the tumor was excised and immediately frozen in liquid nitrogen. 
Immunohistochemical studies were performed on acetone-fixed 7 µm cryostat sections. The 
tumor sections were fixed for 30 min with 4% paraformaldehyde and after rinsing with PBS 
the endogenous peroxidase activity was blocked by incubation for 5 minutes in 
methanol/3% H2O2. The slides were incubated for 1 hour with 1:50 mouse-anti-rat-CD31, 
CD4, CD8, antibodies to granulocytes (clone HIS48) (Becton Dickinson, Alphen aan den 
Rijn, the Netherlands) or macrophages (ED-1) (Serotec, Breda, the Netherlands) diluted in 
5% rat serum/PBS. Thereafter, sections were washed with PBS and incubated for 1 h with 
goat-anti-mouse peroxidase-labeled antibody (DAKO, ITK Diagnostics BV, Uithoorn, the 
Netherlands) diluted 1:100 in PBS with 5% rat serum. After rinsing with PBS, positive cells 
were revealed by immunoperoxidase reaction with DAB solution (DAB-kit, DAKO) and 
counterstained lightly with haematoxylin (Sigma).  
For quantification of macrophage, CD4+ cell, CD8+ cell and granulocyte infiltration and 
microvessel density two independent persons performed blinded analysis. Six 
representative fields (magnification 16x) in each slide and three tumors per treatment were 
evaluated. The sections were examined on a Leica DM-RXA and photographed using a 
Sony 3CCD DXC 950 camera. For macrophage, T cell and granulocyte infiltration the total 
number of positive cells per field of interest were counted. For the microvessel 
quantification, the area of vessels per field of interest was measured in calibrated digital 
images (Research Assistant 3.0, RVC, Hilversum, the Netherlands) and number of vessels 
counted.  
 
RT-PCR 
Total RNA was extracted from frozen tumor tissue using the guanidine isothiocyanate 
based TRIzol reagent (Life Technologies, Breda, the Netherlands) according to the 
manufacturer's specifications. BN175 cells in vitro were treated with medium, 10 µg/ml IL-
2, 8 µg/ml melphalan or IL-2 plus melphalan and after 30 min of incubation total RNA was 
extracted. All procedures were carried out with sterile, RNase-free solutions, reagents and 
disposables. Total RNA was quantified by spectrophotometric analysis at wavelengths of 
260 and 280 nm. To assure the quality of the RNA isolates, samples were analyzed by 
electrophoresis in agarose gel. 
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Table 1. RT-PCR primers for the immune related genes and for β-actin, which was used as 
a housekeeping gene. 
Gene Primers Annealings 
temp. 
Product  
size (bp) 
β-actin f: 5’-ATGGATGACGATATCGCTG-3’ 
r: 5’-ATGAGGTAGTCTGTCAGGT-3’ 
60ºC 569 
IL-6 f: 5’-GACTTCACAGAGGATACC-3’ 
r: 5’-TAAGTTGTTCTTCACAAACTCC-3’ 
55ºC 294 
GRO/ 
CINC-A  
f: 5’-GAAGATAGATTGCACCGATG-3’ 
r: 5’-CATAGCCTCTCACACATTTC-3’ 
57ºC 367 
IL-10 f: 5’-TGACAATAACTGCACCCACTT-3’ 
r: 5’-TCATTCATGGCCTTGTAGACA-3’ 
60ºC 402 
IL-12 f: 5’-TCATCAGGGACATCATCAAACC-3’ 
r: 5’-CGAGGAACGCACCTTTCTG-3’ 
65ºC 210 
TNF-α f: 5’-TACTGAACTTCGGGGTGATCGGTCC-3’ 
r: 5’-CAGCCTTGTCCCTTGAAGAGAACC-3’ 
60ºC 295 
IFN-γ f: 5’-GCCTCCTCTTGGATATCTGG-3’ 
r: 5’-GTGCTGGATCTGTGGGTTG-3’ 
60ºC 239 
MCP-1 f: 5’-ATGCAGGTCTCTCTGTCACG-3’ 
r: 5’-CTAGTTCTCTGTCATACT-3’ 
57ºC 446 
MIP-2 f: 5’-GGCACAATCGGTACGATCCAG-3’ 
r: 5’-ACCCTGCCAAGGGTTGACTTC-3’ 
55ºC 287 
TGF-β1 f: 5’-TGGAAGTGGATCCACGAGCCCAAG-3’ 
r: 5’-GCAGGAGCGCACGATCATGTTGGAC-3’ 
55ºC 240 
f: forward primer, r: reverse primer 
 
A volume of 20 µl containing 1.0 µg of total RNA of each sample was used for generation 
of cDNA with Omniscript Reverse Transcriptase (Qiagen, Leusden, the Netherlands) and 
oligo d(T)16 (Life Technologies, Breda, the Netherlands). After incubation at 42˚C for 1 
hour, the samples were heated for 5 min at 93˚C to terminate the reaction. Titanium Taq 
DNA polymerase (Becton Dickinson, Alphen aan den Rijn, the Netherlands) was used for 
the PCRs and 1.5 µl of cDNA per 37.5 µl of reaction mixture was used. The primers were 
purchased from Life Technologies (Breda, the Netherlands) and primer sequences are 
shown in table 1. β-actin was used as an internal standard. PCRs were performed on a 
Biometra T-gradient PCR machine using the following parameters: initial denaturation at 
94˚C for 5 min followed by a maximum of 40 cycles of 94˚C for 45 sec, annealing for 45 
sec (temperatures see table 1) and extension 72˚C for 1 min and a final extension step at 
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72˚C for 7 min. The resulting DNA fragments were electrophoretically separated on a 1.5% 
agarose gel, stained with ethidium bromide and photographed under UV light. A 100-bp 
ladder was used as the standard. 
 
Semi-quantitative RT-PCR 
Total RNA isolation, cDNA preparation and RT-PCR were performed as described above 
(see RT-PCR). Semi-quantification of cytokine expression was carried out as followed, 
every 2 cycles, 5 µl of PCR product was collected and the samples were electrophoretically 
separated on a 1.5% agarose gel, stained with ethidium bromide and photographed under 
UV light. The threshold cycle was determined as the cycle where the visible band of a 
specific PCR product first appeared on the gel. Intensities of the PCR product bands were 
determined by ImageJ v1.34 software (W. Rasband, Research Services Branch, National 
Institute of Mental Health, Bethesda, Maryland, USA) and normalized for b-actin. 
 
Statistical analysis 
Results were evaluated for statistical significance with the Mann Whitney U test. P-values 
below 0.05 were considered statistically significant. Calculations were performed on a 
personal computer using GraphPad Prism v3.0 and SPSS v11.0 for Windows 2000. 
 
 
0 2 4 6 8 10
0
1000
2000
3000
4000
5000
6000
IL-2
Sham
melphalan
IL-2 + melphalan
Days after perfusion
Tu
m
or
 v
ol
um
e 
(m
m
3 ) 
 
 
 
 
 
 
 
 
 
 
Figure 1. Tumor volumes of the subcutaneously implanted soft-tissue sarcoma 
BN175 after isolated limb perfusion with perfusate alone, 50 µg IL-2, 40 µg 
melphalan, or a combination of IL-2 and melphalan. Mean tumor volumes are 
shown ± SE. Number of rats per group is shown in Table 2. 
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Results 
Tumor response in IL-2 based ILP 
To evaluate the antitumor activity of melphalan when combined with IL-2 in an isolated 
limb perfusion, soft tissue sarcoma-bearing rats were perfused with the agents alone or 
combined. Sham perfusion with haemaccel alone resulted in progressive disease in all 
animals (Figure 1 and Table 2), whereas application of melphalan resulted in a slight 
inhibition of the tumor growth, with a tumor response rate of 17% (PR and CR combined). 
Progressive disease was also seen in all animals perfused with 50 µg IL-2. Perfusion with 
IL-2 plus melphalan resulted in a strong synergistic antitumor response and tumor response 
reaching 67% (p<0.05 compared with melphalan alone). We statistically proved the IL-2 
plus melphalan synergy (p<0.02). No obvious regional or systemic toxicity was observed in 
any of the treatments. 
 
Table 2. Tumor response in soft tissue sarcoma-bearing rats after isolated limb perfusion 
with IL-2 and melphalan over a total period of 10 days. 
 Response ratea 
Treatment PDb NC            PR               CR RR 
sham (n=8) 100% - - - 0 
IL-2 (n=9) 100% - - - 0 
melphalan (n=6) 66% 17% 17% - 17% 
IL-2 + melphalan (n=8) 22% 11% 56% 11%  67% * 
a responses were scored as described in Materials and Methods, b PD: progressive disease, NC: no change, PR: 
partial remission, CR: complete remission, RR: response rate (PR plus CR), * p < 0.05 compared to melphalan 
alone. 
 
Direct effect of IL-2 and melphalan on BN175 and endothelial cells 
In vitro experiments were performed to define whether direct cytotoxicity contributed to the 
improved tumor response. Because the target can be tumor vascular endothelial cells as 
well as tumor cells, both HUVECs and BN175 cells were tested. No direct cytotoxicity 
could be observed when BN175 cells or HUVECs were exposed to concentrations of IL-2 
up to 10 µg/ml. Exposure of BN175 cells or HUVECs to melphalan resulted in a response 
curve with an IC50 of 0.25 and 11.4 µg/ml respectively. Addition of IL-2 to melphalan did 
not alter the IC50 of melphalan in both cell types. Incubation of HUVEC with IL-2 did not 
change the typical cobblestone-shape of these cells. IL-2 had also no additive effect on 
HUVECs when co-incubated with leukocytes (data not shown).  
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Tissue concentrations of melphalan 
Accumulation of melphalan in tumor and normal muscle tissue was determined. A highly 
significant tumor-selective increase of melphalan uptake was observed in the rats treated by 
an ILP with IL-2 and melphalan in comparison to rats treated with an ILP with melphalan 
alone. Figure 2 demonstrates a 3.7-fold increase in melphalan concentration in tumor tissue 
after perfusion with IL-2 plus melphalan (n=4) in comparison with perfusion with 
melphalan alone (n=4) (p<0.01). Importantly, IL-2 had no effect on the uptake of 
melphalan by muscle tissue. 
 
Figure 2. Accumulation of 
melphalan in soft tissue sarcoma 
BN175 and muscle during 
isolated limb perfusion. Rats 
were perfused with 40 µg 
melphalan or 50 µg IL-2 plus 40 
µg melphalan, after which tumor 
and muscle were excised and 
total melphalan content 
determined as described in 
Materials and Methods. The 
mean of six rats is shown ± SD. 
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Vascular permeability and damage by IL-2 
Since we observed an increased accumulation of melphalan especially in tumor tissue after 
ILP with IL-2 and melphalan, we investigated the effect of IL-2 on the tumor vascular 
lining in more detail. First, we looked at extravasation of a larger tracer molecule (FITC-
BSA) into the tumor tissue. During the perfusion, FITC-BSA was added to the perfusate 
and after ILP tumors were excised and frozen sections were stained with CD31PE to 
visualize blood vessels. We saw no increased vascular permeability for this molecule in the 
IL-2 plus melphalan group compared to the sham group (data not shown). Most of the 
FITC-BSA was still present in the blood vessels and hardly any extravasation of the 
albumin had taken place. For this we hypothesized that permeability of the relatively small 
melphalan (0.3 kD) molecule is differently affected as compared to FITC-BSA (66.4 kD).  
 
These results were confirmed in vitro in which we assessed the capacity of IL-2 to induce 
permeability in endothelial cell monolayers. A transwell insert with only fibronectin 
coating and no cells was used to determine the maximum passage of FITC-BSA or 
fluorescein across the membrane. Incubation of HUVECs with 10 µg/ml IL-2 did not cause 
an increase in monolayer permeability for FITC-BSA in a period of 24 hours (data not 
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shown). These experiments were repeated with fluorescein, a smaller molecule. Incubation 
with IL-2 resulted in a 1.6-fold increased permeability compared to untreated cells after 15 
min of exposure and incubation times of 1 hour or longer showed no increased permeability 
anymore (Figure 3). In conclusion, there was a transient effect of IL-2 on the permeability 
of endothelial cells in vitro for small molecules like fluorescein and not for proteins like 
BSA. This could explain why an increased melphalan uptake in vivo directly after ILP was 
seen and no increased permeability of FITC-BSA in vivo. 
 
Figure 3. Effect of IL-2 on 
HUVEC monolayer per-
meability. HUVECs were 
cultured on the filter of a 
transwell unit for 48 hours 
before the addition of 
fluorescein containing medium 
(control) or IL-2 (see Material 
and Methods). The amount of 
fluorescein in the lower 
compartment was measured for 
period of 2 hours. Values are 
from two experiments, each 
done in duplicate. The mean is 
shown ± SD. 
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pH measurement in perfusate 
Before and during perfusion the pH of the perfusate was measured. The pH of Haemaccel is 
6.9 and oxygenation lowered the pH to 6.2. Directly after start of the perfusion the pH 
increased up to 6.5 ± 0.3. Different treatments did not have an effect on the pH of the 
perfusate and the pH at the end of the perfusion was 6.9 ± 0.1 for all four treatments. 
 
HE staining and apoptosis in vivo 
Histopathological examination was performed on the tumors from animals treated with 
sham, IL-2, melphalan or IL-2 plus melphalan to evaluate damage to the endothelial lining 
of tumor vessels. The animals were autopsied directly after ILP and the tumor slides were 
stained with hematoxylin. The tumor sections of the IL-2 and IL-2 plus melphalan treated 
animals revealed scattered extravasation of erythrocytes compared to the sham and 
melphalan treated animals, although the endothelial lining seemed mostly to be intact 
(Figure 4). In the IL-2 and the IL-2 plus melphalan treatment there was a small increase in 
edema in the tumor in comparison with the other two groups. Because the BN175 tumor is 
a fast growing tumor, necrotic areas were seen in all four treatments (data not shown). At 
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this immediate post-ILP time-point there seemed to be no difference in the number and size 
of the necrotic areas between the treatments. 
The subtle changes in vascular leakage and damage to the tumor vessels evoked by IL-2 
were further confirmed by double staining of tumor sections for apoptosis and for CD31 
expression. Only a few apoptotic tumor and endothelial cells were detected in both the 
sham and the IL-2 treated rats, without differences between the two groups (data not 
shown). These results indicate that IL-2 has a much less pronounced effect on the tumor 
vasculature when compared to TNF, which inflicts massive haemorrhagic necrosis when 
Figure 4. Paraffin sect
used in ILP (25). 
ions of BN175 tumor tissue after isolated limb perfusion, haematoxylin-eosin stained.  
ssessment of tumor vascular functionality 
orrelate with the functionality of the tumor-
treatments in the number of vessels, area endothelium or the area per vessel (Table 3). 
Sham (a), 50 µg IL-2 (b), 40 µg melphalan (c) and IL-2 plus melphalan (d). Original magnification x40. 
 
A
The increased uptake of melphalan might c
associated vasculature. Quantification of the microvessel density and functionality was 
performed by immunohistochemical staining of endothelial cells. The number of vessels as 
well as vessel area was measured. The area per vessel is computed by dividing the total area 
of vessels by the number of vessels. There was no significant difference between the 
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Table 3. Microvessel density, area of the vessels and tumor infiltration after isolated 
perfusion with sham, IL-2, melphalan or IL-2 plus melphalan.  
 sham IL-2            melphalan        IL-2 + melphalan 
number of vesselsa 33 ± 9 64 ± 24 22 ± 2 29 ± 5 
area endotheliumb .6 
sselc .09 04 .03 .02 
tesd 
hagesd     
6.8 ± 0 9.2 ± 1.3 5.9 ± 0.9 6.4 ± 0.8 
area endothelium/ve 0.30 ± 0 0.16 ± 0. 0.28 ± 0 0.24 ± 0
CD4d 0.4 ± 0.2 2.4 ± 0.2 0.2 ± 0.2 0.1 ± 0.1 
CD8d 
granulocy
macrop
51 ± 7 
60 ± 4 
210 ± 7
36 ± 10 
79 ± 4* 
222 ± 52
67 ± 47 
48 ± 3* 
201 ± 20
37 ± 10 
63 ± 4# 
189 ± 20
Note: Directly after ILP the tum xcised a ections ed for g s, macrophages 
nd CD8 posit t least er gr lds o r tumor were 
evaluated. Average ± SEM is shown.  number of vessels per field of interest,  % of total vessel area per field of 
interest,  area per vessel,  amount of positive cells per field of interest,  p=0.05 compared with sham treatment,   
p=0.05 compared to melphalan treatment 
nd macrophages 
 vitro IL-2 seems to have a small and transient effect on endothelial cells and no effect on 
thesized that IL-2 stimulates immune-
ytes compared to 
 clear differences 
 
ors were e nd frozen s  were stain ranulocyte
and CD31, CD4 a ive cells. A
a
 2 animals p oup and 6 fie
b
f interest pe
c d *
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Tumor infiltration of leukocytes a
In
tumor cells, which is also seen with TNF. We hypo
cells to contribute to the increased vascular leakage. To see if there is an increased 
infiltration of leukocytes into the tumor tissue, tumors were excised directly after isolated 
perfusion with sham, IL-2, melphalan or IL-2 plus melphalan. Immunohistochemical 
staining for CD4 and CD8 was performed on frozen sections. There were hardly any CD4 
positive cells present in all four treatments (Table 3). The number of infiltrating CD8 cells 
was much higher compared to the number of CD4 cells. However, no clear differences in 
the amount of infiltrating CD8 cells were seen between the four groups.  
Infiltrated granulocytes were detected in tumor tissue in slightly larger numbers than CD8 
cells. ILP with melphalan resulted in a decreased number of granuloc
sham perfusions (p=0.05). Addition of IL-2 to the sham perfusion increased the number of 
infiltrating cells and addition of IL-2 to melphalan ILP also resulted in an increase in 
infiltrating granulocytes (p=0.05). However, no increased infiltration of granulocytes in the 
IL-2 plus melphalan group compared to sham perfusions was found. In none of the 
treatments a difference in distribution pattern of granulocytes was found. 
Macrophages were present is all treated and untreated tumors in larger proportions than T 
cells and granulocytes, without differences between the treatments. But,
were seen in the localization of ED-1 cells, with an even distribution in the treatments 
sham, IL-2 and melphalan, while in the IL-2 plus melphalan group clustered ED-1 cells 
were found (Figure 5). 
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Figure 5. Representative 
pictures of macrophage loca-
lization in BN175 tumor. Rats 
were perfused with sham (a), 50 
ble macrophage activation. These activated macrophages could produce non-specific 
ffector molecules like cytokines and reactive oxygen and nitrogen intermediates, all of 
re obtained directly after ILP 
 
vels of 
µg IL-2 (b), 40 µg melphalan 
(c) and IL-2 plus melphalan (d), 
after which tumors were excised 
and an immunohistochemical 
staining for ED-1 positive cells 
was performed on frozen tumor 
section. Treatment with IL-2 
plus melphalan resulted in a 
redistribution of macrophages 
and clustered ED-1 cells were 
found. Original magnification 
16X. 
 
Cytokine expression in tum
The different macrophage 
possi
or tissue and tumor cells in vitro 
distribution after perfusion with IL-2 and melphalan indicates 
e
which exhibit potent antitumor properties. Tumor biopsies we
and RNA extracted from these samples was amplified in order to create an overview of 
cytokine-profile in the tumor microenvironment and the effect of treatment on this profile.  
All cytokines tested were expressed in sham treated tumors (data not shown). In these 
tumors, TGF-β1 showed to have the highest expression level followed by MCP-1 and 
expression of TNF was the lowest compared to the other cytokines tested. Strikingly, only 
for TNF expression a response to IL-2 treatment was observed. The threshold cycle of TNF
expression in IL-2 and IL-2 plus melphalan treated tumors was 5 cycles lower than that of 
sham treated tumors (p<0.05). Integrated density was measured and TNF mRNA levels 
were expressed as a ratio of TNF to b-actin (Figure 6). A 5.7-fold increase in TNF mRNA 
expression was found in tumor tissue treated with IL-2 plus melphalan compared to sham 
treatment (p<0.05). IL-2 ILP caused a 3.2-fold increased TNF mRNA expression compared 
to sham (p<0.05), whereas melphalan ILP had no effect on TNF mRNA expression. 
To investigate which cytokines the tumor cells produced, RNA was isolated from BN175 
tumor cells in vitro. Cells were also incubated with 10 µg/ml IL-2 and 8 µg/ml melphalan 
or the combination for 30 minutes. Clear differences were seen between cytokine 
expression levels in vivo and in vitro. mRNA expression in tumors showed higher le
IL-12, MCP-1 and TGF-β1 than tumor cells in vitro. Levels of the other cytokines tested 
were comparable. Treatment with IL-2 and/or melphalan had no effect on the cytokine 
expression of tumor cells in vitro (data not shown).  
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Figure 6. Semi-quantitative RT-PCR. 
BN175-bearing rats were treated with 
melphalan or a combination of IL-2 1.5
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the tumors were excised. RNA was 
isolated and RT-PCR with TNF 
primers was carried out. Integrated 
density of the PCR bands was 
measured and TNF mRNA levels are 
presented as a ratio of TNF to b-actin. 
The mean of 3 animals per group is 
shown ± SEM. * p<0.05 compared to 
sham (Mann Whitney U test). 
 
 
 
 
 
n of IL-2
BN175 tumor r
CR combined) of 67% was much higher than the tumor response of melphalan alone (17%), 
while progressive disease was seen in all animals treated with IL-2 alone. These results are 
comparable with those of our previous study with TNF and melphalan where we found 
similar synergy for the combination of TNF and melphalan (8,10). Importantly, the 
application of high dose IL-2 in ILP was without any local or systemic toxicity indicating 
possible translation of this cytokine to loco-regional settings in the clinic.  
In different animal models IL-2, as a single agent, has been shown to have antitumor 
activity (17,18). In the systemic setting this requires high doses and multiple dosing, which 
is associated with serious systemic toxicity with hypotension, massive vascular leakage 
syndrome and multiple organ failure leading to death (13-15,26). The adva
regional application, i.e. an ILP, is the minimal systemic exposure while maintaining a high 
therapeutic dose locally. For this reason we hypothesized that IL-2 could be a good 
candidate to be used in a melphalan-based ILP. IL-2 is known not to have direct antitumor 
effects and thus seems to be an unlikely candidate to be used in the isolated limb perfusion 
setting. However, we speculated that IL-2 with its multiple effects, could well impact on the 
pathophysiology of large tumors in a similar way as TNF and might thus significantly 
potentiate the distribution and uptake of melphalan throughout the tumor. A critical step for 
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TNF-based ILP is the accurate and real-time monitoring of systemic leakage with the aim 
of avoiding severe systemic TNF mediated toxicity. Because IL-2 is used in a systemic 
clinical setting, we hypothesized that IL-2 is a potentially safer drug than TNF and 
therefore a useful alternative for ILP with TNF. Moreover, the lack of toxicity warrants 
exploration of IL-2 in loco-regional treatment of liver cancer, in which TNF cannot be used 
effectively due to its inherent dose limiting liver toxicity.  
Here we demonstrate that IL-2 alone in the ILP-setting had no effect on tumor growth, in 
spite of the high dosage we were using. A strong synergistic tumor response was observed 
when IL-2 was combined with melphalan. A set of experiments to investigate potential 
mechanisms behind the observed synergy between IL-2 and melphalan was performed both 
d the presence of IL-2 receptors on cells in head and neck squamous 
old 
in vitro and in vivo. We showed that IL-2 did not have an effect on the proliferation or 
morphology of HUVECs or BN175 tumor cells in vitro. We speculate that the improved 
antitumor effect shown in vivo is probably not caused by a direct cytotoxic effect on tumor 
or endothelial cells. 
IL-2 is a 15 kD glycoprotein produced by antigen-activated T lymphocytes that plays a 
varied and critical role in immunoregulation. IL-2 binds to the IL-2 receptor and the IL-2R 
is expressed not only on hematopoietic cells, but also on non-hematopoietic cells. Different 
reports have indicate
cell carcinoma (27) and different human melanomas (28). We evaluated the direct effect of 
IL-2 on endothelial cells. We did not see an effect on the proliferation of HUVECs, nor 
morphologic changes. Holzinger et al. showed that HUVECs possess low numbers of IL-2 
receptor, although IL-2 had no effect on the proliferation of the endothelial cells neither on 
the typical cobblestone-shape morphology of the cells (29). This in contrast with the study 
of Hicks et al. where they showed that HUVECs do proliferate in response to IL-2 (30). To 
test whether IL-2 had an indirect effect on HUVECs we co-cultured leukocytes with 
HUVECs and treated them with different concentrations of IL-2. We showed that there was 
no effect on proliferation of endothelial cells nor did we observe morphologic changes. 
Systemic IL-2 administration is often complicated by significant capillary leakage, with 
consequent extravasation of interstitial fluid and plasma proteins (14,15,26). In this study 
we evaluated whether IL-2 could cause capillary leakage in the tumor and therefore 
enhance the delivery of melphalan at the tumor site. We showed that IL-2 caused a 3.7-f
augmented accumulation of melphalan specifically in tumor tissue, which correlated closely 
with the enhanced tumor responses. This increase could very well explain the improved 
efficacy, as ILP with IL-2 alone did not induce any tumor response. The 3.7-fold increase 
in local melphalan results in a shift from a hardly effective dose of 0.14 µg/ml to an 
effective dose of 0.53 µg/ml, when translated to the in vitro cytotoxicity profile of 
melphalan on BN175 tumor cells. Taken into account that we expect a heterogeneous 
distribution of melphalan especially around the tumor vessels in the well-perfused region of 
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the tumor, actual local drug levels are likely to be even higher. Further more, IL-2 did not 
have an effect on the accumulation of melphalan in muscle tissue, indicating that IL-2 
works specifically on the tumor-associated vessels.  
The mildly acidic condition of the perfusate (pH 6.2) might enhance the antitumor effect of 
melphalan as suggested by a study of Kelley et al. (31). Others showed that hypoxia and 
acidosis both in vitro and in vivo are able to augment the cytotoxicity of melphalan (32,33). 
Addition of IL-2 did not have an effect on the pH of the perfusate. The final pH for all 
e expected comparable histological changes. However, the HE slides 
we do not see more pronounced 
treatments was 6.9.  
We showed in a previous study that TNF comparably augmented the accumulation of 
chemotherapeutic drugs specifically in tumor tissue 4- to 6-fold (7,11). As the augmented 
melphalan accumulation in tumor tissue induced by IL-2 correspond with our observations 
in TNF-based ILP w
of tumor tissue after IL-2-based ILP showed a much less pronounced extravasation of 
erythrocytes when compared to TNF-based ILP (25). However, in IL-2 and IL-2 plus 
melphalan treated tumors, although the endothelial lining seemed to be intact, scattered 
extravasation of erythrocytes was observed next to locally increased edema. These findings 
indicate that IL-2 has a much more subtle effect on the endothelial lining, compared to 
TNF. Moreover, IL-2 did not increase the permeability to FITC-BSA in vivo. Also in vitro 
endothelial permeability for FITC-BSA was not increased when HUVECs were treated 
with IL-2, while an enhanced permeability of 1.6-fold for fluorescein was seen after 15 
minutes of incubation with IL-2. An explanation can be that FITC-BSA is a much larger 
molecule than fluorescein (molecular weight 66.400 D and 332 D, respectively) and the 
molecular weight of melphalan (305 D) is comparable with fluorescein. The lack of a 
strong tumor-vascular effect was confirmed by staining of tumor section for apoptosis. We 
could only detect few apoptotic tumor and endothelial cells and no differences between 
sham and IL-2-based ILP were noted. The increased tumor accumulation of melphalan 
might be correlated with the vessel functionality of the tumors. However, we did not see 
any differences between the treatments in the vessel area. 
As IL-2 did not seem to have an effect on endothelial or tumor cells directly we 
hypothesized that immune cells are involved. We performed immunohistochemical 
stainings on tumor tissue collected directly after ILP. We did not see an effect on the 
number of infiltrating CD4 or CD8 cells. A reason why 
differences in the amount of infiltrating cells between the treatments could be explained by 
the time-point at which tissues were collected, after only 30 minutes of treatment. None of 
the perfusions had an effect on the number of infiltrating macrophages, but clear 
differences were seen in the localization of macrophages. After ILP with IL-2 and 
melphalan clustered macrophages were present, while in the other treatments macrophages 
were evenly distributed. LPS, IFNγ and IL-2 are established as activating agents for 
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monocytes/macrophages. Activated monocytes/macrophages produce cytokines (such as 
TNF) and free radicals (superoxide and nitric oxide) that have cytotoxic effects on tumor 
cells (34-37). We showed in tumor tissue treated with IL-2 alone or IL-2 plus melphalan a 
5.7-fold increased expression of TNF, while in vitro stimulation of tumor cells did not 
result in an increased TNF expression. These results indicate that activated macrophages 
could play a role in the antitumor response of IL-2-based ILP. Additional studies are 
ongoing to further elucidate the mechanism. 
In conclusion, IL-2 in a melphalan-based ILP is causing a strong synergistic antitumor 
response in soft-tissue sarcoma BN175. Importantly, the addition of IL-2 inflicted no 
toxicity locally or systemically. The results in our study indicate that the novel combination 
of IL-2 and melphalan in an ILP can be of value and therefore possibly a useful alternative 
 2.  Eggermont AM, Schraffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis 
factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue 
nter trial. J Clin Oncol. 1996;14(10):2653-2665. 
 5.  
1
1
for ILP with TNF and melphalan, or as a novel candidate for isolated hepatic perfusion. 
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Abstract 
e have previously shown how tumor response of isolated limb perfusion (ILP) with 
melphalan was im Taking 
to account that LP, we 
aluated histamin sess the 
mbined effects o  (n=6), 
and tissue histolog ted the 
rowth of BN175 mor cells as well as apoptosis, necrosis, y, and 
aracellular permeability of human umbilical vein endothelial cells (HUVECs) after Hi 
treatment alone and in combination with melphalan. The antitumor effect of the 
mbination of Hi and melphalan in vivo was synergistic, and Hi-dependent reduction in 
educed after ILP treatment with Hi and melphalan 
ro results paralleled in vivo results. BN175 tumor 
lls were more sensitive to the cytotoxicity of combined treatment than HUVECs, and Hi 
mechanisms. These results warrant further evaluation in the clinical ILP setting and, 
perfusion.  
Isolated limb perfusion (ILP) is a treatment method in which high concentrations of drugs 
are administered to a limb containing an unresectable tumor that is temporarily isolated 
rfusion 
ircuit and a tourniquet placed at the root of the limb. ILP with tumor necrosis factor alpha 
NF-α) and melphalan is associated with synergistic antitumor effects against melanoma 
), large soft-tissue sarcomas (2,3), and various other tumors in the clinical setting (4-6). 
e have previously shown that the basis for the synergy is both a substantial enhancement 
f tumor-selective melphalan uptake (7) and the complete destruction of the tumor 
vasculature (2). The enhanced tissue uptake of different cytotoxic agents, when combined 
ith TNF-α, shown in various limb and liver tumor models in our laboratory (7-12), 
rompted us to investigate a number of vasoactive substances for similar effects.  
istamine (Hi) is an obvious candidate to enhance tissue uptake of cytotoxic agents during 
P. It is an inflammatory mediator that is formed and stored mainly in the granules of mast 
ells and basophils, but it has also been identified in epidermal cells, gastric mucosa, 
em, and in cells in regenerating or rapidly growing 
W
proved when tumor necrosis factor alpha (TNF
other vasoactive drugs could also improve tumo
e (Hi) as an alternative to TNF-α. We used a rat I
f Hi and melphalan (n=6) on tumor regression, m
y (n=2) compared with Hi or melphalan alone.  
 tu
-α) was added. 
r response to I
LP model to as
elphalan uptake
We also evalua
cell morpholog
in
ev
co
g
p
co
tumor volume was blocked by H1 and H2 receptor inhibitors. Tumor regression was 
observed in 66% of the animals treated with Hi and melphalan, compared with 17% after 
treatment with Hi or melphalan alone. Tumor melphalan uptake increased and vascular 
integrity in the surrounding tissue was r
ompared with melphalan alone. In vitc
ce
treatment increased the permeability of HUVECs. In conclusion, Hi in combination with 
melphalan in ILP improved response to that of melphalan alone through direct and indirect 
importantly, in organ 
 
Introduction 
from the rest of the body’s circulatory system by the use of an extracorporeal pe
c
(T
(1
W
o
w
p
H
IL
c
neurons of the central nervous syst
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tissues. Its effect on fine vessels is to cause edema by increasing the flow of lymph and 
d (8). Tumor growth was measured daily with a caliper, 
nd tumor volume was calculated using the formula 0.4(A2xB) (where B represents the 
meter and A is the diameter perpendicular to it). When tumor diameter 
lymph proteins into the extracellular space and also by promoting the formation of gaps 
between endothelial cells, thus increasing transcapillary vesicular transport (13). The same 
mechanism that causes edema in fine vessels could potentially be used to increase drug 
concentrations in tumor tissues.  
In this study, we performed ILP in a rat model by using combinations of Hi and melphalan 
to determine if Hi would increase the effects of melphalan. To determine the in vivo 
mechanisms involved, we measured melphalan uptake and performed histologic analysis 
after treatment. In addition, cultured sarcoma (14) and normal endothelial cells were treated 
in vitro with Hi, melphalan, or a combination of the two, and cytotoxicity, necrosis, 
apoptosis, and paracellular permeability were assayed. 
 
Materials and Methods 
ILP 
Male inbred Brown Norway rats weighing 250–300 g were obtained from Harlan-CPB 
(Austerlitz, the Netherlands) and were fed a standard laboratory diet ad libitum (Hope 
Farms, Woerden, the Netherlands). The studies were done in accordance with protocols 
approved by the Animal Care Committee of the Erasmus University Rotterdam (Rotterdam, 
the Netherlands). Small fragments (diameter = 3 mm) of the spontaneous, nonimmuno-
geneic, syngeneic BN175 sarcoma (14) were inserted subcutaneously in the right hind legs 
of the rats, as previously describe
a
largest tumor dia
exceeded 25 mm or at the end of the experiment, rats were anesthetized and killed by 
cervical dislocation.  
The treatment consisted of the experimental ILP previously described (8,11). In brief, 7–10 
days after tumor fragments were inserted (when they reached a diameter of 12–15 mm) rats 
were anesthetized by intraperitoneal ketamine and intramuscular hypnomidate. An incision 
parallel to the inguinal ligament was made, and the inguinal vessels were cannulated and 
connected by way of a low-flow roller pump (Watson Marlow, Falmouth, U.K.) to an 
oxygenated reservoir where drugs were added, in bolus, to the perfusate (total volume = 5 
mL). A groin tourniquet was used to occlude collateral vessels, allowing a proper isolation 
of the limb. The temperature of the limb was maintained at 38°C using a warm-water 
blanket.  
The perfusate consisted of Haemaccel alone (sham) (Boehring Pharma, Amsterdam, the 
Netherlands), Haemaccel plus µ40 g of melphalan (Alkeran Wellcome, Beckenham, UK), 
Haemaccel plus 40 µg of melphalan and 1000 µg of Hi (kindly provided by Maxim 
Pharmaceuticals, San Diego, CA), or Haemaccel plus 1000 µg of Hi.  
47 
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To evaluate the role of the different Hi receptors in the Hi-based ILP, the Hi receptor 
blockers promethazine (H1-R) (Centrafarm, Etten-Leur, the Netherlands) and famotidine 
(H2-R) (Sigma, Zwijndrecht, the Netherlands) were added to the perfusate (200 and 50 
µg/mL, respectively) and allowed to circulate into the limb for 5 minutes before melphalan 
and Hi were added.  
Tumor dimensions were measured every day and used to monitor tumor volume. Volume 
on day 9 was compared with that on day 0, and response was classified as follows: 
progressive disease, increase of more than +25%; no change, volume between -25% and 
+25%; partial remission, decrease between -25% and -90%; or complete response, tumor 
volume less than 10% of initial volume.  
Limb function was clinically observed as the ability to walk and stand on the perfused limb 
fter ILP. On a scale from grade 0 to 2, grade 0 is severely impaired function in which the 
 is slightly impaired function (cannot use it in a normal way 
an stand on it), and grade 2 is an intact function (normal walking and standing pattern) 
ribed previously (7,15). Given the tumor and muscle values for 
. Images of stained samples were taken on a Leica DM-RXA microscope (Leica 
a
rat drags its hind limb, grade 1
but c
(8). 
 
In vivo melphalan uptake 
To evaluate melphalan distribution, we killed 11 rats (six treated with Hi plus melphalan 
and five treated with melphalan alone) immediately after ILP was performed. Tumors and 
muscle from the limb were removed, snap-frozen in liquid nitrogen, and stored at -80°C. 
Tissues were homogenized in 2 mL of acetonitrile with a PRO 200 homogenizer (Pro 
Scientific, Oxford, CT) and centrifuged at 2500g and 4°C. Melphalan concentration 
(reported as nanograms of melphalan per gram of tissue) was measured by gas 
chromatography–mass spectrometry on at least three different pieces of similar final weight 
per sample, as desc
melphalan uptake, the tumor-to-muscle ratio was calculated, considering the amount of 
melphalan measured in muscle as 100% and calculating the tumor value in comparison with 
it. 
 
Histologic evaluation 
Two animals from each treatment group were killed by cervical dislocation directly after 
ILP; tumors and a piece of muscle from the limb were excised and cut in half. One half was 
fixed in 4% formaldehyde solution, embedded in paraffin, and stained with hematoxylin 
and eosin
Microsystems, Rijswijk, the Netherlands) with a Sony 3CCD DXC camera (Sony 
Netherlands, Badhoevedorp, the Netherlands). 
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Cell culture 
BN175 cells (spontaneous rapidly growing and metastasizing soft-tissue sarcoma) (14) 
were grown in RPMI 1640 medium (Life Technologies, Leiden, the Netherlands) 
supplemented with 10% fetal calf serum (FCS) and 0.1% penicillin–streptomycin (Life 
Technologies). For growth assays, BN175 cells were plated in 96-well flat-bottomed 
th factor, human basic fibroblast growth factor, and 0.1% penicillin–streptomycin 
ife Technologies). For growth assays, HUVECs were plated 24 hours before treatment at 
ltured for 48 hours with various concentrations of Hi (0 to 200 
sorbance of test well/absorbance of control well) x 100%. The Hi concentration leading 
 50% reduction in absorbance compared with control (i.e., 50% inhibitory concentration 
 from the growth curve. Each experiment was performed four times 
r well and grown to confluence. Cells were 
en incubated at 37°C in 5% CO2 with various concentrations of Hi for various times. At 
ach time point, medium was discarded and replaced with 500 µL of HUVEC medium plus 
microtiter plates (Costar, Cambridge, MA) at 105 cells per well (in 100 µL) 24 hours before 
treatment and allowed to grow to confluence. Next, the cells were incubated at 37°C in 5% 
CO2 for 72 hours in the presence of medium alone or medium plus various concentrations 
of melphalan and Hi. Hi concentrations ranged from 0 to 200 µg/mL. Melphalan 
concentration ranged from 0 to 8 µg/mL.  
HUVECs were prepared by collagenase treatment of freshly obtained human umbilical 
veins and cultured in human endothelial serum-free medium–RPMI medium (Cambrex 
Bioscience, Verviers, Belgium) supplemented with 10% heat inactivated human serum 
(Invitrogen Life Technologies, Breda, the Netherlands), 20% FCS, human epidermal 
grow
(L
6x104 cells per well and cu
µg/mL) and melphalan (0 to 200 µg/mL).  
 
Cell growth 
Growth of BN175 cells and HUVECs was measured using the Sulforhodamine-B (SRB) 
assay (16). In brief, cells were washed with phosphate-buffered saline, incubated with 10% 
trichloroacetic acid for 1 hour at 4°C, and washed again with phosphate-buffered saline. 
Cells were stained with SRB (0.5% SRB in 1% acetic acid) for 15 to 30 minutes, washed 
with 1% acetic acid, and air-dried. Protein-bound SRB was dissolved in Tris base (10 mM, 
pH 9.4). Absorbance at 540 nm was measured for each well, and tumor cell growth was 
calculated according to the following formula: percentage of tumor cell growth = 
(ab
to
[IC50]) was determined
in duplicate. The mean of all values and the 95% confidence intervals (CIs) were 
determined and reported.  
 
HUVEC morphology and necrosis–apoptosis assays 
HUVECs were plated 24 hours before treatment at 6x104 cells per well in flat-bottomed 12-
well plates (Costar) in a volume of 900 µL pe
th
e
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0.05% YO-PRO for detection of apoptotic cells (Molecular Probes) or with propidium 
ith 300 µL of trypsin-EDTA (Biowhitaker), 
uplicate, and the mean and 95% CIs of the 
ercentage of living, apoptotic, and necrotic cells were reported. 
urve based on known concentrations of FITC-BSA.  
ext, to evaluate whether melphalan would have any effect on endothelial cell 
HUVEC monolayer was exposed to 
iodide to detect necrotic cells (Sigma). Cells were incubated for 30 minutes in the dark at 
37°C, and pictures were taken with a Zeiss AxioVert 100M inverted microscope with an 
AxioCam camera (Carl Zeiss, Sliedrecht, the Netherlands).  
Cells were cultured and treated using the time points above with the Vybrant Apoptosis 
assay kit #3 (Molecular Probes) for both adherent and detached cells. In brief, cells were 
treated with various concentrations of Hi alone (0 to 200 µg/ml), melphalan alone (0 or 8 
µg/ml), or with combinations of the drugs for 15 or 30 minutes. Culture medium containing 
floating cells was removed from the wells and transferred to 5-mL tubes. Adherent cells 
were washed with RPMI medium, trypsinized w
neutralized with 100 µL of HUVEC medium containing 20% FCS, and added to the 5-mL 
tubes. Tubes were centrifuged for 5 minutes at 250g, and the supernatant was discarded. 
Cells were then incubated in 200 µL of annexin binding buffer and propidium iodide, with 
or without annexin V (both reagents from the Vybrant Apoptosis assay kit) at room 
temperature for 15 minutes in the dark and evaluated by flow cytometry with a FACScan 
(Becton Dickinson, Alphen aan den Rijn, the Netherlands) flow cytometer. Data were 
processed with Winmidi software version 2.7 (J. Trotter; Salk Institute, San Diego, CA). 
Experiments were done three times in d
p
 
Endothelial cell monolayer permeability assay 
HUVECs were plated 48 hours before treatment at 6x104 cells per well in a monolayer on a 
fibronectin-coated polycarbonate membrane (diameter = 6.5 mm; pore size = 0.4 µm) in a 
transwell device (Costar). HUVEC medium (1 mL) was added to the lower compartment. 
Approximately 24 hours after the cells reached confluence, medium in the upper chamber 
was replaced with 50 µL of fluorescein isothiocyanate-bovine serum albumin (FITC-BSA) 
(1 mg/mL; Sigma) plus 250 µL of HUVEC medium containing various concentrations of 
Hi. At the same time, medium in the lower chamber was replaced with 700 µL of HUVEC 
medium. Fiftymicroliter samples were taken from the lower chamber at various times, and 
FITC fluorescence was measured with a fluorescence photospectrometer (Victor2 FSR; 
Perkin Elmer, Bucks, U.K.) at 490 nm excitation and 530 nm emission. Values were 
compared with a standard c
N
permeability, directly or in conjunction with Hi, the 
250 µL of HUVEC medium alone (control), melphalan at 8 µg/mL, or Hi at 100 µg/mL 
with or without melphalan (8 µg/mL). Permeability was assayed as described above. 
Experiments were done three times in duplicate. The data were reported as the mean and 
95% CIs of all values. 
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Statistical analysis 
Tumor growth curves were plotted as means and 95% CIs of the data from all animals. We 
used repeated-measure analyses of variance on the three most representative days, taken 
from the growth curve patterns 4, 8, and 10 using SAS Software release 8.2 for Windows 
index was calculated by 
ividing the initial tumor volume by the tumor volume on a given day after treatment; then, 
reated group was randomly added to the 
 A range of 
0.001). Perfusion with Hi or melphalan alone reduced or stabilized 
2000 (SAS institute, Cary, NC) using PROC MIXED. Main effects of treatment and day 
(three levels: days 4, 8, and 10) were included in the models, as was the interaction between 
treatment and day. For days in which response was statistically significant, interaction 
terms were further investigated by testing for differences following treatment on that day.  
The data from HUVEC monolayer permeability assays was also analyzed as described 
above. The effects of treatment and time (5 levels: 0, 15, 30, 45, and 60 minutes) were 
evaluated. Viability of HUVECs after Hi incubation data was presented and analyzed using 
the Kruskal-Wallis test with SPSS version 10.0 for Windows 2000. 
Melphalan accumulation was shown both as mean values (with 95% CIs) of three 
measurements performed using different tumor areas and as a ratio between tumor and 
muscle values, expressed in percentages of tumor versus muscle melphalan uptake. Data 
were analyzed using the Mann-Whitney U test with SPSS version 10.0 for Windows 2000.  
Synergism between Hi and melphalan was evaluated by determining whether tumor 
response after Hi alone or melphalan alone added together was different from the tumor 
response after Hi plus melphalan. First, the tumor response 
d
the tumor response index of a rat from the Hi-t
tumor response index of a rat from the melphalan-treated group and compared with the 
tumor response index from the Hi-plus-melphalan group. Next, the data were analyzed with 
the Mann-Whitney U test (exact significance [2x(one-tailed significance)] using SPSS 
version 10.0 for Windows 2000. All statistical tests were two-sided. For all statistical tests, 
a P value less than .05 was considered statistically significant. 
 
Results 
Tumor response after Hi-based ILP 
We previously showed that TNF-α improves the response to ILP by increasing the amount 
of melphalan delivered to tumor tissues (7). In this study, we used a similar model to test 
whether another vasoactive molecule, Hi, could also enhance melphalan uptake.
Hi concentrations were tested (20 to 200 µg/mL), and the concentration that led to optimal 
tumor regression was determined to be 200 µg/mL. Tumors grew exponentially in the 
Brown Norway rats after control ILP. However, the response to Hi plus melphalan ILP was 
striking, with a regression (more than a 25% decrease in tumor volume) in four (66%) of 
the six treated animals, including two (33%) with no palpable tumors approximately 10 
days after treatment (p<
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Figure 1 A) Tumor response after histamine-
based isolated limb perfusion (ILP): small 
inserted in the right
stable (50%) and one regression (17%) (Figure 1A and Table 1). The 
 
fragments of BN175 soft-tissue sarcoma were 
 hind limb of Brown Norway 
with perfusate alone (sham), 8 µg/mL melphalan 
exceeded 25 mm, rats were killed. * p<0.001 on 
B) Involvement of histamine receptors in 
L) were added in bolus to the 
perfusate and allowed to circulate for 5 minutes 
before Hi and melphalan were added. Mean 
tumor volumes and upper 95% confidence 
intervals are depicted in both graphs. The 
combination of Hi plus melphalan showed a synergistic effect because the response index 
of the combination group was statistically significantly greater than that when the response 
index from the Hi and melphalan alone groups was randomly added (p=0.043, Mann-
Whitney U test {exact significance [2x(one-tailed significance)]}. Perfusion with Hi, either 
alone or combined with melphalan, did not cause systemic toxicity. Only a transient, mild 
edema after Hi ILP, both with and without melphalan, was observed, leading to a temporary 
grade 1 toxicity in two rats for each group. After 2 days, the edema disappeared and limb
tu
m
0 4 8 12
days
number of in-independent experiments (rats) for 
each treatment is shown in parentheses. 
 
Involvement of Hi receptors in Hi-based ILP  
To determine which Hi receptor (H1-R or H2-R) is involved in the effects observed above, 
specific Hi inhibitors were used during the treatment. Both pyrilamine, an H1-R blocker, 
and famotidine, an H2-R blocker, could block the effect of Hi in the ILP setting, which 
means that either H1 or H2 receptors are involved (Figure 1B). 
 
0
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Table 1. Tumor response after histamine-based ILP 
Treatment CR (%) PR (%) NC (%) PD (%) 
Sham (n=5) 
Melphalan (n=6) 
Hi (n=6) 
Hi + melphalan (n=6) 
- 
- 
- 
33 
- 
17 
- 
33 
- 
17 
50 
33 
100 
66 
50 
- 
Volume on day 9 was compared with that on day 0, and response was classified as follows: PD = progressive 
disease, increase of more than 25%; NC = no change, volume between -25% and 25%; PR = partial remission, 
decrease between -25% and -99%; CR = complete response, no palpable tumor. Values are expressed in 
percentage of animals per response per group. 
 
Figure 2. Indirect effect of Hi on the accumulation of 
melphalan in tumors treated with isolated limb 
perfusion (ILP). Both tumor and adjacent muscle were 
excised immediately after ILP and snapfrozen in liquid 
nitrogen. Melphalan was measured by gas 
chromatography–mass spectrometry on at least three 
different pieces per sample as described in “Materials 
and Methods”. A) Tumor melphalan concentration. 
Closed bar, melphalan alone; open bar, Hi plus 
melphalan. * p=0 .024 (Mann-Whitney U test, two-
tailed). B) Ratio between tumor and muscle melphalan 
uptake. Closed bar, melphalan alone; open bar, Hi plus 
melphalan. * p=0.02 (Mann-Whitney U test, two-
tailed). Mean values with upper 95% confidence 
intervals are shown. 
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We next evaluated whether Hi treatment 
vasculature by increasing vascular permeability, which could cause more melphalan to 
accumulate in tumors than in normal tissue, as we previously showed using TNF combined 
with melphalan in ILP (7). To compare melphalan uptake in tumors and adjacent muscle, 
we excised tumors and muscle immediately after ILP with me
c
Chapter 3  
twofold increase in the amount of melphalan in tumor tissue (p=0.024) but also reduced 
tration in th . As addin rease io of 
 the tumor to that i he adjacent m y four ( 0.02) (Figur
 
rect and indirect effects i-based IL  the tumor or-
Hi alone resulted in vasodilatation of the tumor 
asculature, extravasation of red blood cells into the tumor, and damage to the endothelial 
i and melphalan, most of the tumor vessels 
rrhage was observed. Tumor vessels showed 
, indicating edema. Red and white blood cells 
igure 3. Histology of tumor and adjacent muscle after isolated limb perfusion (ILP). Tumors and muscle were 
eatment, fixed in 4% formaldehyde solution, and 
 alone (sham) ILP with intact vessels and normal 
melphalan concen e muscle a result, g Hi inc d the rat
melphalan in n t uscle b p= e 2).  
 
Histology
To evaluate both the di of H P on and the tum
associated vasculature, we histologically examined tissue sections taken right after ILP was 
performed. After ILP with 200 µg/mL Hi alone, scattered vascular damage was observed 
(Figure 3). After ILP with 200 µg/L Hi and 8 µg/L melphalan, vascular damage became 
more pronounced. Perfusion with 
v
cell lining of tumor vessels. After ILP with H
were severely damaged and massive haemo
loss of integrity and extensive gap formation
observed in the tissue suggested extravasation.  
F
excised immediately after and 24 hours after ILP for each tr
embedded in paraffin for hematoxylin-eosin staining. Perfusate
tumor tissue; melphalan 8 µg/mL ILP with some spots of necrosis on tumor tissue but no vascular damage; Hi-
alone 200 µg/mL ILP showing vascular vasodilatation, extravasation of red blood cells into the tumor and damage 
to the endothelial cell lining of tumor vessels; Hi plus melphalan (200 µg/mL and 8 µg/mL, respectively) ILP 
showing the damage to tumor vessels and massive hemorrhage. Pictures illustrate representative examples of each 
treatment. 
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We hypothesize that the edema observed in tumor tissue may indicate an augmented influx 
of melphalan from the blood stream into the tumor. In the muscle, however, no apparent 
changes in terms of hemorrhage, vasodilatation, or infiltrates after treatment, as above, 
ere observed (data not shown).  
ular effects were not observed when rats received sham ILP or melphalan via 
lines evaluated. BN175 tumor cells were 
more sensitive to Hi, with an IC50 of 30 µg/mL. HUVEC appeared less sensitive to Hi with 
an IC50 of approximately 100 µg/mL (Figure 4). The cytotoxic effect of Hi combined with 
melphalan in vitro was not synergistic, it was only additive. 
 
 
 
 
 
 
 
Figure 4. In vitro cytotoxicity of Hi 
according to percentage of tumor growth 
inhibition. Cells were incubated for 72 
hours with different concentrations of Hi 
with or without melphalan, and cell growth 
was evaluated using the Sulphorhodamine 
B assay as described in “Materials and 
of the mean. 
 
 
w
These vasc
ILP (Figure 3). After sham ILP, vessels were intact and tumor tissue was unaffected. When 
tumors were perfused with melphalan alone, some necrosis of the tumor tissue could be 
observed, but no vascular damage was seen. Together, these results indicate that Hi has 
tumor vascular-selective activity against the endothelial lining. This vascular effect was 
even more pronounced when Hi was combined with melphalan. 
 
Cytotoxicity of Hi 
The direct cytotoxic effects of Hi on BN175 tumor cells and HUVEC endothelial cells were 
evaluated by means of in vitro cytotoxicity assays. Cell growth was inhibited in a 
concentration-dependent manner for both cell 
Methods”. A) BN175 sarcoma (Hi 50% 
inhibitory concentration [IC50] of 30 
µg/mL); B) Human umbilical vascular 
endothelial cells (HUVECs) (Hi IC50 of 
100 µg/mL). Each point represents an 
average of four independent experiments. 
Error bars show 95% confidence intervals 
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Direct effect on HUVEC: morphology and apoptosis assay 
In vitro, Hi was only slightly cytotoxic to HUVEC cells after long-term treatment (Figure 
4B). Moreover, addition of Hi to melphalan did not enhance the sensitivity of HUVEC 
toward melphalan (Figure 4B). However, after ILP, a strong effect of Hi on the endothelial 
d to medium alone did not 
how these morphologic changes.  
Figure 5. Direct effect of Hi on endothelial cells. Human umbilical 
incubated with medium alone, melphalan (8 µg/mL) alone, Hi (100 µg
for 15 and 30 minutes. Gap formation and morphologic changes 
incubation both with 100 and 200 µg/mL (a more pronounced effect fo
 
The observed differences in HUVEC morphology af
investigate whether these changes were irreversible, th
apoptosis or necrosis. With YO-PRO and propidium iodi
of adherent cells, respectively, we found no differenc
necrotic cells after exposure of HUVECs to Hi compar
(data not shown). When all cells, adherent as well as detached, were examined using the 
Vybrant apoptosis assay, no increase in the number of apoptotic cells or the number of 
necrotic cells was observed when Hi was added compar d with medium alone (p=0.4 and 
lining of tumor vessels was observed (Figure 3). Therefore, we examined the morphology 
of HUVECs after short incubations (no longer than 60 minutes) with Hi plus melphalan. 
We observed a dose- and time-dependent effect of Hi on HUVEC, starting with the 
appearance of gaps between the cells. As time progressed, some cells became rounded and 
others became extended. In the higher concentration range or after prolonged incubation, 
cell fragments were seen in the medium (Figure 5). Cells expose
s
vascular endothelial cells (HUVECs) were 
/mL or 200 µg/mL) alone or in combination 
can be observed already after 15 minutes 
r 200 µg/mL). 
ter Hi treatment prompted us to 
at is, whether they could lead to 
de to detect apoptosis and necrosis 
es in the number of apoptotic or 
ed with exposure to medium alone 
e
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p=0.5, respectively) (Figure 6). Moreover, when Hi was combined with melphalan, still no 
45% increase in permeability for long- and recently 
confluent cultures, respectively.  
 
 
 
 
 
 
Figure 6. Viability of human umbilical 
vascular endothelial cells (HUVECs) after 
short incubation with Hi. HUVECs were 
plated 24 hours before treatment at 6x104 
cells per well and grown to confluence. Cells 
were cultured at 37°C in 5% CO2 with 
different concentrations of Hi (0 to 200 
µg/mL) and melphalan (0 or 8 µg/mL) for 15 
or 30 minutes. The Vybrant Apoptosis assay 
kit was used to detect apoptosis and necrosis 
of adherent and detached cells prior to flow 
own. 
 
increase in the number of apoptotic or necrotic cells was seen. 
 
Hi and paracellular permeability in vitro 
We observed an increase in melphalan concentration in tumors treated with both drugs, 
which was accompanied by strong effect of Hi on the tumor associated vasculature after 
ILP (Figure 2 and 3). Histopathologic examination revealed the Hi-induced formation of 
gaps in vivo in a concentration-dependent manner, requiring a minimum concentration of 
200 µg/mL (data not shown). Andriopoulou et al. (17) reported that incubation of 
microvascular endothelial cells for 25 minutes with a relatively low Hi concentration (11 
µg/mL) resulted in a 120% and 
cytometric evaluation of the cells. 
Experiments were done three times in 
duplicate. The mean percentage, per group of 
cells, and upper 95% confidence intervals are 25
50%
 c
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We investigated the pattern of permeability using Hi concentrations 10-fold higher than in 
that study. In line with the findings of Andriopoulou et al. (17), we found a concentration- 
and time-related effect of Hi on HUVEC monolayer permeability as well as a sharper 
crease in permeability in the first 15 minutes. The results presented in Figure 7A show 
i alone resulted in an increase in permeability of 
ven at 60 minutes, the response of HUVECs to Hi did not 
arallel the control curve. Incubation with melphalan had no effect on the permeability of 
UVEC monolayer, neither alone nor in combination with Hi (Figure 7B). The ongoing 
ermeability increase might be essential to the observations in vivo. 
 
 
 
Figure 7. Effect of Hi on human 
umbilical vascular endothelial cell 
(HUVEC) monolayer permeability. 
HUVECs were cultured on the filter of 
a transwell unit for 48 hours before the 
addition of fluorescein isothiocyanate 
and bovine serum albumin (FITC-
BSA)-containing medium (control) or 
A) Hi in different concentrations, B) 
plus or minus melphalan to the upper 
compartment (see “Material and 
Methods”). The amount of FITC-BSA 
in the lower compartment was 
measured every 15 minutes for an 
hour. Values are from three 
experiments, each done in duplicate. 
Error bars show 95% confidence 
intervals of the mean. * p-values using 
repeated-measure analysis of variance 
test p=0.001 for 200 µg/mL Hi at 15, 
30, 45, and 60 minutes compared with 
control. 
 
 
in
that exposure of HUVEC to 200 µg/mL H
fivefold (5.6, 95% CI=3.5 to 7.7) compared with the control, and 100 µg/mL Hi alone 
resulted in a two- to threefold (2.8, 95% CI =1.5 to 4.1) increase compared with the control. 
Incubation with 50 µg/mL Hi caused only a very slight increase of about 1.5-fold (1.5, 95% 
CI=1.0 to 2.0). Interestingly, when HUVECs were exposed to 50 µg/mL or 100 µg/mL Hi, 
no additional effect on permeability was observed after 15 and 30 minutes of incubation 
(curves start to parallel the control), respectively. Exposure of HUVECs to 200 µg/mL Hi 
resulted in an ongoing response of HUVECs as shown by the continuing permeability 
increase compared with control. E
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Discussion 
rved tumor response in 
vivo. Hi alone is capable of changing the morphology of ndothelial cells after a short 
incubation period, resulting in gap formation and rounde ls, as shown in Figure 5. 
When combined with melphalan in vivo, the effect on the vasculature is much more 
evident, with diffuse gap formation and destruction of e
immediately after the ILP. In the standard treatment 
destruction of the endothelial lining is a secondary effect
become evident (20). Therefore, ILP with Hi would like
quickly and effectively than ILP with TNF-α.  
The in vitro permeability results were in accordance w
augmented uptake of melphalan in the tumor as well a
concentration, reducing regional toxicity. It is remarkable th
the ILP (200 µg/mL) led to a continuous increase in the pe
which is different from the standard described short-term e
the first 15 minutes of exposure (18). We speculate that wi
the ILP, a threshold is reached that triggers a prolonged cell
is currently under investigation.  
Another potential advantage of Hi over TNF-α is its pharm
half-life in serum - 0.35 minutes versus 20 minutes for T
through two major pathways in humans; the main pathway i
catalyzed by the enzyme histamine-N-methyltransferase, wh idely distributed in the 
tissues. Most of the product, N-methylhistamine, is converted by monoamine oxidase to N-
This study shows for the first time, to our knowledge, the activity of Hi plus melphalan in 
ILP for the treatment of soft-tissue sarcomas. The strong effect of Hi-based ILP with 
melphalan was explained by three mechanisms: 1) direct cytotoxicity to the tumor cells, 2) 
direct cytotoxicity to the tumorassociated vasculature, and 3) an indirect effect through 
Himediated, increased melphalan concentration in the tumor.  
The direct inhibitory effect of Hi on tumor cells is in accordance with previous reports on 
Hi receptor expression on different cell lines and human neoplasias, suggesting that it might 
regulate tumor cell growth (18,19). This growth-inhibitory effect on the tumor cells, 
combined with the observed direct effect on the endothelial cells, seen by us both in vitro 
and in vivo, might be an explanation for the antitumor effect of Hi alone (50% of the tumors 
stopped growing), compared with control perfusions (all tumors continued to grow). 
Nevertheless, chemotherapeutic drugs, such as melphalan, for example, must be added to 
the ILP to achieve a good antitumor response, which coincides with our observations in 
TNF-α-based ILP (8).  
The direct effect of Hi on endothelial cells in vitro is more pronounced than that of TNF-α, 
the current drug of choice for ILP, which we believe adds to the obse
 e
d cel
ndothelial cell lining observed 
using TNF-α plus melphalan, 
 and takes a couple of days to 
ly enhance drug uptake more 
ith the in vivo findings of an 
s a decrease in the muscular 
at the Hi concentration used in 
rmeability of endothelial cells, 
ffect of Hi that occurs only for 
th the Hi concentration used in 
ular response, a supposition that 
acokinetics. Hi has a very short 
NF-α (21). Hi is metabolized 
nvolves ring methylation and is 
ich is w
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methyl imidazole acetic acid. Alternatively, Hi can undergo oxidative deamination, 
ly by the nonspecific enzyme diamine oxidase. The products are imidazole 
 open new possibilities of 
ere involved in Hi-induced tumor regression in our model. Each 
mal model, also results in erythema and 
catalyzed main
acetic acid and its riboside, which have little or no activity and are excreted in the urine 
(13). Although these data come from studies with lower dosages or endogenous Hi, the 
wide distribution of and fast action of the enzymes that metabolize Hi means that Hi is a 
potentially safer drug than TNF-α in case of leakage into the systemic circulation during 
ILP. Furthermore, these properties of Hi pharmacokinetics
application in, for example, isolated liver perfusion. More studies on the pharmacokinetics 
of higher doses and evaluation in the clinical setting are, however, essential for the clinical 
translation of Hi.  
Our findings support a tumor endothelial cell-specific targeting effect of Hi resulting in 
dramatic hemorrhage and destruction of the endothelial cell lining of tumor vessels 
(confirmed with CD-31 staining [data not shown]) in vivo. We hypothesize that the 
pronounced direct effect of Hi on the endothelial cell lining is fundamental for the better 
response than that achieved by melphalan alone in the ILP model discussed here.  
H1 and H2 receptors w
receptor inhibitor alone blocked the Hi effect in vivo. The two receptors are located in 
different cell types and have independent mechanisms of action: H1-R has a higher affinity, 
a rapid but short-lived effect, and is located in the endothelial cells; H2-R has a lower 
affinity, a slower but more sustained effect, and is located in the vascular smooth muscle 
cells.  
Toxicity would be unlikely to be a limiting factor for the use of Hi in ILP in humans 
because no systemic toxicity was observed, and the regional toxicity, affecting 33% of the 
rats receiving Hi either alone or combined with melphalan, was very mild and completely 
reversible after 2 days of recovery. Accordingly, ILP with TNF-α and melphalan in the 
clinical setting, as Hi plus melphalan did in the ani
edema, which sometimes slightly impairs motility (grades II and III of Wieberdink, 
respectively) in most of the patients (6,22).  
F-α, to be evaluated in the clinical setting. 
In conclusion, Hi combined with melphalan had a striking effect in the ILP for the 
treatment of soft-tissue sarcomas in rats. The mechanism of action involved both direct and 
indirect effects - cytotoxicity on the tumor and endothelial cells and tumor-associated 
vasculature with a twofold increase in the tumoral uptake of melphalan combined with a 
reduction in the uptake in the adjacent muscle. Therefore, Hi plus melphalan in ILP seems 
to be a promising alternative to TN
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Abstract 
istamine (Hi) combined to melphalan in isolated limb perfusion (ILP) resulted in overall 
response rates (OR , when 
mbined to melph  and Hi 
as been used on s used 
ur well-establishe c effect 
between the two d rates in 
loco-regional set . Histological evaluation was done directly ter ILP. 
elphalan uptake by tumor and muscle was measured. Hi and IL-2 ined to 
melphalan ILP led to OR of only 28%. Histology of tumors demonstrated partial loss of Hi-
duced haemorrhagic effect when IL-2 was present. Melphalan accumulation in the tumor 
  
ntroduction 
mas (2,3) and 
various other tumors in the clinical setting (4-6). The basis for the synergy being primarily 
significant enhancement of tumor-specific melphalan accumulation and secondarily the 
own in various limb and liver tumor models in our laboratory 
umber of 
asoactive drugs for similar potential effects (7-12). The inflammatory mediator histamine 
(Hi) was an almost obvious candidate due to its effects on fine vessels with the formation of 
dema and also the formation of gaps between endothelial cells (13). Indeed, it strongly 
ugmented tumor response in melphalan-based ILP with OR of 66% (14). Similarly we 
und that the cytokine IL-2, known to cause significant changes in vascular permeability 
nd the vascular leakage syndrome when administered at high concentrations (15-17), 
ramatically improved tumor response in melphalan-based ILP (18). 
terleukin-2 (IL-2) has been widely used in the systemic immunotherapy of solid tumors 
and leukemias (19) based on immunomodulatory effects which can be further enhanced by 
combining histamine (20).  
ased on this synergistic effects of IL-2 and Hi seen in the systemic setting we evaluated 
hether this could be also present in the loco-regional setting further improving the good 
tes observed with Hi or IL-2 alone in melphalan-based ILP. 
 
H
) of 66%. Likewise, Interleukin-2 (IL-2) resulte
alan in ILP. In systemic immunotherapy the com
olid tumors based on immunomodulatory effects
d ILP experimental rat model to evaluate whethe
ru s seen in the systemic setting, could further img
ting
d in OR of 67%
bination of IL-2
. In this study we 
r the synergisti
prove response 
and 24 hours af
 together, comb
co
h
o
a 
M
in
when both Hi and IL-2 were added (3.1 fold) was very similar to accumulation with Hi only 
(2.8 fold), or IL-2 only (3.5 fold) combined to melphalan. In vitro there was no synergy 
between the drugs. In conclusion, the positive synergistic effect between IL-2 and Hi is lost 
in the regional setting.
 
I
We have demonstrated that isolated limb perfusion with TNF and melphalan leads to 
excellent antitumor effects against melanoma (1), large soft tissue sarco
a 
complete destruction of tumor associated vasculature (2,7). The enhanced uptake of 
different cytotoxic agents sh
with the combination of TNF and melphalan, prompted us to investigate a n
v
e
a
fo
a
d
In
B
w
response ra
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Materials and Methods  
animals as previously described (7,9). Tumor growth was measured 
aily with a caliper and the volume was calculated using the formula 0.4(A2xB) (where B 
gest tumor diameter and A is the diameter perpendicular to B). When 
 the range of –25% to +25%; partial remission (PR) decrease 
lk and stand on the 
erfused limb was scored after ILP. On this scale grade 0 means a severe impaired function 
Animals and tumor cell line 
Male inbred Brown Norway (BN) rats were obtained from Harlan-CPB (Austerlitz, the 
Netherlands), weighing 250-300g. Animals were housed at the Central Animal Facility of 
the Erasmus MC Rotterdam and fed a standard laboratory diet ad libitum (Hope Farms 
Woerden, the Netherlands). 
The syngeneic spontaneous rapidly growing and metastasizing BN175 soft tissue sarcoma 
(21) was kept in liquid nitrogen and implanted on the dorsum of a BN rat for further growth 
before being inserted in the right hind limb of the experimental animals. 
All animal studies were done in accordance with protocols approved by the Animal Care 
Committee of the Erasmus University Rotterdam, the Netherlands. 
 
Isolated limb perfusion protocol 
Small fragments (3 mm) of the syngeneic BN175 sarcoma were inserted subcutaneously in 
the right hind leg of the 
d
represents the lar
tumor diameter exceeded 25 mm or at the end of the experiment rats were killed by cervical 
dislocation, under anesthesia. 
The treatment consisted of the experimental ILP, previously described (7,9). Briefly, 7-10 
days after inserting tumor fragments they reached a diameter between 12-15 mm and were 
amenable to the procedure. Under anesthesia (intraperitoneal ketamine and intramuscular 
hypnomidate), the inguinal vessels were reached through an incision parallel to the inguinal 
ligament, canulated and connected via a roller pump to an oxygenated reservoir where 
drugs were added in boluses. A groin tourniquet occluded collateral vessels, warranting a 
proper isolation of the limbs. 
Drugs, 40 µg melphalan (Alkeran Wellcome, Beckenham, United Kingdom), 50 µg IL-2 
(kindly provided by Chiron Amsterdam, the Netherlands) and/or 1000 µg of Hi (kindly 
provided by Maxim Pharmaceuticals Inc., San Diego, CA) were added to the reservoir 
containing 5 ml Haemaccel (Boehring Pharma, Amsterdam, the Netherlands). Between six 
and nine rats were included in each group. 
Tumor dimensions were measured every day and response was classified, according to the 
lowest value obtained, as progressive disease (PD) volume increase of more than 25%; no 
change (NC) volume kept in
between –25% and –90% or complete response (CR), tumor volume less than 10% of initial 
volume (22)  
Limb function was a clinical observation in which the rat’s ability to wa
p
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where the rat drags its hindlim  ab without ny function; grade 1 indicates a slightly impaired 
b is not used in a normal way but the rat stands on it when 
LP 
CD DXC camera. 
ight after ILP with either melphalan alone; melphalan plus Hi; melphalan plus IL-2 or 
were killed by cervical dislocation. Tumors and muscle 
ncubated at 37oC in 5% CO2 for 72 hours in the presence of 
 4oC and washed again. Cells were then stained 
 reduction in the absorbance, as compared to control (IC50), was determined 
function, meaning the hindlim
rising; finally grade 2 indicates an intact hindlimb function and normal walking and 
standing pattern is observed.  
 
Histologic evaluation after I
Two animals for each group were killed right after ILP, tumors were excised, fixed in 4% 
formaldehyde solution and embedded in paraffin before staining with hematoxylin and 
eosin. Images were taken on a Leica microscope supplied with a Sony 3C
 
In vivo melphalan uptake 
R
melphalan plus Hi and IL-2, rats 
were removed and quickly frozen in liquid nitrogen and stored at -80oC. Next, they were 
homogenized in 2 ml acetonitrile (PRO 200 homogenizer, Pro Scientific, CT, USA) and 
centrifuged before melphalan was measured by gas chromatography-mass spectrometry 
(GC-MS), as previously described (7,23). Between five and six rats were included in each 
group. 
 
Cytotoxicity assay 
BN175 tumor cells were first grown in RPMI-1640 medium (Life Technologies, the 
Netherlands) supplemented with 10% fetal calf serum and 0.1% penicillin-streptomycin 
(Life Technologies, the Netherlands).  
Cells were plated 24 hours before treatment in 96-wells, flat-bottomed, microtiter plates 
(Costar, Cambridge, MA, USA) at 105 cells per well (100µl) and allowed to grow as a 
monolayer. Next, they were i
medium alone or medium plus different concentrations of IL-2 and Hi. Hi ranged from 0 to 
200 µg/ml and IL-2 from 0 to 20 µg/ml. 
Growth of tumor cells was measured using the Sulphorhodamine-B (SRB) assay (24). In 
brief, cells were washed with phosphate buffered saline, incubated with 10% trichloric 
acetic acid for one hour at a temperature of
with SRB for about 15 to 30 minutes, washed with 1% acetic acid and allowed to dry. 
Protein-bound SRB was dissolved in TRIS (10mM, pH 9.4). Extinction was measured at 
540 nm and the percentage of growth inhibition was calculated according to the formula: 
percentage of tumor cell growth = (test well/control well) x 100%. The drug concentration 
leading to 50%
from the growth curve. The experiments were repeated four times. 
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Human umbilical vein endothelial cells (HUVEC) were prepared by collagenase treatment 
of freshly obtained human umbilical veins and cultured in Human endothelial SFM/RPMI 
medium (Biotechnologies, the Netherlands) supplemented with heat inactivated human 
serum (Biowhitaker, the Neth s
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Results  
erland ), new born calf serum, human EGF, human bFGF and 
0.1% pe cillin-streptomycin (Life Technologies, the Netherlands).  
fore treatment at 6x104 cells per well and cultured as 
ruskal-Wallis and Mann-Whitney U tests were used to evaluate statistical significance of 
sts were two-sided and P values less than 0.05 were considered 
 
 
 
 
Tumor res
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tumor grow
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ni
HUVEC were plated 24 hours be
described above. Growth inhibition and IC50 were determined as for the BN175.  
 
Statistical analysis 
K
the results. All statistical te
as statistical significant. Calculations were performed on a personal computer using Prism 
v3.0 software (GraphPad Software Inc.) and SPSS v10.0 for Windows 2000.  
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mFigure 1. Tumor response after isolated limb perfusions. Small fragments of BN175
soft tissue sarcomas were inserted in the right hind limb of brown Norway rats (see
Material and methods). When tumors reached 12-15 mm (7-10 days), rats were
randomly submitted to ILP with perfusate alone (sham); 8 µg/mL melphalan; 200
µg/mL Hi plus 50 µg/mL IL-2 plus 8 µg/mL melphalan; 50 µg/mL IL-2 plus 8 µg/mL
melphalan or 200 µg/mL Hi plus 8 µg/mL melphalan. Tumors were measured daily
with a caliper and volumes were calculated. Mean tumor volume are shown +/- SEM. ponse study 
usion and IL-2 alone perfusions did not inhibit tumor growth, whereas ILP with 
esulted in tumor growth stabilization in 50% of the rats. Melphalan ILP arrested 
th in 2 rats for at least 4 days. As expected from the previous studies, Hi plus 
 and IL-2 plus melphalan had both 66% OR.  
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ILP with the triple combination of IL-2, Hi and melphalan resulted in a tumor growth 
inhibition apparently slightly less pronounced as observed after ILP with IL-2 or Hi 
combined with melphalan. With the triple combination an OR of only 28% was obtained, 
accounting for 2 rats out of 7 with a PR. As for the other 5 rats there was 2 NC (29%) and 3 
PD (42%) (Figure 1, Table 1).  
No serious regional toxicity was observed in any of the treatments. There was only some 
edema associated with the use of Hi but without any implication on limb function. 
n BN175 soft tissue sarcoma-bearing rats after melphalan-based ILP in 
 
Table 1. Response i
combination with histamine and IL-2. 
Treatmenta CR (%)b PR (%) NC (%) PD (%) 
Sham (n=5) 
Melphalan (n=6) 
- 
- 
- 
17% 
- 
17% 
100% 
66
Hi+IL-2+Melphalan (n=7) 
-2+Melphalan (n=9) 
i+melphalan (n=6) 
- 
11% 
33% 
29% 
56% 
33% 
29% 
11% 
33% 
% 
42% 
22% 
- 
IL
H
a) Melphalan (40 µg), histamine (Hi, 1000 µg) and IL-2 (50 µg) were added as boluses to the perfusate (5 mL), b) 
sponses were scored as described in materials and methods. CR complete response, PR Partical response, NC no 
ange, and PD progressive disease. 
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in materials and methods section. (A) BN175 soft 
tissue sarcoma cells and (B) Human umbilical vein 
 
re
ch
A
 
 
 
Figure 2. In vitro cytotoxicity of H
according to percentage of tumor growt
on. Cells were incubated for 72h wi
concentrations of Hi plus IL-2 and cel
10 2
histamine(µg/ml)
endothelial cells. Each point represents an average of 
four independent experiments. Error bars show 
Standard Deviations. 
 10
1 10 2
0
25
histamine (µg/ml)
%
10 1
0
25
50
75
100
125 20µg/ml IL-2
10µg/ml IL-2
2.5µg/ml IL-2
0.31µg/ml IL-2
0µg/ml IL-2
100
125
17
5
N
-
%
 g
ro
w
th
 B
B
50
 g
ro
w
t
75
h 
H
U
VE
C
68 
Histamine plus IL-2 in melphalan-based ILP 
Figure 3. Histology of 
tumors after isolated limb 
were excised immedia-tely 
after and 24 hours after ILP 
perfusion (ILP). Tumors 
for each treatment and fixed 
solution and embedded in 
matoxylin-
eosin staining. Pictures illus-
tative example for each 
treatment, right after ILP. 
m (A halan 
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In vitro synergy between Hi and IL-2 
Searching for an explanation for the decrease in the response rates o
combined to Hi, we first used in vitro cytotoxicity assays.  
We knew from previous studies that IL-2 had no direct cytotoxic
HUVEC (18) whereas with Hi we observed an IC50 of respectively 
100 µg/ml (HUVEC) (14). We tested the hypothesis whether IL-2 c
effect of Hi on the cells. The addition of IL-2 was however inef
overlapping each other (Figure 2). 
 
Direct effects on tumor cells and tumor associated vasculature (TA
Next we evaluated tumor histology right after ILP, searching for di
previously seen. Observations right after ILP and 24 hours after w
striking loss in the haemorrhagic effect related to Hi. Although
extravasation of red blood cells, the diffuse pattern seen after Hi plus
Moreover, the massive destruction of the endothelial cell lining c
melphalan ILP is softened. The edema between tumor cells is also 
look less dilated than expected after a Hi ILP (Figure 3). 
 
Figure 4. Melphalan accumulation in tumor tissue 
during melphalan-based ILP. Tumors and muscle 
were excised right after ILP and quickly frozen in 
liquid nitrogen. Melphalan was measured by gas 
chromatography-mass spectrometry (GC-MS) as 
described material and methods. A) Values 
obtained in the tumor. * p=0.03 (Hi + melphalan as 
compared to melphalan); ** p=0.006 (IL-2 + 
melphalan as compared to melphalan). B) Ratio 
between tumor and muscle melphalan uptake. * 
p=0.02 (Hi + melphalan as compared to 
melphalan); ** p=0.01 (IL-2 + melphalan as 
compared to melphalan). 
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Indirect effect on TAV 
Finally we evaluated melphalan accumulation in tumor and muscle and compared these 
values to those previously reported for Hi and IL-2. Accumulation of melphalan after ILP 
e have shown in this study that the synergy between Hi and IL-2 seen in the systemic 
te, as compared to 
esides, we hypothesize that the mechanism of action of Hi in the regional setting is quite 
 of the immunological effect involved in the 
t action of Hi in the ILP: a direct cytotoxic effect 
tumor cells and an indirect effect on tumor 
e tumor (14). 
n when IL-2 is combined to ILP with Hi and 
y had no direct effect on endothelial cells nor on 
l cells. Still, IL-2 also increased melphalan 
ording to our findings, there was a very similar 
her or not IL-2 and Hi were combined. Based on 
ost in Hi-induced haemorrhage and vascular 
estruction would be responsible for the reduced OR (from 66% to only 28%), when IL-2 
was combined. 
In conclusion the association of Hi and IL-2 in the Melphalan-based ILP setting does not 
improve response, far the opposite, it diminishes response rates observed with either drug 
alone plus melphalan in the ILP.  
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with the triple combination of Hi, IL-2 and melphalan is very similar to the levels obtained 
after ILP with Hi or IL-2. An increase in melphalan accumulation in tumor of 3.1 fold Hi 
plus IL-2 against 2.8 fold for Hi and 3.5 fold with IL-2 (Figure 4). 
 
Discussion 
W
treatment is lost in the regional setting, with a 30% decrease in OR ra
each drug alone plus melphalan. 
A possible explanation might be the dose used in the regional setting, which is in the order 
of 6 to 8 times higher than those reported for the systemic treatment (14,25), or the much 
shorter exposure time in the ILP. In this different pharmacokinetic scenario the combination 
of two inflammatory agents could lead to a down regulation of their action and 
consequently to the lost in efficacy. A similar effect was previously reported with the 
combination of histamine and TNF-α (26,27).  
B
different from the systemic one. Instead
systemic setting effect, we propose a triple
on TAV, a direct cytotoxic effect on 
vasculature, increasing drug accumulation in th
The reduction on haemorrhagic effect see
melphalan is surprising, as IL-2 apparentl
the activity of Hi towards endothelia
accumulation in the tumor after ILP. Acc
melphalan accumulation in the tumor, whet
these findings, we speculate that the l
d
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Abstract 
ddition of high-dose TNF to melphalan-based isolated limb perfusion (ILP) enhances 
anti-tumor effects i te. Here 
e investigate the ondary 
munological eve s. 
lready during IL six-fold 
enhanced drug upt ly after 
erfusion with TN us melphalan a slight increase in vascular hrocyte 
travasation and necrosis were detected. Strikingly, interstitial fluid and pH 
in the tumor were not altered by TNF. No clear immune effects, cellular infiltration and 
tokine expression were observed, although we identified PMNs as key effector cells in 
se related to TNF to be detected. Importantly, 
is not due to an altered IFP, but most likely 
sults from an increased permeability of the tumor vasculature. 
Isolated limb perfusion (ILP) with tumor necrosis factor-α (TNF) and melphalan is 
 therapies available for the treatment of patients with advanced bulky 
elanoma and sarcoma of the limbs. Addition of high-dose TNF to the melphalan-based 
of tumors (reviewed in (1)). Angiographic studies revealed that 1 or 2 weeks after ILP all 
tumor-associated vessels had disappeared, indicating that TNF only targets tumor 
after ILP 
e have shown that the effects of TNF in a melphalan-based ILP starts with intratumoral 
ndothelial cell activation followed by over-expression of adhesion molecules, which in 
rn leads to polymorphonuclear leukocyte (PMN) homing, endothelium injury and finally 
oagulative and haemorrhagic necrosis (3,4). Ruegg et al. demonstrated that TNF in 
ombination with interferon-γ (IFN) induced downregulation of αvβ3 resulting in 
detachment and subsequent apoptosis of endothelial cells after ILP (5). Yet, ILP with TNF 
lone does not cause tumor regression without the combination with a chemotherapeutic 
gent (6). 
e developed TNF-based isolated limb perfusion models in rats, with similar results 
ompared to the clinical setting, to gain further insight in the mechanisms underlying the 
ynergy. Directly after perfusion with TNF and melphalan or doxorubicin 
softening of the tumor tissue and significantly enhanced drug uptake were observed (7,8). 
A
mpressively. The mechanism of action of TNF is 
 effects of TNF on the tumor microenvironm
nts during and shortly after ILP in soft-tissue sarc
P softening of the tumor was observed. At the en
e of melphalan in the tumor could be demoak
F pl
still under deba
ent and on sec
oma-bearing rat
d of the ILP a 
nstrated. Direct
destruction, eryt
 pressure (IFP) 
w
im
A
p
ex
cy
TNF-mediated permeability of the endothelial lining. 
Taken together, these results indicate that the TNF-induced augmentation of drug 
accumulation is the key explanation for the observed synergistic anti-tumor response, 
whereas it is too early for an immune respon
he augmented accumulation of melphalan t
re
 
Introduction 
currently one of the
m
ILP results in impressive enhancement of the response rates of over 80% in a great variety 
vasculature and not normal vessels (2). At the histopathological level at 3 hours 
w
e
tu
c
c
a
a
W
c
observed s
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Changes in tumor pathophysiology during TNF-ILP 
Subsequent events were haemorrhagic necrosis, edema, extravasation of erythrocytes, 
et A 
. The complexity of the interaction of 
aterials and methods 
or model 
harmaceutica, Tilburg, the Netherlands). The femoral artery and vein were 
infiltration of polymorphonuclear neutrophils and destruction of tumor vasculature (7,9). 
Inadequate blood supply in necrotic areas will result in hypoxic and acidic tumor regions 
and acidic products will accumulate (10,11). Although others showed direct cytotoxic 
effects of TNF on several different cell lines in vitro (12,13) and tumors in vivo, like M
sarcoma, B16BL6 melanoma and Lewis lung carcinoma (13-15), we observed in our tumor 
models that TNF alone had no anti-tumor activity (12-15). Besides a direct cytotoxic effect 
of TNF, a reduction in the interstitial fluid pressure (IFP), as shown by others, could lead to 
enhanced uptake of large molecules (16).  
It is also known that TNF induces the production of other cytokines (e.g. IL-1, IL-6 and IL-
8) as well as cytotoxic factors (e.g. nitric oxide) by T lymphocytes, granulocytes and 
macrophages, which could mediate tumor suppression
TNF with various immune modulators within the tumor microenvironment is yet not well 
defined (17-19).  
Here we focus on early effects inflicted by TNF during and shortly after ILP, which could 
explain the improved tumor response when used in a melphalan-based ILP. 
 
M
Animals and tum
Male inbred Brown Norway rats, obtained from Harlan-CPB (Austerlitz, the Netherlands), 
were used. Small fragments (3 mm) of the syngeneic BN175 soft tissue sarcoma were 
implanted subcutaneously in the right hind leg just above the ankle as previously described 
(7,8). Tumor growth was recorded daily by caliper measurement and tumor volume was 
calculated using the formula 0.4(A2xB) (where B represents the largest diameter and A the 
diameter perpendicular to B). Rats were sacrificed if tumor diameter exceeded 25 mm or at 
the end of the experiments. All animal studies were done in accordance with protocols 
approved by the committee on Animal Research of the Erasmus MC, Rotterdam, the 
Netherlands. 
 
Isolated limb perfusion 
The perfusion technique was performed as described previously in detail (7,8). Briefly, 
perfusions were performed at a tumor diameter of 12-15 mm at least 7 days after 
implantation. During perfusion animals were anaesthetized with Hypnorm and Ketamine 
(Janssen P
cannulated and connected to an extracorporal circuit including an oxygenation reservoir and 
a low-flow roller pump. Drugs, 50 µg TNF (Boehringer Ingelheim GmbH, Austria) and/or 
40 µg melphalan (Alkeran, 50 mg per vial, Wellcom, Beckenham, UK), were added as 
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bolus to the reservoir. A washout was performed at the end of the perfusion. During ILP 
and washout, the hind leg was kept at a constant temperature of 38-39°C.  
The classification of tumor response was: progressive disease (PD) = increase of tumor 
volume (>25%); no change (NC) = tumor volume equal to volume during perfusion (in a 
range of -25% and + 25%); partial remission (PR) = decrease of tumor volume (-25% and -
90%); complete remission (CR) = tumor volume less than 10% of initial volume. 
 
Interstitial fluid pressure (IFP) 
IFP was measured in tumor and muscle during ILP with the Wick-in-Needle technique 
nnulating the femoral artery and vein, but before applying the tourniquet, 
umor during ILP a pH electrode in 20 Gauge Needle (Harvard 
 in paraffin. 4 µm sections were stained with haematoxylin and eosin using 
tandard procedures. Three or four different tumors in each experimental group were 
tion. At least 6 slides were examined from each tumor. All slides 
the endothelium and of tumor cells.  
(20). A 23-gauge needle (Venisystems, Abbott Ireland LTD) with a 2-3 mm side hole 5 mm 
from the tip was filled with five surgical sutures 6/0 (Braun Medical B.V., Oss) and 
connected to a pressure transducer (DTXTM Plus Transducer, Becton Dickinson, Alphen 
aan den Rijn, the Netherlands). Pressure was recorded on an analog-digital converter (AS/3 
DATEX). After ca
the needle was inserted in the tumor and in the muscle of the same leg. The IFP was 
recorded until the end of the perfusion. 
 
pH measurements 
To measure the pH of the t
Apparatus, Inc, Holliston, MA, USA) was used. The calibrated pH electrode was inserted in 
the tumor just before the roller pomp was started and the pH was measured throughout the 
perfusion. At the mean time the pH of the perfusate was measured (pH meter HI 8424, 
Hanna Instruments, Inc, Ann Arbor, USA).  
 
HE staining 
Directly or 6 hours after perfusion tumors were excised cut in two equal parts. Both parts 
were divided into a peripheral part and a central part. The tissues were stored in formalin 
and embedded
s
subjected to blind evalua
were examined on a Leica DM-RXA and photographed using a Sony 3CCD DXC 950 
camera. 
 
Apoptosis assay: TUNEL/CD31PE double staining 
Apoptotic cell death was detected using the technique of 3'hydroxy end labeling (In Situ 
Cell Death detection Kit, Fluorescein labelled, Roche, Almere, the Netherlands). Tumor 
tissues were also stained for endothelial cells (CD31) to differentiate between apoptosis of 
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After ILP the tumors were excised and immediately frozen in liquid nitrogen. Stainings 
were performed on acetone-fixed 7 µm cryostat sections. The tumor sections were fixed in 
 to allow 
ermeabilization. The slides were incubated with the TUNEL mixture for 60 min at 37°C 
ed three times in PBS and counterstained with 300 µg/ml 
d at -80°C. Tumor and muscle tissues were 
omogenized in 2 ml acetonitrile (Pro 200 homogenizer, Pro Scientific, CT, USA) and 
elphalan was measured in the supernatant by gas chromatography-
umn and measured selectively by single-ion 
onitoring GC-MS in the positive EI mode described earlier by Tjaden and de Bruijn (21). 
n, Alphen aan den Rijn, the Netherlands) and -macrophages (ED-1) (Serotec, 
reda, the Netherlands). Thereafter, sections were washed with PBS and incubated for 1 h 
100, DAKO, ITK Diagnostics BV, 
4% paraformaldehyde for 30 minutes and incubated for 1 hour with mouse-anti-rat 
CD31PE (1:50, Becton Dickinson, Alphen aan den Rijn, the Netherlands). After washing 
with PBS the sections were again fixed in 4% paraformaldehyde for 10 minutes and 
incubated in 0.1% Triton X-100 in 0.1% sodium citrate for 2 minutes on ice
p
and after that the slides were rins
Hoechst (Molecular Probes, Leiden, the Netherlands) for 10 min. After washing with PBS 
the slides were mounted with mounting medium containing polyvinyl alcohol (Mowiol 4-
88, Fluka, Zwijndrecht, the Netherlands).  
 
Measurement of melphalan in tissue 
At the end of the perfusion directly after the washout the tumor and part of the hind limb 
muscle were excised. The tissues were immediately frozen in liquid nitrogen to stop 
metabolism of melphalan and store
h
centrifuged at 2500 g. M
mass spectrometry (GC-MS). p-[Bis(2-chloroethyl)amino]-phenyl-acetic methyl ester was 
used as an internal standard. Samples were extracted over trifunctional C18 silica columns. 
After elution with methanol and evaporation, the compounds were derived with 
trifluoroacetic anhydride and diazomethane in ether. The stable derivates were separated on 
a methyl phenyl siloxane GC capillary col
m
 
Immunohistochemistry 
Directly or 6 hours after ILP immunohistochemical studies were performed on acetone-
fixed 7 µm cryostat sections. The tumor sections were fixed for 30 min with 4% 
formaldehyde and after rinsing with PBS, the endogenous peroxidase activity was blocked 
by incubation for 5 minutes in methanol/3% H2O2. The slides were incubated for 1 hour 
with 1:50 mouse-anti-rat-CD31, -CD4, -CD8, -granulocytes (clone HIS48) (Becton 
Dickinso
B
with goat-anti-mouse peroxidase-labeled antibody (1:
Uithoorn, the Netherlands). After rinsing with PBS, positive cells were revealed by 
immunoperoxidase reaction with DAB solution (DAKO, ITK Diagnostics BV, Uithoorn, 
the Netherlands) and counterstained lightly with haematoxylin (Sigma, Zwijndrecht, the 
Netherlands).  
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For quantification of ED-1, CD4, CD8 and granulocyte infiltration and microvessel density 
two independent persons performed blinded analysis. Six representative fields 
(magnification 16x) in each slide and three tumors per treatment were evaluated. The 
sections were examined on a Leica DM-RXA and photographed using a Sony DXC950 
camera. For macrophage, T cell and granulocyte infiltration the total amount of positive 
cells were counted per field of interest. For the microvessel quantification, the number of 
tumor blood vessels and the area of vessels per field of interest were measured in calibrated 
digital images (Research Assistant 3.0, RVC, Hilversum, the Netherlands).  
 
RT-PCR 
Total RNA was extracted from frozen tumor tissue using TRIzol reagent (Invitrogen, 
reda, the Netherlands). BN175 cells in vitro were treated with medium, 10 µg/ml TNF, 8 
lan and after 30 min of incubation total RNA was 
in followed by a maximum of 40 cycles of 94˚C for 45 sec, annealing for 45 sec 
 and extension 72˚C for 1 min and a final extension step at 72˚C 
B
µg/ml melphalan or TNF plus melpha
extracted. Total RNA was quantified by spectrophotometric analysis and quality of the 
RNA isolates was assured by electrophoresis in agarose gel. 
A volume of 20 µl containing 1.0 µg of total RNA of each sample was used for generation 
of cDNA with Omniscript Reverse Transcriptase (Qiagen, Leusden, the Netherlands) and 
oligo d(T)16 (Invitrogen, Breda, the Netherlands). After incubation at 42˚C for 1 hour, the 
samples were heated for 5 min at 93˚C to terminate the reaction. Titanium Taq DNA 
polymerase (Becton Dickinson, Alphen aan den Rijn, the Netherlands) was used for the 
PCRs and 1.5 µl of cDNA per 37.5 µl of reaction mixture was used. The primers were 
purchased from Invitrogen (Breda, the Netherlands) and primer sequences are shown in 
table 1. β-actin was used as an internal standard. PCRs were performed at a Biometra T-
gradient PCR machine using the following parameters: initial denaturation at 94˚C for 5 
m
(temperatures see Table 1)
for 7 min. The resulting DNA fragments were electrophoretically separated on a 1.5% 
agarose gel, stained with ethidium bromide and photographed under UV light. A 100-bp 
ladder was used as the standard. 
  
Semi-quantitative RT-PCR 
Total RNA isolation, cDNA preparation and RT-PCR were performed as described above 
(see RT-PCR). Semi-quantification of cytokine expression was carried out as followed, 
every 2 cycles, 5 µl of PCR product was collected and the samples were electrophoretically 
separated on a 1.5% agarose gel, stained with ethidium bromide and photographed under 
UV light. The threshold cycle was determined as the cycle where the visible band of a 
specific PCR product first appeared on the gel. Intensities of the PCR product bands were 
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determined by ImageJ v1.34 software (W. Rasband, Research Services Branch, National 
Institute of Mental Health, Bethesda, Maryland, USA) and normalized for β-actin. 
 
Table 1. RT-PCR primers for the immune related genes and for β-actin, which was used as 
a housekeeping gene. 
Gene Primers Annealings 
temperature 
Product  
size (bp) 
β-actin f: 5’-ATGGATGACGATATCGCTG-3’ 60ºC 
r: 5’-ATGAGGTAGTCTGTCAGGT-3’ 
569 
IL-6 f: 5’-GACTTCACAGAGGATACC-3’ 55ºC 294 
r: 5’-TAAGTTGTTCTTCACAAACTCC-3’ 
GRO/ 
CINC-A  
f: 5’-GAAGATAGATTGCACCGATG-3’ 
r: 5’-CATAGCCTCTCACACATTTC-3’ 
57ºC 367 
IL-10 f: 5’-TGACAATAACTGCACCCACTT-3’ 
r: 5’-TCATTCATGGCCTTGTAGACA-3’ 
60ºC 402 
IL-12 f: 5’-TCATCAGGGACATCATCAAACC-3’ 
r: 5’-CGAGGAACGCACCTTTCTG-3’ 
65ºC 210 
TNF-α f: 5’-TACTGAACTTCGGGGTGATCGGTCC-3’ 
r: 5’-CAGCCTTGTCCCTTGAAGAGAACC-3’ 
60ºC 295 
IFN-γ f: 5’-GCCTCCTCTTGGATATCTGG-3’ 
r: 5’-GTGCTGGATCTGTGGGTTG-3’ 
60ºC 239 
MCP-1 f: 5’-ATGCAGGTCTCTCTGTCACG-3’ 
r: 5’-CTAGTTCTCTGTCATACT-3’ 
57ºC 446 
MIP-2 f: 5’-GGCACAATCGGTACGATCCAG-3’ 
r: 5’-ACCCTGCCAAGGGTTGACTTC-3’ 
55ºC 287 
TGF-β1 f: 5’-TGGAAGTGGATCCACGAGCCCAAG-3’ 
r: 5’-GCAGGAGCGCACGATCATGTTGGAC-3’ 
55ºC 240 
f: forward primer, r: reverse primer 
 
Cell culture 
75 soft tissue sarcoma were maintained in culture in RPMI Cells isolated from the BN1
1640 supplemented with 10% fetal calf serum and 0.1% penicilline-streptomycine (all 
Cambrex, Verviers, Belgium). Human Umbilical Vein Endothelial Cells (HUVEC) were 
isolated from normal human umbilical cords by the method of Jaffe et al. (22). Cells were 
cultured in fibronectin coated tissue culture flasks containing Human Endothelial-serum 
free medium (GIBCO-BRL, Invitrogen, Breda, the Netherlands), with 20% heat inactivated 
newborn calf serum, 10% heat inactivated human serum (Cambrex, Verviers, Belgium), 20 
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ng/ml human recombinant Basic Fibroblast Growth Factor (Peprotech EC Ltd, London, 
United Kingdom) and 100 ng/ml human recombinant Epidermal Growth Factor (Peprotech 
C Ltd, London, United Kingdom). Passages 5-7 were used for the experiments. 
rphonuclear leukocytes (PMN) 
V bloo ealthy adult volunteers was collected in N b  
Dickinson, Alphen aan den Rijn, the Netherlands). After centrifu , 
r pe s collected maining blood 
cells were ly  mM Hepes, pH = 7.0) for 30 min at 
r mpe 00 rpm, room erature) pellet 
was resuspe TA, 20 mM Hepes, pH = 7.4) in 
a ub ntially ad  the bot f the 
t f 1.095 g/ml Optiprep. The tube was 
t rifu e. The t 4 ml, ning 
PMN was re ifuged at 1500 rpm for 5 min. The 
P re d  of 120 ells/ml. 
 
HUVEC per
To study the meability, a transwell device 
( a per chamb h a pol onate 
membrane ( laced inside a 24-well plate (lower 
c w nectin co per cha , at a 
density of 1. t 1 ml of HUVEC medium was added. 
T s a d and t dium was replaced 
with 250 µl l melphalan and/or PMN together 
w  F ed e low ber 
was replaced and 90 min, 50 µl medium 
of the lower chamber was taken and fluorescence activity was measured under excitation at 
. A standard curve was prepared with known concentrations 
 or fluorescein. Induction of permeability was indicated by a higher 
and the medium was replaced with 250 µl of 0.1, 1 or 10 µg/ml TNF. After incubation for 
E
 
Preparation of polymo
enous d from h a-heparin tu es (Becton
ging for 20 min (1500 g
oom tem rature), total white blood cell fraction wa  and re  red 
sed with lysis buffer (0.15 M NH4Cl, 10
oom te rature. After centrifuging for 30 min (15  temp , the 
nded in 4 ml diluent (0.15 M NaCl, 10 mM ED
 15 ml t e. A density gradient was created by seque ding to tom o
ube 4 ml of Optiprep at 1.077 g/ml followed by 4 ml o
hen cent ged at 800 g for 20 min at room temperatur layer a  contai
moved and washed in diluent and then centr
MN we issolved in HUVEC medium at a concentration .104 c
meability assays 
 effect of TNF on transendothelial monolayer per
Costar, C mbridge, MA, USA) consisting of an up er wit ycarb
6.5 mm diameter, 0.4 µm pore size), p
hamber) as used. HUVEC were plated on the fibro ated up mber
2x104 cells. In the lower compartmen
wo day fter seeding, non-adhering cells were remove he me
 medium containing 10 µg/ml TNF, 8 µg/m
ith 50 µl ITC-BSA or fluorescein (1 mg/ml, Sigma). The m ium in th er cham
 with 700 µl of HUVEC medium. At 5, 15, 30, 60 
490 nm and emission at 530 nm
of FITC-BSA
concentration of FITC-BSA or fluorescein in the lower chamber of the transwell, relative to 
untreated controls. 
 
Nitrite measurement 
Nitrite concentrations were measured using the Griess reaction. Cells were trypsinized and 
seeded on fibronectin-coated 24 well plates (HUVEC, 3.6x104 cells/well) or on non-coated 
plates (BN175, 6x104 cells/well). 24 hours after seeding, non-adhering cells were removed 
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72 hours, culture supernatant was collected and spun down to remove cell debris. 50 µl of 
supernatant was incubated with equal volumes of 1% (w/v) sulfanilamide in 5% phosporic 
acid and 0.1% (w/v) N-1-napthylethylene-diamine dihydrochloride. After 10 min of 
cubation at room temperature, absorbance of the chromophore so-formed was measured 
oncentrations were calculated by 
d black 96 
ell plates with clear bottom (Costar, Cambridge, MA, USA). One day after seeding 
l concentration of 10 µM and incubated for 60 min at 37ºC. 
h melphalan results in strong tumor response, which is caused by 
ugmented drug accumulation. 
in
at 545 nm using a microtiter plate reader. Nitrite c
comparison with a standard calibration curve with sodium nitrite (NaNO2: 1.25 – 20 µM). 
 
Measurement of ROS production by dichlorofluorescin fluorescence 
Reactive oxygen species (ROS) generation in cells was assessed using the probe 2,7-
dichlorofluorescein diacetate (DCFF-DA, 10 µM; Molecular Probes, Leiden, the 
Netherlands). Within the cell esterases cleave the acetate group, thereby trapping the 
nonfluorescent DCFH probe intracellularly. Subsequent oxidation by ROS, particularly 
H2O2 or the hydroxyl radical (OH·), yields the fluorescent product dichlorofluorescin 
(DCF). DCF fluorescence was measured with excitation wavelength of 490 nm and 
emission at 530 nm using a microtiter plate reader. 
HUVECs were trypsinised and 6x103 cells/well were seeded on fibronectin-coate
w
DCFH-DA was added at a fina
The cells were washed once with medium without FCS and then incubated with 0, 0.1, 1 or 
10 µg/ml TNF with or without PMN (6x104 cells/well) for 30 min. Also ROS production by 
PMN alone was measured. PMN (120.104 cells/ml) were incubated with 10 µM DCFH-DA 
for 60 min at 37ºC. The cells were washed once with medium without FCS, plated on black 
96 well plates with clear bottom (6x104 cells/well), incubated with 0, 0.1, 1 or 10 µg/ml 
TNF for 30 min and DCF fluorescence measured.  
 
Statistical analysis 
Results were evaluated for statistical significance with the Mann Whitney U test. P-values 
below 0.05 were considered statistically significant. Calculations were performed on a 
personal computer using GraphPad Prism v3.0 and SPSS v11.0 for Windows 2000. 
 
Results 
TNF based ILP wit
a
 
In vivo response to melphalan and TNF 
Typically, the combination of TNF and melphalan resulted in increased anti-tumor activity 
with a response rate of 75% (PR and CR) (p<0.001 compared with melphalan alone) (Table 
2). Progressive disease was found in all animals treated with buffer or TNF alone. Although 
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ILP with melphalan alone resulted in a slight inhibition of the tumor growth when 
compared with the sham control, none of the rats showed a tumor response. In tumors 
treated with TNF and melphalan softening of tumor tissue was observed.  
 
Table 2. Tumor response and drug accumulation after TNF-based ILP with melphalan 
Response ratesb Melphalan  
(ng/g tissue)d 
Treatment Tumor volume  
at day 8 (mm3)a 
 PDc NC PR CR 
Sham > 5000 100%    - 
TNF 4570 ± 511 100%    - 
Mel 1918 ± 293 38% 38% 23% - 136 ± 24 
TNF + mel 491 ± 245 19% 6% 44% 31%* 831 ± 293** 
a average ± SEM, b responses were scored as described in Materials and Methods, c PD: progressive disease,  
NC: no change, PR: partial remission, CR: complete remission, RR: response rate (PR plus CR), d average ± SD,  
* p < 0.001 compared to melphalan alone, ** p = 0.01 compared to melphalan alone 
to be mostly intact. Treatment with 
elphalan caused a mild increase in oedema. No clear differences were seen between 
al part of the tumors and comparable results were seen 6 hours after 
reased 
umber of apoptotic endothelial cells were detected directly after ILP. No differences were 
n 0 and 6 hours after perfusion (data not shown). 
portantly, a six-fold increased melphalan uptake in tumor tissue directly after ILP with 
mparison with perfusions with melphalan alone 
 
 
Histological analysis 
Previously we demonstrated TNF-induced vascular damage days after ILP, although TNF 
alone had no effect on tumor progression (4). Directly after perfusion with TNF plus 
melphalan a slight increase in the number and size of necrotic areas was observed 
accompanied by scattered extravasation of erythrocytes (Figure 1). Tumors showed a few 
areas with complete destruction of the vasculature, something that was not seen in other 
treatments. Extravasation of erythrocytes was also seen in TNF-treated animals, but to a 
smaller extent and endothelial linings seemed 
m
central and peripher
ILP, except that after 6 hours slightly more necrotic areas were detected (data not shown). 
In all four treatments apoptotic tumor cells were observed and sporadically apoptotic 
endothelial cells (Figure 2). In the TNF and TNF plus melphalan treated rats an inc
n
seen betwee
 
Melphalan uptake in tumor and muscle tissue 
Im
TNF and melphalan was observed in co
(p=0.01) (Table 2). In contrast in the normal tissues skin and muscle no effect of TNF is 
found on the uptake of melphalan (data not shown). 
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Figure 1. Paraffin sections of BN175 tumor tissue directly after isolated limb perfusion, haema-toxylin-eosin 
stained. (A and B) Intact blood vessel lining in periphery of sham-treated tumor. (C and D) ILP with 50 µg TNF, 
central part of tumor. Arrowheads: extravazated erythrocytes. (E and F) Central part of tumor treated with 40 µg of 
melphalan. (G and H) Periphery of TNF plus melphalan-treated tumor. Arrow-head: extravasated erythro-cytes, 
rows: necrotic area. Original magnification 16X (A,C,E,G) and 40X (B,D,F,H). ar
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Figure 2. Double staining with CD31PE and TUNEL. Photographs demonstrating apoptotic tumor cells (green), 
on of BN175 tumor biopsies collected 
magnification 40X. 
firmed in vitro. Incubation of 
eability to fluorescein in 15 
an or PMN resulted in an 
lphalan and PMN increased 
nal effect. TNF however, did 
inutes nor in 24 h perfusion 
 
Figure 3. Effect of TNF, melphalan 
and PMNs on HUVEC monolayer 
permeability. HUVECs were cul-
tured on the filter of a transwell unit 
for 48 hours before the addition of 
fluorescein-containing medium 
(=control) with 10 µg/ml TNF, 8 
µg/ml melphalan (mel) and/or 
120.104 cells/ml PMN (see Material 
and Methods). The amount of 
fluorescein in the lower compart-
ment was measured after 15 min of 
endothelial cells (red) and apoptotic endothelial cells (yellow). Frozen secti
directly after isolated limb perfusion with melphalan (A) or TNF (B). Original 
 
Vascular permeability in vitro 
The observed increased drug accumulation in vivo was con
HUVEC with 10 µg/ml TNF resulted in an increased perm
minutes (Figure 3). Also incubation with 8 µg/ml melphal
increased permeability. TNF in combination with me
permeability 4.7-fold. Longer incubation times had no additio
not increase monolayer permeability to FITC-BSA in 30 m
timeframe. 
600
700
incubation. Values are from two 
experiments, each done in duplicate. 
The mean is shown ± SD. 
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In another experiment we showed that IFN-γ influences HUVEC permeability for proteins. 
We found a 4.1-fold increased permeability for FITC-BSA after 15 minutes of incubation 
with 10 µg/ml TNF, 0.1 µg/ml IFN-γ and PMN (data not shown). 
 
IFP measurements in tumor and muscle tissue 
As TNF was shown to reduce IFP in tumor tissue (16), IFP measurements were performed 
in both tumor and muscle tissue to investigate if in our experimental setting TNF-induced 
lowering of the IFP could be an explanation for the enhanced drug accumulation and 
softening of the tumor. Under normal conditions the IFP of tumor tissue is much higher 
than of muscle tissue (11 ± 5 and –5 ± 8 mm Hg, respectively) (p<0.0001) (Figure 4). 
Tightening of the tourniquet resulted in a 2.4-fold increased IFP in tumor tissue with an 
r 
 
se was only 
een in the melphalan treated group after 20 and 30 min (14 ± 5 and 20 ± 4 mm Hg, 
A). 
 
average of 26 ± 11 mm Hg (p<0.0001) and start of the perfusion pump did not furthe
increase the IFP. None of the treatments had an effect on the IFP. Also IFP in muscle tissue
increased after tightening of the tourniquet (1 ± 9 mm Hg), and further increa
s
respectively) (p=0.02) (Figure 4
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We speculated that pressure inflicted by the pump in the extracorporal circuit might have a 
major impact on the IFP. Indeed, when we increased the pump rate, tumor IFP increased 
and decreased again when the pump rate was reduced (data not shown). The effect of the 
ump rate on the IFP was confirmed in de clinical setting in which comparable results were 
halan on the IFP was seen throughout the 
e beginning of the perfusion was slightly acidic (6.9 ± 
.1). At the end of the ILP the pH in the tumor was somewhat lower (6.6 ± 0.3) and stayed 
at the same level till after the washout. None of the treatments had an effect on the
lar functionality 
lphalan might be correlated with the functiona ty of the tumor-
antification of the microvessel density and ctionality was 
emical staining of endothelial cells. The num er of vessels as 
d. The area per vessel was computed by dividing the total 
ber of vessels. There were no differences found between the 
perfusions (Table 3). T  endothelium in center and/or 
 decreased six hours after ILP compared to the area measured 
 sham, TNF or melphalan. In the central part of the tumor of the 
 decrease in area endothelium per vessels was measured.  
ecies production in vitro 
HUVEC produced NO above the detection l it of 1 µM, a 1.3-
ion was found in HUVEC exposed to 0.1 µg/ml TNF compared 
ely 2 and 3.2 µM NO). Treatment with 10 µg/ml TNF resulted 
in a reduction of the NO pro uction (2.2 µM). Exposure of BN175 to TNF (0.1 µg/ml) 
sulted in a 1.7-fold increased NO production (4.0 µM), whereas exposure to 10 µg/ml 
TNF resulted in the same production as untreated cells (6.8 µM). 
p
obtained (figure 4B). No effect of TNF or melp
ILP (data not shown). 
 
pH measurements in tumor and perfusate 
It is thought that TNF causes damage to the tumor vasculature inducing hypoxia in tumor 
regions with inadequate blood supply (4,11). In our experiments we tested the hypothesis 
whether treatment with TNF could cause a lower pH in tumor tissue because of early 
effects on the tumor vasculature. 
The pH of Haemaccel is 6.9 and oxygenation lowered the pH to 6.2. Directly after start of 
the perfusion the pH increased to 6.5 ± 0.3. Different treatments did not have an effect on 
the pH of the perfusate and the pH at the end of the perfusion was 6.9 ± 0.1 for all four 
treatments. The pH of the tumor at th
0
 pH of 
the tumor. 
 
Assessment of tumor vascu
The increased uptake of me
associated vasculature. Qu
performed by immunohistoch
well as vessel area was measure
area of vessels by the num
treatments and the sham 
periphery was significantly
directly after perfusion with
sham and TNF treated tumors
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Only after 72 h incubation 
fold increased NO product
to untreated cells (respectiv
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fun
b
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Table 3. Microvessel density and area of the tumor vessels after isolated perfusion with 
sham, TNF, melphalan or TNF plus melphalan.  
 sham TNF            melphalan     TNF + 
melphalan 
number of vesselsa 
    center 0 hours 
      
    periphery 0 hours 
19 ± 6 
43 ±12 
21 ± 7 
32 ± 9  
4 ± 13 
22 ± 2 
34 ± 6  
32 ± 14 
34 ± 25  
19 ± 5 
18 ± 7     center 6 hours 46 ± 31 3
    periphery 6 hours 36 ± 15 29 ± 5 38 ± 26 25 ± 6 
area endotheliumb 
    center 0 hours 
    periphery 0 hours 
  
7.6 ± 0.7 
7.6 ±0.3 
  
10.7 ± 2.7 
  
5.9 ± 0.9 
  
5.7 ± 1.0 
    center 6 hours 
    periphery 6 hours  
4.0 ± 1.1* 
3.8 ± 0.5* 
4.0 ± 0.7* 
3.5 ± 0.4* 
6.1 ± 1.4 
3.9 ± 1.5* 
7.2 ± 2.4  
3.6 ± 0.5 
area endothelium/vesselc 
    center 0 hours 
    periphery 0 hours 
    center 6 hours 
    periphery 
  
0.44 ± 0.09 
0.22 ± 0.08  
0.16 ± 0.05* 
  
0.59 ± 0.25 
0.28 ± 0.10 
0.14 ± 0.0* 
  
0.27 ± 0.03 
0.23 ± 0.03 
0.22 ± 0.03 
  
0.41 ± 0.17 
0.30 ± 0.08 
0.48 ± 0.16 
7.2 ± 0.4 7.2 ± 0.1 5.0 ± 1.1 
6 hours  0.14 ± 0.04 0.13 ± 0.02  0.18 ± 0.08  0.18 ± 0.07  
Note: directly after ILP or 6 hours later the tumors were excised and frozen sections were stained for CD31 
 quantified. Average ± SEM are shown. 
compared with 0 hours and the same tumor region 
er 
hange the ROS production. Incubation of TNF and PMN did not have any effect on the 
positive cells. 6 fields of interest per tumor and 3 animals per group were
a number of vessels per field of interest, b % of total vessel area per field of interest, c area per vessel, * p=0.05 
 
Oxygen radicals are released by various cell types in response to stimulation with factors 
such as TNF and can cause DNA and membrane damage (23,24). Incubation of HUVEC 
with 0.1 µg/ml TNF for 30 min resulted in a 1.9-fold increased ROS production compared 
to medium alone, although this increase was not significant. On the other hand, incubation 
with the highest concentration of 10 µg/ml TNF did not change the ROS production 
compared to the control. Addition of PMN to the HUVEC monolayer caused an enhanced 
ROS production of 1.6 fold (not significant) and co-incubation with TNF did not furth
c
ROS generation by PMN. 
 
Secondary immunological effect of TNF 
Tumor infiltration of leukocytes and macrophages 
Directly or 6 h after ILP no evident alterations in number nor in localization of the tumor 
infiltrating cells was observed in all treatment groups (Table 4). 
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Table 4. Tumor infiltration after isolated perfusion with sham, TNF, melphalan or TNF 
plus melphalan.  
 sham       el TNF         melphalan    TNF + m
    center 0 hours 
    periphery 0 hou
    center 6 hours 
    periphery 6 hou
1.0 ±
1.0 ± 
0.5 ± 0
1.4 ±
0.9 ±
0.6 ± 
0.7 ±
1.2 ± 
0.8 ± 0
 
1
0.5 ± 0.3
0.4 ± 0
1.6 ± 0
CD8a 
    center 0 hours 
    periphery 0 hours 
rs  
34 ± 21 
 
 
27 ± 21 
 
67 ± 47 
 
 
6 ± 55 
rs 
rs  
    center 6 hours 
  periphery 6 hours 
60 ± 4 
171 ± 34 
246 ± 39 
89 ± 18 
174 ± 18 
214 ± 34 
48 ± 3* 
230 ± 29 
180 ± 16 
8 ± 12 
147 ± 10 
189 ± 2# 
    center 6 hours 
    periphery 6 hou
 
64 ± 26
22 ± 12
62 ± 20 
 
35 ± 7 
51 ± 16
33 ± 3* 
 
75 ± 27
41 ± 13
51 ± 7 
 
5
139 ± 25 
48 ± 29 
42 ± 8# 
Granulocytesa 
    center 0 hours 
    periphery 0 hou
    center 6 hours 
    periphery 6 hou
ED-1a 
 
74 ± 19 
69 ± 10 
109 ± 39 
 
 
81 ± 25 
72 ± 18 
71 ± 12 
 
 
62 ± 10 
79 ± 14 
50 ± 13 
 
 
8
37 ± 5 
47 ± 6*# 
81 ± 12# 
 
CD4a 
rs 
rs  
 
0.3 ±0.1 
 0.5 
0.5 
.3 
 
0.5 ± 0.3 
 0.4 
 0.4 
0.2 
 
0.2 ± 0.1 
 0.5 
0.4 
.3 
3.5 ± 13.0 
 
.1 
.4 
    center 0 hours 
    periphery 0 hours 
189 ± 5 
221 ± 42 
192 ± 33 
165 ± 11 
201 ± 20 
207 ± 23 
172 ± 34 
239 ± 11 
  
Note: directly after ILP or 6 hours later the tumors were excised and frozen sections were stained for CD4, CD8, 
Average ± SEM are shown. a number of positive cells per field of interest, * p=0.05 compared with sham treatment 
at same timepoint and region of the tumor, # p=0.05 compared with 0 hours and the same tumor region. 
 
Cytokine expression in tumor tissue and tumor cells in vitro 
As the number of infiltrating cells was not affected by TNF, we hypothesized that TNF 
could probably activate macrophages and T lymphocytes resulting in the production of non-
specific effector molecules. Increased expression levels of TNF and IFN were found in 
tumor tissue collected dire
granulocytes and ED-1 positive cells. 6 fields of interest per tumor and 3 animals per group were quantified. 
ctly after ILP with TNF plus melphalan compared to sham ILP 
=0.05) (Figure 5). Obviously, sham perfusions did affect cytokine expression in the 
ion of IL-6, GRO/CINC-A, TNF and IL-12 and 
cted in tumor tissue 6 hours after ILP 
(p
tumor microenvironment. Increased express
decreased expression of IFN and TGF-β1 were dete
compared to expression levels in tumor tissue taken out directly after perfusion (p=0.05). 
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Figure 5. Semi-quantitative RT-PCR. BN175-bearing rats were treated with buffer alone, 50 µg TNF, 40 µg 
l 
melphalan or the combination for 30 minutes. Clear differences were seen between 
expression levels in vivo and in vitro. mRNA expression in tumors showed higher IL-6, 
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melphalan or a combination of TNF and melphalan and directly after ILP (A) or 6 hours later (B) the tumor were 
excised. RNA was isolated and RT-PCR was carried out with various cycles of PCR reactions. Numbers given in 
the figures are the cycles where first band of each cytokine appeared minus the first band of b-actin of the same 
cDNA sample (cycle 18-20). The average of each cytokine is shown ± SEM. 
 
To investigate which cytokines are produced by the tumor cells alone, RNA was isolated 
from BN175 tumor cells in vitro. Cells were also incubated with 10 µg/ml TNF, 8 µg/m
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MCP-1 and TGF-β1 and lower IL-10 and MIP-2 levels than tumor cells in vitro. Levels of 
GRO/CINC-A, IL-12, TNF and IFN-γ expression were comparable. Treatment of t mor 
cells in vitro with TNF and TNF resulted in higher expression of all cytokines tested with 
the exception of TGF-β1. Most clear differences were seen for GRO/CINC-A, MCP-  and 
MIP-2 mRNA expression (data not shown). 
 
Discussion 
Clinical studies showed impressive improvement of the anti-tumor activity of melpha n in 
local treatment of different tumor types when TNF was co-administered (reviewed in (1)). 
We demonstrated that the basis for the synergy is a significant enhancement of tumo rug 
uptake (7,8). Subsequent events were haemorrhagic necrosis and destruction of t mor 
vasculature (7,9). Although TNF alone already inflicts these effects in rodent tumor m , 
no significant tumor regression occurs in the clinic nor in the animal models after ILP with 
TNF alone (11-15). Here we focus on the direct effects of TNF on the tumor 
microenvironment and on secondary immunological effects during and shortly er 
perfusion. Already during perfusion with TNF and melphalan softening of the tumo was 
observed and some vascular damage was detected. Perfusion with TNF alone sh wed 
extravasation of erythrocytes, but the endothelial linings seemed to be mostly intact. ILP 
with TNF and melphalan resulted in slight increase of the necrotic areas and sections 
revealed scattered extravasation of erythrocytes. The tumors showed some areas with 
complete destruction of the vasculature. 
In the present study we demonstrate that isolated limb perfusion in soft-tissue sarcoma 
bearing rats with melphalan in combination with TNF results in high response rates. We 
previously showed that the combination therapy is also very effective for th  rat 
osteosarcoma and with another chemotherapeutical agent, namely doxorubicin. In both 
tumor types TNF caused an augmented drug uptake and a synergistic anti-tumor response 
(8,25). Several studies showed that TNF was able to enhance the uptake of macromolecules 
(26,27). In the present study a six-fold increased melphalan uptake in tumor tissue was 
found and no increased drug uptake in skin and muscle tissue. There was a transient effect 
 (e.g. BSA) which might be 
xplained by the absence of IFN-γ. We hypothesize that endogenous IFN-γ is a critical 
u
, 
1
la
 
r d
u
odels
 
 aft
r 
o
 
e
 
of TNF in combination with melphalan and PMN on the permeability of endothelial cells in 
vitro for small molecules like fluorescein (0.33 kD) and melphalan (0.3 kD) and not for 
proteins like BSA (66.4 kD) explaining the improved melphalan accumulation. The 
permeability in vitro was not enhanced to larger molecules,
e
component in the synergistic anti-tumor activity of TNF and chemotherapy (28). We 
showed that IFN-γ in combination with TNF and PMN is needed for an increased 
permeability to proteins.  
92 
Changes in tumor pathophysiology during TNF-ILP 
Destruction of the vasculature was detected only at some areas accompanied by 
extravasation of erythrocytes after perfusion with TNF and melphalan. However, no 
destruction of vessels was seen after treatment with TNF alone. The slightly increased 
amount of apoptotic cells found directly after ILP, only partly explain the vascular damage 
caused by TNF in combination with melphalan. Ruegg et al. showed that inhibition of the 
Vβ3-mediated endothelial cell adhesion results in apoptosis and finally disruption of the 
ture induced by TNF and IFN-γ, but in this study tumor biopsies were 
acidity are thought to lie in the chaotic nature of 
F on tumor blood flow (26,40). To obtain further inside into the 
mechanism underlying the effect of TNF experiments are currently conducted.  
α
tumor vascula
examined 24 hours after ILP (5), which might therefore be a secondary effect. 
Several studies have suggested that increased delivery of macromolecules can be achieved 
by lowering the interstitial fluid pressure (29,30). The IFP in nearly all normal tissues is 
close to atmospheric pressure, but is significantly elevated in most solid malignant tumors 
(31,32). The capillaries in tumors are structurally and functionally abnormal and some are 
hyperpermeable to fluid and serum proteins. Poor uptake of drugs into tumor interstitium is 
thought to, at least in part, be responsible for the low efficiency in pharmacological 
treatment of solid malignancies (33). Kristensen et al. showed that TNF caused a reduction 
in the IFP in human melanoma xenografts, what could lead to enhanced uptake of large 
molecules (16). In our experiments we did not see an effect of TNF on the IFP, but the 
perfusion procedure itself caused a 2.4-fold increase in IFP. We concluded that the 
enhanced drug uptake in the ILP setting was not due to a lowering of IFP. 
Besides an increased IFP in tumor tissue, the microenvironment of most solid tumors is 
acidic. The origins of this extracellular 
tumor vasculature, increased glycolytic flux in tumor cells and diminished buffering 
capacity of tumor interstitial fluid (10,11). In our study we also found that the pH of the 
BN175 tumor is slightly acidic and none of the treatments had an effect on the pH of the 
tumor during ILP. Mildly acidic condition of the perfusate might enhance the antitumor 
effect of melphalan as suggested by a study of Kelley et al. (34). Others showed that 
hypoxia and acidosis both in vitro and in vivo are able to potentiate the cytotoxicity of 
melphalan (35,36). In TNF-based ILP this seems not to play a role of importance. 
Mocellin et al. found significantly higher levels of eNOS mRNA in complete responders 
than in partial/minimal responders after TNF-based ILP (37). Higher levels of NO will 
result in vasodilatation, a higher blood flow and could therefore have a beneficial effect on 
drug uptake (38). This is in contrast with results of de Wilt et al. where in the BN175 tumor 
model an additional antitumor effect was demonstrated when the NO inhibitor L-NAME 
was added to the synergistic combination of melphalan and TNF response rate increased up 
to 100%) (39).  
Some studies showed that administration of TNF resulted in a reduced blood flow, whereas 
others saw no effect of TN
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Although TNF is able to upregulate the expression of some cytokines in vitro, BN175 cells 
are not sensitive to TNF both in vitro and in vivo. Mocellin et al. found 24 hours after ILP 
with TNF and doxorubicin a Th1 type shift in the tumor microenvironment compared with 
tumor tissue before treatment (41). An increased TIA-1 gene expression in tumor biopsies 
24 hours after TNF-ILP compared to the patients treated with doxorubicin alone was found. 
These experiments indicate that TNF-induced TIA-1 overexpression might sensitize 
endothelial cells to proapoptotic stimuli present in the tumor microenvironment and 
enhance NK cell cytotoxic activity against cancer cells (42). We found no clear shift toward 
f the endothelial 
ienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation 
rphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated 
 5.  Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of 
a Th1 or a Th2 type response, but these data do not exclude up- or down-regulation of 
cytokines locally. Imbalance in the cytokine profile within the tumor microenvironment 
more than the absolute level of an individual cytokine may be responsible for an effective 
versus ineffective immune response (18). 
In conclusion, application of TNF in combination with melphalan in an isolated limb 
perfusion strongly improves response rates, which is due to an augmented melphalan 
accumulation in the tumor during ILP. We have recently reported on a similar and crucial 
activity of histamine and interleukin-2 in this setting (43,44), further identifying that 
enhancement of cytotoxic drug uptake in the tumor is key. This increased drug 
accumulation is not explained by a lowering of the IFP. Most likely TNF induces at short 
term, in conjunction with PMN-derived factors and IFN, permeability o
lining facilitating better tumor penetration of small molecules.  
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Abstract 
ere we show that Doxil® has minimal antitumor activity in the isolated limb perfusion 
(ILP) setting and factor 
NF). Doxil® acc NF. In 
ntrast, activity o ude that 
plication of Dox tional 
doxorubicin or me
ntroduction 
Isolated limb perfusion (ILP) provides an excellent tool in the treatment of locally advanced 
mors. During ILP, high local drug concentrations are possible due to minimal leakage 
one (1,2).  
s used most commonly in ILP, but other agents have been applied with varying 
ccess in limb or organ perfusion (3-5). We observed in ILP that local toxicity was dose-
liposomes (Stealth® liposomal 
doxorubicin, Doxil ) prolongs circulation time, decreases toxicity and augments 
calization in tumor tissue (7). We hypothesized that the use of Doxil® in ILP may reduce 
acy of Doxil® in a TNF-based ILP in sarcoma-bearing rats. 
aterials and Methods 
Chemicals 
uman recombinant TNF-α was kindly provided by Dr G Adolf (Bender Wien GmbH, 
ien, Austria). Pegylated liposomal doxorubicin (Doxil®, Caelyx®) was kindly provided by 
r Working (ALZA Corporation, Mountain View, CA, USA). Doxorubicin hydrochloride 
driblastina) was purchased from Pharmacia (Brussels, Belgium).  
nimals and tumor model  
Male inbred BN rats (soft-tissue sarcoma model, BN175) and WAG/RIJ rats (osteosarcoma 
model, ROS-1) were obtained from Harlan-CPB (Austerlitz, the Netherlands). Small 
agments (3mm) of tumor were implanted subcutaneously in the right hindleg, as 
reviously described (8). Tumor growth was recorded by calliper measurements, and tumor 
(A2B) (where B represents the largest diameter 
and A the diameter perpendicular to B). All animal studies were done in accordance with 
H
its activity was not enhanced by the addition of
umulation in tumor tissue was low and also not 
f free conventional doxorubicin was enhanced by 
il® in a TNF-based ILP is not a useful alternativ
lphalan.  
 tumor necrosis 
augmented by T
TNF. We concl
e to free conven
(T
co
ap
 
I
tu
into the systemic circulation, and the effect on vital organs is limited, allowing high 
dosages to be used. We and others have demonstrated that addition of tumor necrosis factor 
(TNF) to an ILP with melphalan increased the tumor response dramatically as compared to 
melphalan al
elphalan iM
su
limiting at suboptimal doxorubicin concentrations (6).  
The formulation of doxorubicin in long-circulating 
®
lo
local toxicity while augmenting tumor accumulation and improving tumor response. In this 
study, we examined the effic
 
M
H
W
D
(a
 
A
fr
p
volume was calculated using the formula 0.4
98 
Doxil® in TNF-based ILP 
protocols approved by the Animal Care Committee of the Erasmus University Rotterdam, 
ocol  
at limbs were perfused as previously described (8). Tumor necrosis factor (50 µg), Doxil® 
400 µg BN175 and 200 µg ROS-1) were added as boluses to the 
cin accumulation in solid tumor during ILP  
re approved as stated above (9). 
esults 
NF-based ILP  
ith Doxil®, TNF or buffer alone resulted in progressive disease in all soft-tissue 
imb perfusion with 
onventional doxorubicin combined with 50 µg TNF increased the antitumor activity with a 
d CR combined) (p<0.01 compared with doxorubicin alone).  
the Netherlands (9).  
A tumor response indicates either a partial remission (PR, decrease of tumor volume 
between –25 and 90%) or a complete remission (CR, tumor volume less than 10% of initial 
volume).  
 
Isolated limb perfusion prot
R
or doxorubicin (
oxygenation reservoir. Control rats were perfused with Haemaccel or placebo liposomes 
alone. The concentration of TNF was adapted from previous animal studies, and 
doxorubicin concentrations that yielded no local toxicity were used. All animal studies were 
approved as stated above (9).  
 
Assessment of doxorubi
Accumulation of doxorubicin in tumor and muscle was determined directly after ILP, as 
previously described (6,10). As the ILP included a thorough washout, there was no 
intravascular doxorubicin present. All animal studies we
 
Statistical analysis 
The results were evaluated for statistical significance using the Mann–Whitney U-test with 
SPSS for Windows. P-values below 0.05 were considered statistically significant. 
 
R
Tumor response to Doxil® in T
Perfusion w
sarcoma-bearing rats (Figure 1A). Perfusion with Doxil® plus TNF resulted in a short 
growth delay followed by rapid outgrowth of the tumor, and all rats showed progressive 
disease. Application of free conventional doxorubicin resulted only in a slight inhibition of 
the tumor growth, and no rats showed a tumor response. Isolated l
c
response rate of 83% (PR an
Isolated limb perfusion in osteosarcoma-bearing rats with buffer or conventional 
doxorubicin alone had no significant effect on tumor growth (Figure 1B). Isolated limb 
perfusion with TNF alone resulted in a response rate of 25%. Isolated limb perfusion with 
conventional doxorubicin combined with TNF further increased the tumor response to 83% 
(p<0.05 compared with TNF alone or doxorubicin alone). Isolated limb perfusion with 
Doxil® only, induced slight tumor growth delay comparable to free conventional 
99 
Chapter 6  
doxorubicin. Strikingly, ILP with Doxil® plus TNF diminished the tumor response, and 
none of the rats showed a tumor response. 
 
coma BN175 after isolated limb perfusion 
ith perfusate alone (n=6), 400 mg Doxil® (n=4), 50 mg TNF (n=6), Doxil® plus 50 mg TNF (n=8), 400 mg free 
es of subcutaneous 
ccumulation of doxorubicin in solid tumor after ILP 
ddition of TNF did not significantly augment the accumulation of 
as added 
 ILP with free doxorubicin (6). 
e 
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doxorubicin (DXR) (n=7), or a combination of TNF and free DXR (n=6). (B) Tumor volum
implanted osteosarcoma ROS-1 after isolated limb perfusion with perfusate alone (n=6), 200 mg Doxil® (n=6), 50 
mg TNF (n=8), 200 mg Doxil® plus 50 mg TNF (n=7), 200 mg free doxorubicin (DXR) (n=6), or a combination of 
TNF and DXR (n=6). The mean tumor volumes are shown ± SE.  
 
A
We observed that a
Doxil® in soft-tissue sarcoma or osteosarcoma when compared to ILP with Doxil® alone 
(data not shown). Levels of doxorubicin were significantly increased when TNF w
to
 
Discussion 
In the present study, we demonstrated that ILP treatment with Doxil® combined with TNF 
in sarcoma-bearing rats does not provide a useful alternative to free conventional 
doxorubicin. The lack of efficacy of Doxil® is not due to failure of the drug to be active at 
the tumor site, as dramatic synergy between Doxil® and TNF after systemic treatment has 
been shown (11). Rather, we speculate that the liposomes are unable to extravasate into the 
tumors during the relatively short ILP interval.  
In spite of the indicated usefulness of doxorubicin in ILP for the treatment of sarcoma, w
and others observed dose-limiting local toxicity after a TNF-based ILP with conventional 
doxorubicin (6,12). Biodistribution and pharmacokinetic studies with Doxil® demonstrated 
a favorable profile of the liposomal formulations over the free drugs, that is, circulation 
time was extended, toxicity reduced and tumor localization was increased (7). Therefore, 
we envisioned that Doxil® could be a good alternative to free conventional doxorubicin in 
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ILP. However, Doxil® failed to induce any response in sarcoma-bearing rats, even when 
applied in combination with TNF. Minimal accumulation of Doxil® in tumor after ILP with 
or without TNF was observed, whereas considerably higher levels of doxorubicin were 
found in tumor after ILP with free doxorubicin plus TNF. A possible explanation for the 
difference in accumulation between free conventional doxorubicin and liposomal 
doxorubicin is the particle size. Whereas distribution of a small molecule like doxorubicin 
is diffusion dependent, the transport of particulate matter is convection dependent (13,14). 
This would indicate that, during ILP, drug distribution is mostly diffusion dependent and 
not convection dependent.  
The increased tumor localization of Doxil® seen after systemic administration is reportedly 
due to the ability of the pegylated liposomes to avoid accumulation in the liver and spleen 
and other parts of the mononuclear phagocytic system (MPS), which results in a long 
circulation time and extravasation through the leaky vasculature of tumors (7). The volume 
e isolated limb obviates the value of avoiding the MPS. Thus, the rapid distribution 
 better choice for ILP procedures, 
interferon-gamma and melphalan for nonresectable extremity soft tissue 
sarcomas: a multicenter trial. J Clin Oncol. 1996;14(10):2653-2665. 
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 and sarcoma. J Clin Oncol. 1992;10(1):52-60. 
n Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha 
of distribution of Doxil® is markedly smaller than that of doxorubicin given systemically, 
reflecting the broad tissue distribution of the latter. The short 30-min circulation time 
imposed by the ILP procedure is likely inadequate for the circulation time advantage of 
Doxil® to have an effect on its distribution, and, of course, the restriction of circulation to 
th
properties of the small doxorubicin molecule makes it a
particularly when it is used in combination with TNF. 
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Abstract 
isplatin is a widely used agent for treatment of solid tumors, but its clinical utility is 
limited by toxicit ® 
posomal cisplati ose of 
travenously adm eatment 
ith low-dose tum mal 
doxorubicin (Dox ystemic 
plications of low-dose TNF on the antitumor activity of SPI-077 t-tissue 
rcoma or osteosarcoma. Addition of TNF to SPI-077 treatmen proved 
tumor growth delay of the soft-tissue sarcoma. The combined SPI-077/TNF treatment 
sulted in a more prolonged antitumor activity, whereas free cisplatin showed a better 
e
 combination with the reduced 
xicity of SPI-077, this combination may be preferable to cisplatin. 
 
, cis-diamminedichloroplatinum(II), is widely used in the treatment of a variety of 
lid tumors, particularly those in the ovary, head, neck, and lung (1-7). The drug’s 
mechanism of action is based on direct binding of cisplatin to DNA. A major drawback of 
vomiting, ototoxicity, nephrotoxicity, neurotoxicity and, to a 
sser extent, myelosuppression (1,7,8). Other problems influencing efficacy of the agent 
re the rapid inactivation of the drug and the development of platinum resistance (9). 
everal studies have shown that encapsulation of antineoplastic agents in liposomes can 
duce systemic toxicity while retaining, or even improving, in vivo efficacy (10-13). SPI-
077 (Stealth® liposomal cisplatin) is a formulation of cisplatin encapsulated in sterically 
tabilized, long-circulating liposomes that contain methoxy-polyethylene glycol (MPEG). 
ecause of their small size, long circulation time and reduced interaction with formed 
lements of the blood, sterically stabilized liposomes tend to accumulate in tumors, 
resumably due to leakage through the often compromised tumor vasculature (5,10-12,14-
6). 
PI-077's antitumor activity has been studied in various animal tumor models and in human 
enografts. These preclinical studies demonstrated toxicity which was less acute as 
t was at least equivalent to that of free 
C
y. Preclinical studies have shown less acute t
n (SPI-077) is used, with antitumor effects e
inistered free cisplatin. We previously reported t
or necrosis factor-α (TNF) augments the activity
i ). In this study, we examined the effect l®
oxicity when Stealth
quivalent to th
hat systemic tr
 of Stealth® liposo
of repeated s
 in rats with sof
t showed an im
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w
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re
tumor response, however with a rapid outgrowth a few days after the end of therapy. In the 
osteosarcoma, free cisplatin did not have an antitumor effect, but addition of TNF caused a 
clear tumor growth delay. SPI-077 alone resulted in a tumor growth d lay, but combination 
with TNF had no additive effect. SPI-077 yielded less systemic toxicity than cisplatin. 
Depending on the type of tumor, the addition of TNF to SPI-077 results in a better tumor 
growth delay with a prolonged antitumor effect and, in
to
Introduction 
Cisplatin
so
this powerful agent is its acute, dose-limiting toxicity. Administration of cisplatin is 
associated with nausea and 
le
a
S
re
s
B
e
p
1
S
x
compared to cisplatin, and the antitumor effec
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cisplatin (1,5,6,17,18). In clinical studies, SPI-077 showed a markedly different 
uman recombinant tumor necrosis factor-α (specific activity 5x107 IU/ml) was kindly 
ehringer (Boehringer Ingelheim GmbH, Austria) and stored at a 
thanol 
 inbred Brown Norway rats were used for the soft-tissue sarcoma model (BN175); 
pharmacokinetic profile to cisplatin. However, despite the favorable pharmacokinetic 
properties, enhanced antitumor activity was not observed (7,8,19,20). 
We previously showed that alteration of the pharmacokinetic profile of Doxil® (Stealth® 
liposomal doxorubicin) by co-administration of tumor necrosis factor-α (TNF) has a strong 
beneficial effect. Repeated administration of Doxil® and low-dose TNF resulted in a 
pronounced tumor response in soft tissue sarcoma-bearing rats with most of the rats 
showing tumor regression (21,22). When Doxil® was administered alone, however, there 
was no tumor response in any of the rats. Comparable results were seen in melanoma-
bearing mice (23). Administering TNF with Doxil® augmented accumulation of the 
chemotherapeutic drug in the tumor tissue and probably explains the enhanced tumor 
regression.  
In this study, we compared placebo liposomes, free cisplatin, SPI-077, low-dose TNF, and 
combination therapies of cisplatin/TNF and SPI-077/TNF and evaluated the antitumor 
activity and side effects. 
 
Materials and Methods 
Chemicals 
H
provided by Bo
concentration of 2 mg/ml. Endotoxin levels were less than 1.25 units (EU) per mg protein.  
Cisplatin was purchased from Pharmachemie B.V. (Haarlem, the Netherlands) in 1 mg/ml 
solution ready for use. SPI-077 (Stealth® liposomal cisplatin) was kindly provided by 
ALZA Corporation (Mountain View, CA, USA). SPI-077 liposomes were comprised of 
hydrogenated soy phosphatidylcholine, methoxypolyethylene-glycol-distearoyl 
phosphatidyl-ethanolamine and cholesterol at an approximate 51:5:44 molar ratio. Briefly, 
preparation of the liposomes begins with dissolving the lipid components in e
followed by addition to an aqueous cisplatin solution. The resulting liposomes are then 
sized by extrusion through polycarbonate membranes and diafiltered to remove 
unencapsulated cisplatin. The process produces liposomes with an average particle size of 
110 nm, no unencapsulated drug in the stored preparation, a final drug concentration of 1 
mg/ml and a drug to lipid ratio of 0.014. 
 
Animals and tumor model 
Male
WAG/RIJ rats were used for the osteosarcoma model (ROS-1). Rats were obtained from 
Harlan-CPB, (Austerlitz, the Netherlands), weighed 250-300 g and were fed a standard 
laboratory diet ad libitum (Hope Farms Woerden, the Netherlands). 
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Small fragments (3 mm) of the syngeneic BN175 or ROS-1 sarcoma were implanted 
subcutaneously in the right hindleg of each rat, as previously described (24). Tumor growth 
was recorded by caliper measurement, and tumor volume was calculated using the formula 
quivalent amounts of buffer or lipids), 2) free cisplatin, 3) SPI-077, 4) low-
-077. Both rat strains received 15 µg/kg TNF. Rats were given a 
tal of five intravenous injections, one every four days. When the rats were treated with the 
platin/TNF or SPI-077/TNF, the agents were injected 
ne shortly after the other. 
 
final density of 1x104 cells per well and allowed 
 grow as a monolayer. Cells were incubated at 37ºC in 5% CO2 for 72 hours in the 
rations of TNF, cisplatin, and SPI-077. Concentrations of TNF 
 saline, incubated 
0.4(A2xB) (where B represents the largest diameter, and A is the diameter perpendicular to 
B). Rats were sacrificed when tumor diameter exceeded 25 mm or at the end of the 
experiment. All animal studies were done in accordance with protocols approved by the 
Committee on Animal Research of the Erasmus MC, Rotterdam, the Netherlands. 
 
Treatment protocol 
About 7-8 days after implantation, the tumors reached an average diameter of 9-11 mm and 
treatment was started. The rats were randomized into the following six groups: 1) placebo 
liposomes (e
dose TNF, 5) cisplatin/TNF and 6) SPI-077/TNF. For the BN rats concentrations of 0.1, 
0.3, 1 and 3 mg/kg cisplatin or SPI-077 were used. The WAG/RIJ rats received 1 or 3 
mg/kg of cisplatin or SPI
to
combination therapies of cis
separately, o
Tumor response was classified as follows: progressive disease (PD) = increase of tumor 
volume (> 25%) over a 16-day period; no change (NC) = tumor volume equal to volume as 
start of treatment (in a range of -25% and +25%); partial remission (PR) = decrease of
tumor volume (-25 and -90%); complete remission (CR) = tumor volume less than 10% of 
initial volume. 
 
In vitro cytotoxicity assay 
Cells isolated from a BN175 soft-tissue sarcoma were maintained in cell culture in RPMI 
1640 supplemented with 5% fetal calf serum and 0.1% penicillin-streptomycin. The rat 
osteosarcoma ROS-1 cells were maintained in modified Eagle's medium supplemented with 
10% fetal calf serum and 0.1% penicillin-streptomycin. Media and supplements were 
obtained from Life Technologies, the Netherlands. 
BN175 or ROS-1 cells were added in 100-µl aliquots to 96-well, flat-bottomed, microtiter 
plates (Costar, Cambridge, MA, USA) at a 
to
presence of various concent
ranged between 0 and 10 µg/ml. Concentrations of cisplatin ranged between 2.5 ng and 100 
µg/ml, while those of SPI-077 were between 50 ng and 1 mg/ml. The growth of tumor cells 
was measured using the Sulphorhodamine-B (SRB) assay according to the method of 
Skehan (25). In short, cells were washed twice with phosphate buffered
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with 10% trichlor-acetic acid (1 hour, 4ºC), and washed again. The cells were stained with 
0.4% SRB (15-30 min), washed with 1% acetic acid and were allowed to dry. Protein-
bound SRB was dissolved in TRIS (10 mM, pH 9.4). The optical density was read at 540 
nm. In vitro tumor cell growth was calculated using the following formula: tumor cell 
growth = (test well/control) x 100%. The drug concentration required to reduce the 
absorbance to 50% of the control (IC50) was determined from the growth curves. The 
experiments were repeated at least five times. 
 
Nephro- and hepatotoxicity 
H, which is needed for the reaction, was measured. 
lin and eosin, examined on a Leica DM-RXA and photographed using a 
ony DXC950 camera.  
using GraphPad Prism v3.0 and SPSS 
The WAG/RIJ rats treated with 3 mg/kg cisplatin or SPI-077 were observed at regular 
intervals for signs of toxicity, and weight was recorded daily. Two days after every round 
of administration, 1 ml blood was taken from the tail vein. Levels of alanine 
aminotransferase (ALAT), aspartate aminotransferase (ASAT), creatinine, urea and γ-
glutamyl transpeptidase (γ-GT) were measured using Granutests in order to detect renal and 
hepatic toxicity (Merck, Darmstadt, Germany). The principle of the creatinine measurement 
is the reaction of creatinine with picric acid in alkaline solution, which leads to a yellow-
orange colored compound. Urea was calculated from an enzymatic reaction in conjunction 
with urease, where the decrease of NAD
Histopathological examination was performed on the kidneys and livers from another group 
of animals treated with 3 mg/kg cisplatin or SPI-077. The animals were autopsied at day 17 
(24 hours after fifth and last treatment), the kidneys and liver were removed and fixed in 
4% formaldehyde and embedded in paraffin. Tissue sections of 4 µm were cut and stained 
with haematoxy
S
 
Statistical analysis 
The results were evaluated for statistical significance with the Kruskal-Wallis followed by 
the Mann Whitney U test or the Fisher’s Exact test (tumor progressors vs. non-progressors 
(NC + PR + CR)). P-values below 0.05 were considered statistically significant. 
Calculations were performed on a personal computer 
v11.0 for Windows 2000. 
 
Results 
Effect of low-dose TNF on antitumor activity of SPI-077 in soft-tissue sarcoma- and 
osteosarcoma-bearing rats 
BN175 soft-tissue sarcoma-bearing rats were treated with a dose range of free cisplatin or 
SPI-077 in combination with low-dose TNF. The highest dose of 3 mg/kg cisplatin showed 
severe toxicity, whereas the lower concentrations (0.1 and 0.3 mg/kg) resulted in 
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progressive diseases for both cisplatin and SPI-077 (data not shown). Treatment with 1 
mg/kg provides the best efficacy versus toxicity ratio and, therefore, we chose to further 
evaluate the concentration of 1 mg/kg free cisplatin or SPI-077 in combination with TNF. 
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Figure 1. Growth curves of subcutaneous implanted BN-175 sarcoma after systemic
5000
SPI-077
cisplatin + TNF
SPI-077 + TNFe 
(
treatment with SPI-077 and low-dose TNF. Rats were injected five times intravenously
with an interval of 4 days between the injections with buffer alone (n=5), 15 µg/kg TNF
(n=5), 1 mg/kg cisplatin (n=3), 1 mg/kg SPI-077 (n=4), 1 mg/kg cisplatin combined
with 15 µg/kg TNF (n=3) and 1 mg/kg SPI-077 combined with 15 µg/kg TNF (n=4).
Arrows indicate injections. Median tumor volumes are shown. Statistical analysis (Mann
Whitney U test): a. cisplatin vs. cisplatin + TNF (p=0.05), b. cisplatin vs. SPI-077
(p=0.05), c. cisplatin + TNF vs. SPI-077 + TNF (p=0.05). 
Administration of 1 mg/kg SPI-077 to BN175 soft-tissue sarcoma-bearing rats resulted in 
ity of the combined TNF and SPI-077, the addition of low-dose 
NF to the free cisplatin regimen resulted in a slightly reduced antitumor efficacy. 
s administration of TNF alone or placebo liposomes had no significant effect on 
combined SPI-077/TNF treatment, tumor regrowth occurred a 
pronounced growth delay of the tumor, but no regression was observed (Figure 1 and Table 
1). Addition of 15 µg/kg TNF to this regimen resulted in an improved, but not significant, 
tumor response. Administration of free cisplatin had a much more pronounced antitumor 
effect, inducing strong tumor regression, compared to SPI-077. However, in spite of the 
augmented antitumor activ
T
Intravenou
tumor progression in any of the animals. Although tumor regression in the cisplatin treated 
animals was better than the 
few days after the end of therapy. The SPI-077/TNF treated animals did not show tumor 
outgrowth, indicating a prolonged antitumor effect. 
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Table 1. Tumor response in soft tissue sarcoma-bearing rats after repeated systemic 
treatment with Stealth® liposomal cisplatin (SPI-077) combined with low-dose TNF over a 
total period of 16 days. The animals were treated on day 0, 4, 8, 12 and 16. 
 Response ratea 
reatment PDb NC             PR                CR T
placebo 5    
TNF (15 µg/kg) 5    
isplatin (1 mg/kg)   3*  
PI-077 (1 mg/kg) 4    
isplatin (1 mg/kg) + TNF (15 µg/kg) 1 2   
PI-077 (1 mg/kg) + TNF (15 µg/kg) 4    
c
S
c
S
a responses were scored as described in Materials and Methods, b PD: progressive disease, NC: no change, PR: 
partial remission, CR: complete remission, * p=0.018 compared with placebo (Fisher’s Exact test)  
 
ROS-1 osteosarcoma treated animals with 3 mg/kg free cisplatin showed severe toxicity, 
and therefore 1 mg/kg concentration was chosen as in the BN175 experiments. In contrast 
to the BN175 soft tissue sarcoma, the ROS-1 osteosarcoma was not sensitive to 1 mg/kg 
free cisplatin with all treated animals exhibiting progressive disease (Figure 2 and Table 2).  
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 Figure 2. Growth curves of subcutaneous implanted ROS-1 osteosarcoma after systemic 
treatment with SPI-077 and low-dose TNF. Rats were injected five times intravenously 
with an interval of 4 days between the injections with buffer alone (n=5), 15 µg/kg TNF
(n=5), 1 mg/kg cisplatin (n=3), 1 mg/kg SPI-077 (n=4), 1 mg/kg cisplatin combined with 
15 µg/kg TNF (n=3) and 1 mg/kg SPI-077 combined with 15 µg/kg TNF (n=4). Arrows 
indicate injections. Median tumor volumes are shown. Statistical analysis (Mann
Whitney U test): a. cisplatin vs. cisplatin + TNF (p<0.05), b. cisplatin vs. SPI-077 
(p<0.05).  111 
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Administration of 15 µg/kg TNF alone had also no effect on the tumor response. Treatment 
with 1 mg/kg SPI-077 resulted in progressive disease in all animals; however, these tumors 
did not grow as fast as those in animals treated with free cisplatin. Addition of low-dose 
NF to free cisplatin improved tumor r  and there were six animals with 
 disease, one no change, and o ho was ficant 
 to other treatments with Fishe xact test). The comb ation of TNF with SPI-
 an additive effect on tumor response, which is in contrast with the 
NF did have an ad tive effect. 
o ring rats after repeated systemic ent 
I- ) combin  with low-dose TNF o otal 
T esponse slightly,
progressive ne w  a complete responder (not signi
compared r’s e in
077 did not have the 
BN175 tumor where T di
 
Table 2. Tumor response in osteosarc ma-bea  treatm
with Stealth® liposomal cisplatin (SP 077 ed ver a t
period of 16 days. The animals were treated on day 0, 4, 8, 12 and 16. 
 Response ratea 
reatment PDb NC             PR                CR T
placebo 5    
TNF (15 µg/kg) 5    
cisplatin (1 mg/kg) 5    
SPI-077 (1 mg/kg) 7    
cisplatin (1 mg/kg) + TNF (15 µg/kg) 6 1  1 
PI-077 (1 mg/kg) + TNF (15 µg/kg) 5    S
a responses were scored as described in Materials and Methods, b PD: progressive disease, NC: no change, PR: 
artial remission, CR: complete remission  
n vitro activity of cisplatin or SPI-077 combined with TNF on BN-175 and ROS-1 tumor 
ells 
xposure of the BN175 sarcoma cells to cisplatin caused dose-related cytotoxicity with an 
50 of 0.18 µg/ml (data not shown). The cytotoxicity of cisplatin was strongly reduced 
pon liposomal encapsulation (IC50 of 59.1 µg/ml). No significant cellular toxicity could be 
bserved when BN175 cells were exposed to TNF alone. The IC50 decreased to 0.14 µg/ml 
hen the cells were co-incubated with cisplatin and 10 µg/ml TNF. When the cells were 
cubated with SPI-077 and 10 µg/ml TNF the IC50 was lowered to 25.0 µg/ml (not 
significant compared to cisplatin and SPI-077 alone).  
 the osteos duced 
e cytotoxic /ml 
nd 203.4 µ rowth 
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In arcoma cell line, ROS-1, liposomal encapsulation of cisplatin strongly re
ity of this agent; the IC50 values for free cisplatin and SPI-077 were 1.24 µg
g/ml, respectively (data not shown). A maximal dose-dependent g
40% was observed when ROS-1 cells were exposed to TNF concentratio
 Although TNF had some effect on the ROS-1 cells no synergy was ob
as combined with SPI-077 or free cisplatin. The IC50 values for free cis
th
a
re
to
w
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and SPI-077 in combination with 10 µg/ml TNF were 0.72 and 214.6 µg/ml, respectively 
(not significant compared to cisplatin and SPI-077 alone).  
 
Toxicity evaluation 
Weight changes during the course of the systemic treatment are presented in Figure 3. We 
observed that repeated administration of free cisplatin at a dose of 3 mg/kg per injection 
resulted in dramatic weight loss (29% ± 10% after day 16; p<0.05) as compared to baseline 
in the WAG/RIJ rats. However, none of the rats treated with 3 mg/kg SPI-077 showed 
ignificant weight loss. The rats treated with free cisplatin showed general lethargy, 
ight loss of WAG/RIJ rats 
ic treatment with 3 mg/kg 
=3) or 3 mg/kg SPI-077 (n=3). 
nal weight ± SE is 
animals in the 
ificed because of 
 
 
 
To determine the nephro- and hepatotoxicity in WAG/RIJ rats, serum toxicity parameters 
were measured. Creatinine and urea levels were elevated 1.9 and 2.5-fold, respectively, in 
rats treated with cisplatin, indicating renal failure (Table 3). No significant effects in these 
values were seen when the animals were treated with SPI-077. Both free cisplatin and SPI-
077 appeared to affect liver function, as shown by elevated ALAT and ASAT levels. After 
treatment with cisplatin, the levels of γ-GT were 0 U/L. The levels increased up to more 
than 5 U/L after five treatments with SPI-077. The levels of γ-GT even continued to 
increase a few days after the last treatment, which is indicative of liver damage. 
Histopathological examination was performed on the kidneys and livers from animals 
treated with 3 mg/kg cisplatin or SPI-077. The animals were autopsied 24 hours after the 
fifth and last treatment. The renal sections of the cisplatin-treated animals revealed 
remarkable degenerative changes in the proximal tubules, including cytoplasmic 
vacuolization, necrosis and pyknotic degeneration. Rats treated with SPI-077 showed no 
s
whereas no such observation was made with animals treated with SPI-077. Addition of 
TNF to the cisplatin or SPI-077 treatment did not cause an extra effect on the weight loss 
(data not shown).  
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damage to the kidney (Figure 4). Treatment with cisplatin or SPI-077 did not cause any 
obvious histologically evident liver damage, in spite of increased ALAT and ASAT levels 
in both groups and elevated γ-GT levels in the SPI-077 group. 
 
Table 3. Kidney and liver toxicity and function of WAG/RIJ rats after treatment with 
cisplatin (3 mg/kg) or SPI-077 (3 mg/kg).  
  day 2 day 6 day 10 day 14 day 18 
Urea  cisplatin 8.4 ± 2.5 7.2 ±1.1 10.4 ± 3.0 15.6 ± 6.7 22.1 ± 7.6# 
  mmol/L SPI-077 8.9 ± 2.1 8.5 ± 0.8 7.5 ± 0.9 8.0 ± 0.1 8.6 ± 0.4 
Creatinine  cisplatin 49.0 ± 11.8 43.7 ± 8.0 56.0 ± 5.3 70.3 ± 10.7 70.0 ± 9.5# 
  µmol/L SPI-077 45.0 ± 18.0 43.3 ± 9.0 47.0 ± 8.5 34.0 ± 11.3 29.3 ± 6.5 
ALAT  cisplatin 49.8 ± 7.1 57.8 ± 3.6 49.1 ± 3.9 48.5 ± 8.3 92.3 ± 32.4 
U/L SPI-077 65.5 ± 9.4 80.8 ± 10.3# 90.7 ± 12.5# 88.5 * 96.2 ± 12.5 
108.8 ± 28.8 128.2 ± 47.8 126.9 ± 26.7 140.9 ± 40.3 
203.3 ± 41.5# 180.2 ± 23.8 169.8 * 189.2 ± 67.3 
0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
0.0 ± 0.0 0.4 ± 0.7  1.3 ± 1.8 4.1 ± 1.9# 
  
ASAT  cisplatin 82.2 ± 20.0 
  U/L SPI-077 148.0 ± 13.9# 
γ-GT  cisplatin 0.0 ± 0.0 
  U/L SPI-077 0.0 ± 0.0 
note: The animals were treated on day 0, 4
077. Blood samples were taken two days after
p<0.05 compared to the other group at 
, 8, 12 and 16 (n=3 for both groups) with 3 mg/kg free cisplatin or SPI-
 every treatment. Mean ± SD is shown. * values are missing, # 
the same timepoint (Mann Whitney U test). Normal serum values: urea 8.7 
0.5 mmol/L, creatinine 36.7 ± 1.2 µmol/L, ALAT: 58.5 ± 9.4 U/L, ASAT: 83.3 ± 10.2 U/L, γ-GT: 0.0 ± 0.0 U/L 
iscussion 
e have examined the efficacy of Stealth® liposomal cisplatin (SPI-077) combined with 
NF in the treatment of solid tumors. We demonstrated that repeated systemic 
 antitumor 
± 
 
D
W
T
administration of SPI-077 alone to soft-tissue sarcoma-bearing rats resulted in less 
antitumor activity compared to free cisplatin. Combination treatment of cisplatin and low-
dose TNF was less potent than cisplatin alone, but addition of TNF to a SPI-077 treatment 
caused a better tumor growth delay than SPI-077 alone. The combined SPI-077/TNF 
treatment resulted in a more prolonged antitumor activity, whereas free cisplatin showed a 
better tumor response, but with a rapid tumor outgrowth a few days after end of therapy. 
In the ROS-1 osteosarcoma-bearing rats, free cisplatin alone had no antitumor activity, 
whereas treatment with a similar dose of SPI-077 resulted in a slightly improved
activity. Addition of low-dose TNF improved the cisplatin treatment, but not the SPI-077 
treatment. Although SPI-077 did not effect a better tumor response in the osteosarcoma 
compared to free cisplatin, fewer systemic side effects were detected. No weight loss, 
histological liver and kidney damage or lethargy were observed in the rats treated with SPI-
077. 
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Figure 4. Paraffin sections of the kidney from osteosarcoma-bearing rats, after systemic treatment, haematoxylin-
eosin stained. Overview of kidney after 5-fold treatment with 3 mg/kg cisplatin (a and b) (n=3) or 3 mg/kg SPI-
077 (c and d) (n=3). Representative pictures are shown. Pycnotic degeneration (arrowheads) and cytoplasmic 
ws) is indicated. Original magnification x16 (a and c) or x40 (b and d). Bar, 100 µm (a and c) 
d). 
l 
 less than 5 minutes and an elimination half-life of about 35 hours (28-30). The longer 
vacuolization (arro
and 50 µm (b and 
 
In the current study, we showed that repeated administration of free cisplatin in soft- tissue 
sarcoma-bearing rats resulted in a pronounced antitumor effect, inducing strong tumor 
regression. Previously, we reported on the antitumor activity of free doxorubicin, which 
delayed tumor growth only slightly (22). Given that in vitro experiments showed 
comparable IC50 values for both drugs, the in vivo activity of cisplatin may be explained by 
pharmacokinetic differences between doxorubicin and cisplatin. It has been reported, by 
several investigators, that plasma levels of cisplatin decay in a biphasic mode with an initia
half-life of 25 to 49 min and a secondary phase ranging from 2 to 3 days after a single 
intravenous administration of cisplatin (26,27). Cisplatin is nonenzymatically converted to 
several products (metabolites) which are not believed to be active as antitumor agents, but 
are highly bound to proteins in the serum, primarily to albumin. The conversion of the 
parent cisplatin to metabolites is rapid with a half-life of less than 2 hours (27). 
Doxorubicin shows a relatively rapid fall in plasma concentration, yielding an initial half-
life of
Chapter 7 
circulation half-life of cisplatin may enable a better accumulation at the tumor site. One 
reason why no antitumor activity of 1 mg/kg cisplatin was seen in the osteosarcoma-bearing 
rats, could be because this dose was below the effective dose for this tumor type, which is 
supported by our in vitro data showing a lower sensitivity of ROS-1 to cisplatin compared 
to BN175 tumor cells. Possibly the effective level of SPI-077 is being reached. A higher 
dose of 3 mg/kg cisplatin resulted in pronounced antitumor activity (data not shown). 
The antitumor activity of SPI-077 has been studied in various animal tumor models, human 
xenografts and clinical studies. These studies do not give a uniform picture and cisplatin is 
more often more effective than SPI-077 (1,5-7,17-19). Encapsulation of a cytotoxic agent in 
pegylated liposomes does not always guarantee enhanced antitumor activity. Because of the 
low water solubility and low lipophilicity of cisplatin, the lipid formulation results in a very 
low drug-to-lipid ratio, which may explain its lack of efficacy. For SPI-077, the drug-to-
lipid ratio is 14 µg/mg, compared with 125 µg/mg for Doxil®. Therefore, each Doxil® 
liposome delivers approximately nine times more drug than a SPI-077 liposome (19).  
Burger and colleagues (31) described a method for efficient encapsulation of cisplatin in a 
lipid formulation that incorporates repeated freezing and thawing of a concentrated solution 
of cisplatin in the presence of the negatively-charged phospholipid, phosphatidylserine 
(PS). They showed a dramatic 100-fold increased cytotoxicity of the liposomal formulation 
compared to free drug in vitro. This method may be useful for generation of SPI-077 and, 
when combined with TNF, strong antitumor responses may be obtained.  
ed that the formulation had low bioavailability and slow-release kinetics, 
uch that the drug concentration failed to exceed the threshold for therapeutic effects (1). 
Another explanation for the lack of efficacy of SPI-077 may be the stability of the 
liposome. Bandak and colleagues reported less than 10% platinum release from SPI-077 in 
vitro and conclud
s
This is supported by a study of Zamboni et al, where they showed that more SPI-077 
distribute into tumors, but release less active platinum into tumor extracellular fluid, and 
form fewer platinum-DNA adducts than cisplatin (32). 
In this study, we observed that TNF improved the antitumor activity of SPI-077 in the soft-
tissue sarcoma, which is in agreement with the results of our earlier study of Doxil® and 
TNF (22). When rats were injected 3-times with liposomes combined with TNF, 
accumulation increased to 3- to 3.5 fold (p<0.02) compared to liposomes alone. Currently 
the effect of TNF on biodistribution and distribution in tumor tissue is studied in detail. 
TNF probably increases the leakiness of the vasculature by increasing the gaps between the 
endothelial lining in the tumor, possibly explaining the augmented accumulation of 
liposomes (33,34). Besides a favorable effect of TNF in a systemic setting, we have also 
showed there was an increased accumulation of melphalan or doxorubicin when given in 
combination with high-dose TNF after an isolated limb perfusion (21,35). 
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The use of cisplatin is seriously hampered by its side effects, which include acute nausea 
and vomiting and chronic side effects resulting from nephrotoxicity, ototoxicity, and 
neurotoxicity (1,7,8). In the cisplatin-treated animals, urea and creatinine levels were 
elevated, cytoplasmic vacuolization was detected in kidney tissue and severe weight loss 
occurred. Treatment with cisplatin or SPI-077 did not cause any obvious histologically 
evident liver damage, although increased ALAT and ASAT levels in both groups and 
ined 
peutic window of 
locally advanced soft tissue sarcoma of an extremity. Eur J Surg Oncol. 2000;26(3):213-221. 
ts. Eur J Cancer. 
elevated γ-GT levels in the SPI-077 group were observed indicating liver-related toxicity. 
Overall, SPI-077 induced fewer side effects than cisplatin in this study. Our results are in 
agreement with other studies that show the majority of the administered SPI-077 dose is 
found in plasma, with secondary accumulation in the liver and spleen. The latter were not 
associated with observable increases in hepatic or splenic toxicity (1,5). 
In conclusion, we demonstrated that administration of SPI-077 results in less antitumor 
activity than free cisplatin in soft tissue sarcoma-bearing rats. However, the addition of 
low-dose TNF to the SPI-077 treatment enhanced the antitumor activity. The comb
treatment resulted in a prolonged antitumor effect compared to free cisplatin alone, where 
rapid outgrowth of the tumor occurred a few days after the end of therapy. In osteosarcoma-
bearing rats, administration of SPI-077 improved the antitumor activity compared with free 
cisplatin. In these animals, addition of low-dose TNF improved the efficacy of free 
cisplatin, but not of SPI-077. The SPI-077 formulation of cisplatin yielded fewer systemic 
side effects than free cisplatin. Depending on the type of tumor, the thera
the liposomal formulation with the addition of TNF can better than the free drug, especially 
when looking at prolonged treatment. Refinement of the lipid formulation to enhance 
bioavailability and increase drug-to-lipid ratios may improve the efficacy of pegylated 
liposomal cisplatin, and co-administration of TNF is likely to further increase the antitumor 
activity of the liposomal cisplatin.  
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Abstract 
proved efficacy of Doxil® (Stealth® liposomal doxorubicin) compared to free 
doxorubicin has be  shown 
at addition of lo proved 
mor response in t  similar 
hanced efficacy erefore 
examined the effe w-dose 
NF in intermediate vascularized osteosarcoma-bearing rats (ROS ents of 
e osteosarcoma were implanted s.c. in the lower limb. Treatmen hen the 
tumors reached an average diameter of 1 cm. Rats were treated with 5 i.v. injections at 4-
ay interval with Doxil® or doxorubicin and TNF. Systemic treatment with Doxil® resulted 
e to
 with Doxil  alone or with TNF resulted in massive coagulative 
 conclusion, combination therapy of Doxil® and low-dose TNF 
ems attractive for the treatment of highly vascularized tumors, but also of intermediate 
ncapsulation of anticancer agents in liposomes offers a potential means of manipulating 
 that contain methoxy-polyethylene glycol (MPEG). Because 
f their small size, long circulation time, and reduced interaction with formed elements of 
the blood, these liposomes tend to accumulate in tumors, presumably due to leakage 
rough the often-compromised tumor vasculature (1-8). Doxil® (Stealth® liposomal 
oxorubicin) is effective in the treatment of several tumor types, including advanced or 
etastatic soft tissue sarcoma (9), AIDS-related Kaposi's sarcoma (10), metastatic breast 
ancer (11) and epithelial ovarian cancer (12).  
re-clinical and clinical studies have shown impressive improvement of the anti-tumor 
ctivity of melphalan and doxorubicin in local treatment of different tumor types when TNF 
was co-administered (13-18). We demonstrated that the basis for the synergy is, on one 
hand a significant enhancement of tumor selective melphalan and doxorubicin uptake and 
n the other hand the subsequent destruction of tumor vasculature caused by TNF (14,19).  
Im
en demonstrated in the treatment of several tumor
w-dose TNF to systemic Doxil® administration 
he highly vascularized rat soft-tissue sarcoma BN
can be achieved in less vascularized tumors is u
c of systemic administration of Doxil® in combt 
 types. We have
dramatically im
175. Whether a
ncertain. We th
ination with lo
-1). Small fragm
t was started w
th
tu
en
T
th
d
in a better tumor growth delay than free doxorubicin, but with progressive diseases in all 
animals. The 3.5-fold augmented accumulation of Doxil® compared to free doxorubicin 
presumably explains the enhanced tumor regression. Addition of low-dose TNF augmented 
the anti-tumor activity of Doxil®, although no increased drug uptake was found compared 
to Doxil® alone. In vitro studies showed that ROS-1 is sensitiv  TNF, but systemic 
treatment with TNF alone did not result in a tumor growth delay. Furthermore, we 
demonstrated that treatment ®
necrosis of tumor tissue. In
se
vascularized tumors like the osteosarcoma. 
 
Introduction 
E
drug distribution to improve antitumor efficacy and reduce toxicity. Stealth® liposomes are 
sterically stabilized liposomes
o
th
d
m
c
P
a
o
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Successful application of TNF for systemic treatment of tumors however is seriously 
bH, Wien, Austria) and stored at a 
oncentration of 2 mg/ml at -80°C or under liquid nitrogen. Endotoxin levels (LAL) were 
g. Pegylated liposomal doxorubicin (Doxil®) was kindly provided by Dr. 
sarcoma or the soft-tissue sarcoma BN175 
 
committee on Animal Research of the Erasmus MC, Rotterdam, the Netherlands. 
hampered by its severe toxicity and therefore only low dosages can be administered 
(20,21). In previous studies we showed that systemic co-administration of Doxil® and low-
dose TNF resulted in a pronounced tumor response in both rat and mice tumor models. In 
soft-tissue sarcoma-bearing rats systemic treatment with Doxil® in combination with low-
dose TNF improved the anti-tumor activity dramatically resulting in a tumor response 
(complete or partial regression) in most of the animals. Repeated injection of Doxil® 
combined with TNF resulted in augmented accumulation of the drug in tumor tissue which 
could explain the observed synergistic anti-tumor effect (22). When B16BL6 melanoma-
bearing mice were injected with Doxil® combined with TNF, also an increased drug 
accumulation was found compared to liposomes alone (23). TNF increases the leakiness of 
the vasculature by increasing the gaps between the endothelial lining in the tumor, possibly 
explaining the augmented accumulation after extravasation of liposomes (24,25). 
We evaluate in the experiments described here whether the use of TNF in combination with 
Doxil® not only results in synergistic anti-tumor response in the highly vascularized soft-
tissue sarcoma but also in the less vascularized osteosarcoma.  
 
Materials and methods 
Chemicals 
Human recombinant Tumor Necrosis Factor-α (specific activity 5x107 IU/mg) was kindly 
provided by Dr. G. Adolf (Bender Wien Gm
c
below 0.624 EU/m
P. Working (ALZA Corporation, Mountain View, CA, USA). Doxorubicin hydrochloride 
(adriblastina) was purchased from Pharmacia (Brussels, Belgium).  
 
Animals and tumor model 
Male inbred WAG/RIJ rats were used for the osteosarcoma model (ROS-1). This tumor 
originated spontaneously in the tibia of a rat. Rats were obtained from Harlan-CPB, 
(Austerlitz, the Netherlands) and weighing 250-300 g. Rats were fed a standard laboratory 
diet ad libitum (Hope Farms Woerden, the Netherlands). 
Small fragments (3 mm) of the syngeneic ROS-1 
were implanted subcutaneously in the right hindleg as previously described (26). Tumor 
growth was recorded by caliper measurement and tumor volume calculated using the 
formula 0.4(A2xB) (where B represents the largest diameter and A the diameter 
perpendicular to B). Rats were sacrificed if tumor diameter exceeded 25 mm or at the end 
of the experiments. Animal studies were done in accordance with protocols approved by the
123 
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Treatment protocol 
Treatment was started when the ROS-1 tumors reached an average diameter of 9-11 mm. 
The rats were randomized into the following 6 groups: placebo liposomes (equivalent 
amounts of buffer or lipids), low dose TNF, free doxorubicin, Doxil®, doxorubicin plus 
TNF and Doxil® plus TNF. Rats were injected five times intravenously with an interval of 4 
days between the injections; first dose of 4.5 mg/kg Doxil® or free doxorubicin and 1.0 
mg/kg for consecutive doses. TNF was given at a concentration of 15 µg/kg for all five 
doses. When rats were treated with doxorubicin or Doxil® combined with TNF, these 
agents were injected separately, shortly after each other. 
The classification of tumor response was: progressive disease (PD) = increase of tumor 
volume (> 25%) over a 20 day period; no change (NC) = tumor volume equal to volume as 
start of treatment (in a range of - 25% and + 25%); partial remission (PR) = decrease of 
tumor volume (- 25 and -90 %); complete remission (CR) = tumor volume less than 10% of 
he effect of TNF on Doxil® accumulation in ROS-1 tumors was investigated. After three 
ts treated with Doxil® in combination with TNF started to 
he tumor size of rats in the other groups and for this reason we decided to 
ors were homogenized 
RO200 homogenizer with 10 mm generator, Pro Scientific, CT, USA), centrifuged for 30 
pernatants were harvested. A Hitachi F4500 fluorescence 
initial volume. 
 
Measurement of doxorubicin accumulation in tumor tissue 
T
injections the tumor size of ra
differ from t
compare doxorubicin tumor uptake not later than this time point. Rats received 3 injections 
of doxorubicin or Doxil® with or without TNF with an interval of 4 days between the 
injections as described in the treatment protocol. Tumors were excised 24 hours after the 
last injection and tissues were analyzed for doxorubicin and its fluorescent metabolites as 
previously described (27). Briefly, tumors were incubated in acidified isopropanol (0.075 N 
HCl in 90% isopropanol) for 24 hours at 4°C and after that the tum
(P
min at 2500 rpm and su
spectrometer (excitation 472 nm and emission 590 nm) was used for measurement of the 
samples. A standard curve was prepared with known concentrations of doxorubicin diluted 
in acidified isopropanol. All measurements were repeated after addition of an internal 
doxorubicin standard.  
 
Histology 
Rats were treated with placebo liposomes, TNF, Doxil® or Doxil® + TNF. When the tumors 
reached an average diameter of 17±1 mm, they were excised and fixed in 4% formaldehyde 
and embedded in paraffin. Tissue sections of 4 µm were cut and stained with haematoxylin 
and eosin, examined on a Leica DM-RXA and photographed using a Sony DXC950 
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camera. At least three different tumors in each experimental group were subjected to blind 
ides were incubated for 1 hour 
cells were revealed by immunoperoxidase reaction with DAB solution 
AB-kit, DAKO) and counterstained lightly with haematoxylin (Sigma). 
graphed using a Sony 3CCD 
s 0.1 - 10 µg/ml for TNF, 0.001 – 100 µg/ml doxorubicin and 0.05 - 
000 µg/ml Doxil®. Growth of tumor cells was measured using the Sulphorhodamine-B 
y according to the method of Skehan (28). In short, cells were washed twice 
cell growth = (test well/control) x 100 percent. The drug concentration reducing the cell 
evaluation. 
 
Immunohistochemistry 
Untreated BN175 and ROS-1 tumors with a diameter or 9-11 mm were excised and 
immediately frozen in liquid nitrogen. Immunohistochemical studies were performed on 
acetone-fixed 7 µm cryostat sections. The tumor sections were fixed for 30 min with 4% 
formaldehyde and after rinsing with PBS, the endogenous peroxidase activity was blocked 
by incubation for 5 minutes in methanol/3% H2O2. The sl
with 1:50 mouse-anti-rat-CD31 (Becton Dickinson, Alphen aan den Rijn, the Netherlands) 
diluted in 5% rat serum/PBS. Thereafter, sections were washed with PBS and incubated for 
1 h with goat-anti-mouse peroxidase-labeled antibody (DAKO, ITK Diagnostics BV, 
Uithoorn, the Netherlands) diluted 1:100 in PBS with 5% rat serum. After rinsing with 
PBS, positive 
(D
The sections were examined on a Leica DM-RXA and photo
DXC 950 camera. The number of vessels and the area of vessels per field of interest were 
measured in calibrated digital images (Research Assistant 3.0, RVC, Hilversum, the 
Netherlands). For quantification of the microvessel density (MVD) six representative fields 
of interest per slide (magnification 16x), 3 slides per tumor and 4 animals per group were 
examined. 
 
In vitro cytotoxicity assay 
The rat osteosarcoma ROS-1 cells were maintained in modified Eagle's medium 
supplemented with 10% fetal calf serum and 0.1% penicilline-streptomycine. Media and 
supplements were obtained from Life Technologies, the Netherlands. 
ROS-1 cells were added in 100 µl aliquots to 96-well flat-bottomed microtiter plates 
(Costar, Cambridge, MA, USA) at a final concentration of 1x104 cells per well and allowed 
to grow as a monolayer. Cells were incubated at 37ºC in 5% CO2 for 72 hours in the 
presence of various concentrations of TNF, doxorubicin and Doxil®. The range of final 
drug concentrations wa
1
(SRB) assa
with phosphate buffered saline, incubated with 10% trichloric acetic acid (1 hour, 4ºC) and 
washed again. Cells were stained with 0.4% SRB (15-30 min), washed with 1% acetic acid 
and were allowed to dry. Protein bound SRB was dissolved in TRIS (10 mM, pH 9.4). The 
optical density was read at 540 nm. Tumor cell growth was calculated using the formula: 
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growth to 50% of the control (IC50) was determined from the growth curves. The 
experiments were repeated at least 5 times. 
xorubicin uptake in tumor cells 
 emission at 530 
nalysis 
esults were evaluated for statistical significance with the Mann Whitney U test. P-values 
ed statistically significant. Calculations were performed on a 
osteo-sarcoma after systemic
dose 4.5 mg/kg Doxil  or free 
®
plus TNF and Doxil  plus TNF. 
 
In vitro assessment of do
Intracellular doxorubicin levels in osteosarcoma ROS-1 cells were measured by 
flowcytometry to determine whether the observed in vitro toxicity correlated with cellular 
uptake of doxorubicin. ROS-1 cells were plated in 24-well plates at a final concentration of 
5x104 cells per well and allowed to growth as a monolayer. Doxorubicin, Doxil® and TNF, 
diluted in DMEM supplement with 10 % fetal bovine serum, were added to the wells, after 
which cells were incubated for 10, 30, 60 and 120 min. The final drug concentration in the 
wells for all three drugs was 0, 0.1, 1.0 and 10 µg/ml. After incubation, cells were washed 
to discard non-incorporated drug and treated with trypsin-EDTA for 2 min. The cell 
suspensions were washed twice in DMEM supplemented with 10% FCS and resuspended 
in PBS. Cellular uptake was measured on a Becton Dickinson FACScan using Cell Quest 
software on Apple Macintosh computer. Excitation was set at 488 nm and
nm. Fluorescence was corrected for cell size using the forward scatter (FSC) with the 
formula: corrected fluorescence (FLcor) = fluorescence at 530 nm (FL530) / FSC – FL530c 
/ FSCc (FL530c and FSCc are fluorescence and forward scatter with no drug added to the 
cells). 
 
Statistical a
R
below 0.05 were consider
personal computer using GraphPad Prism v3.0 and SPSS v10.0 for Windows 2000. 
 
Figure 1. Growth curves of 6000
subcutaneous implanted ROS-1 
treatment with Doxil® and low dose 
TNF. Rats were injected five times 
intravenously with an interval of 4 
days between the injections; first 
®
doxorubicin and 1.0 mg/kg for 
consecutive doses and 15 µg/kg TNF 
for all five doses. Buffer alone, TNF, 
doxorubicin, Doxil , doxorubicin 
®
Mean tumor volumes are shown ± 
SEM. 
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Results  
Effect of low-dose TNF on anti-tumor activity of Doxil®  
o evaluate the anti-tumor activity of Doxil® in combination with low-dose TNF, 
ions of doxorubicin or Doxil® 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Paraffin sections of the 
rat osteosarcoma after systemic 
treatment, haema-toxylin-eosin 
stained. Rats were treated with 
placebo liposomes, TNF (15 
µg/kg), Doxil® (4.5 mg/kg first 
dose and 1 mg/kg dose 2 to 5) or 
TNF combined with Doxil®. 
Representative pictures are shown. 
Original magnification 2.5 and 
16X. 
T
osteosarcoma-bearing rats were treated with a total of 5 inject
with or without TNF. Treatment with free doxorubicin resulted in a slight delay in tumor 
growth, with progressive diseases in all animals (Figure 1). Progressive disease was also 
seen in all animals treated with Doxil®, but with a better tumor growth delay than free 
doxorubicin. Addition of TNF to the Doxil® treatment enhanced the anti-tumor response, 
resulting in a response rate of 50% (partial plus complete response). In contrast, addition of 
TNF to doxorubicin treatment did not improve the anti-tumor response. Treatment with 
TNF alone had no anti-tumor effect. No obvious systemic toxicity was observed in any of 
the treatments. 
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Histologic examination of anti-tumor activity of Doxil® in combination with TNF 
with the same size, shortly after 
administration of 3 injec-tions of 
first dose and 1 mg/kg dose 2 and 3) with 
or without TNF. Tumors were excised 24 
hours after last injection. The mean of 3 to 
6 rats is shown ± SEM. 
 
 
 
Doxil® and doxorubicin accumulation in tumor tissue  
To investigate whether the observed beneficial effect of TNF n the Doxil® treatment was 
due to an increased liposome extravasation into tumor tissue, doxorubicin concentrations in 
tumors after three treatments were determined. Doxorubicin le els in tumors were 3.5-fold 
higher when Doxil® was injected compared to free doxorubicin, although not significantly 
(Figure 3). Addition of TNF did not induce a further accumula on of Doxil® and TNF had 
also no effect on the tumor uptake of free doxorubicin. 
 
Microvessel density 
Quantification of the microvessel density (MVD) was perform d by immunohistochemical 
staining of endothelial cells in frozen BN175 and ROS-1 tumor sections (Figure 4A-D). 
The number of vessels as well as the total tumor vessel area 
vessel is computed by dividing the total vessel area by the nu
of vessels in the BN175 tumor was 2.9 times higher than i
4A)(p=0.021), although the vessels have the same size (Figure 
 
Direct effect of Doxil® combined with TNF on ROS-1 cells in
In vitro experiments were performed to define whether direct c
improved tumor response of Doxil® in combination with 
exposure of ROS-1 tumor cells to doxorubicin resulted in a dependent cell growth 
Histopathological examination was performed on tumors 
regrowth occurred. Treatment of the rats with Doxil® and Doxil® in combination with TNF 
resulted in severe tumor necrosis and extensive cell death (Figure 2). Massive coagulative 
necrosis of 68% of the tumor area was seen in Doxil® treated tumors and 40% in the Doxil® 
plus TNF treated tumors. Less necrosis was seen in rats treated with placebo liposomes or 
TNF (10 and 17%, respectively). In all four groups infiltrated PMN were detected. 
 
Figure 3. Concentrations of doxorubicin 
in ROS-1 tumors after systemic 
doxorubicin (DXR) or Doxil® (4.5 mg/kg 4
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6
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was measured. The area per 
mber of vessels. The number 
n the ROS-1 tumor (Figure 
4B). 
 vitro 
ytotoxicity contributed to the 
TNF. Figure 5 shows that 
dose 
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inhibition, with an IC50 of 3.8 µg/ml. Doxil® appeared to be less cytotoxic to osteosarcoma 
 
 
 
in)
in a 
cells with an IC50 of 25.7 µg/ml. ROS-1 cells were moderately sensitive to TNF with a 
maximum growth inhibition of 32% at 10 µg/ml TNF. Addition of TNF to doxorubicin or 
Doxil® had no effect on the cytotoxicity of the anti-tumor agents; comparable IC50 values 
were found. 
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doxo
doxo
m
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Disc
In thFigure 4. Microvessel density (MVD) of untreated ROS-1 and BN175 tumors of 9-11 mm in
diameter was assessed by immunohistochemical staining for CD31. (A) Number of vessels per
field of interest. The BN175 tumor has 2.9 times more vessels than the ROS-1 tumor (p=0.021)
(B) area endothelium per vessel. The vessels of the BN175 and ROS-1 tumors are of the same
size. Six representative fields of interest per slide (magnification 16X), 3 slides per tumor and 4
animals per group were examined. The mean ± SEM is shown. Photographs of cryostatsections
of untreated tumors of 8-10 mm in diameter stained for CD31. (C) ROS-1, (D) BN175.
Representative pictures are shown. Original magnification 16X.me (ranging 10 to 120 
. Addition of TNF up to 10 µg/ml did not result in an increased uptake of doxorubicin 
® ®
better tumor growth delay than free doxorubicin in osteosarcoma-bearing rats. 
 
tro uptake of Doxil® or doxorubicin in tumor cells in vitro 
xamined if TNF augmented the intracellular accumulation of doxorubicin or Doxil®, 
h could explain the improved tumor response. Increased intracellular concentrations of 
rubicin or Doxil® were observed when incubated with increasing concentrations of 
rubicin or Doxil® (ranging 0.1 to 10 µg/ml) and increasing ti
xil® (data not shown). 
ussion 
e present study we demonstrated that Stealth  liposomal doxorubicin (Doxil ) resulted 
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However, tumor control was not achieved as progressive disease was observed in all 
animals. Addition of low-dose TNF augmented the anti-tumor activity of Doxil® resulting 
in a response rate of 50%. These experiments are in agreement with earlier studies where 
we demonstrated that TNF improved the anti-tumor activity of Doxil® in a rat soft-tissue 
sarcoma and a mouse melanoma model (22,23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. In vitro growth of the 
ROS-1 tumor cells as a function of 
il® (A) or 
atio with 
er m  The 
ind idual 
 du icate 
 
iffusion whereas transport 
mor types. Vessels of some but not all primary brain tumors are 
early impermeable, while in other tumors cutoff pore sizes between 100 nm and 1.2 µm 
are found. Vascular permeability may depend on tumor type and microenvironment and 
increases with tumor size. It is believed that not the microvessel density is the limiting 
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Transport of small drugs across the blood vessel wall involves d
of macromolecules involves convection. Diffusion is the random motion of small 
molecules. Convection is mediated by the movement of fluid (29-32). In highly 
vascularized tumors more tumor cells will be reached by the chemotherapeutics. In general, 
tumor vessels are more permeable than normal vessels and the maximum size of particles 
that can cross the tumor vessel wall is called the pore cutoff size. There is a large variance 
in cutoff sizes in different tu
n
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factor of macromolecule drug delivery to solid tumors, but the permeability of the tumor 
e through the tumor vasculature (1,3,4,6-
8,36). In the present study we showed that systemic treatment with Doxil® resulted in a 
better tumor growth delay than free doxorubicin and that the 3.5-fold increased drug 
accumulation could explain the observed enhanced anti-tumor effect. The anti-tumor 
activity of Doxil® in the osteosarcoma model is comparable t e anti-tumor activity in the 
soft-tissue sarcoma BN175, although in vitro studies show  a clear difference. BN175 
cells are 10 times more sensitive to Doxil® than ROS-1 cells (22). Four times more Doxil® 
is found in ROS-1 tumor tissue than in the BN175 tumor after 3 i.v. injections of Doxil® 
alone. Most likely this indicates that the tumor vessels o the ROS-1 tumor are more 
permeable than the vessels of the BN175 tumor.  
Previously we reported on the improved anti-tumor activity o ically injected Doxil® 
when combined with low-dose TNF in soft tissue sarcoma-bearing rats. Repeated injections 
of Doxil® plus TNF resulted in augmented tumor uptake orubicin which could 
explain the observed enhanced anti-tumor effect (22). Also i  the B16 melanoma-bearing 
mice an augmented accumulation of Doxil® is seen when co bined with TNF. TNF likely 
increases the leakiness of the vasculature by increasing the
lining in the tumor, possibly explaining the augmented accum
liposomes (24,25). 
In the present study we did not observe an increased drug ac
combined with TNF in the osteosarcoma ROS-1 model. 
endothelial cells and the ROS-1 tumor is less vascularized tha or. Although 
in TNF-based isolated hepatic perfusions a highly vascula umor results in a good 
tumor response and vice versa, no such effect was found in he TNF-based isolated limb 
vessels (33,34).  
Several studies have shown that encapsulation of anticancer agents in liposomes can reduce 
systemic toxicity while retaining or even improving in vivo efficacy (1,4,7,35). Doxil® is 
effective in the treatment of several tumor types, including advanced or metastatic soft 
tissue sarcoma (9), AIDS-related Kaposi's sarcoma (10), metastatic breast cancer (11) and 
epithelial ovarian cancer (12). Stealth® liposomes have a long circulation time and tend to 
accumulate in tumors, presumably due to leakag
 
o th
ed
f 
f system
 of dox
n
m
 gaps between the endothelial 
ulation after extravasation of 
cumulation when Doxil® was 
TNF has an effect on tumor 
n the BN175 tum
rized t
 t
perfusion (ILP). Both the BN175 and the ROS-1 tumor showed a synergistic anti-tumor 
response when TNF is added to the ILP (18,37).  
In vitro studies demonstrated a higher sensitivity of the osteosarcoma cells for TNF as 
compared to the BN175 cells. The dose of TNF used in the systemic treatment is probably 
too low to have an effect on it’s own, but may switch the balance to a better response when 
combined with Doxil®. Also, administration of TNF may trigger local production of TNF 
and other cytokines improving tumor response when combined with Doxil®.  
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We found less coagulative necrosis in tumor tissue after treatment with Doxil® and TNF 
than with Doxil® alone. We think this is due to the fact that the tumors were excised at the 
same size. As the tumors from Doxil® plus TNF treated rats regressed more they also 
regrew more to gain the same size as the Doxil® alone treated tumors. 
es. Nature. 1996;380(6574):561-562. 
Applications of Liposomes, pp. 231-257. New York: Elsevier Science, 1998. 
rd JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin 
X) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a 
 13.  Bickels J, Manusama ER, Gutman M, et al. Isolated limb perfusion with tumour necrosis factor-alpha and 
r extremity. Eur J Surg Oncol. 1999;25(5):509-514. 
cumulative multicenter European experience. Ann Surg. 1996;224(6):756-764. 
We demonstrated for the first time that TNF augments the anti-tumor activity of Doxil® not 
only in highly vascularized tumors like the soft-tissue sarcoma BN175, but also in the 
intermediate vascularized ROS-1. These findings confirm the promising role for TNF as 
enhancer of systemic therapy of solid tumors with Stealth® liposomes. 
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Abstract 
dequate drug uptake at the tumor site remains a crucial problem in solid tumor therapy. 
Drug delivery m ociated 
asculature. We an with an 
ti-tumor vascul atically 
hanced tumor re tions in 
the tumor. We ha  tumor 
ter systemic treatment with long circulating liposomes in co  TNF. 
ddition of TNF to systemic injections with 100 nm liposo  tumor 
accumulation by 5 to 6-fold. Also when 400 and 800 nm liposomes were co-administered 
ith TNF accumulation of liposomes in tumor was increased, although much less 
ors is one of 
e main problems faced in systemic tumor therapy and frequently responsible for failure of 
initially promising agents. The pathophysiology of the tumor vasculature and stromal 
y treatment of solid tumors with anticancer drugs often fails. 
irst, metabolism and clearance of drugs in the body results in low drug concentrations at 
e tumor site. Second, poor perfusion of the tumor, arterio-venous shunting and necrotic 
nd hypoxic areas, as well as a high interstitial fluid pressure (IFP) may limit the 
enetration of drugs into the tumor and prevent drugs in reaching tumor cells distant from 
lood vessels. Finally, most anticancer drugs are also toxic towards normal cells. Hence, 
the dose of administrated drugs is limited by normal tissue tolerance. Inadequate drug 
elivery leads to poor responses and regrowth of tumors and possibly to development of 
rug resistant tumor cells (2).  
umor vessels tend to exhibit an increased permeability to macromolecules when compared 
ith normal vessels. This indicates that blood born elements, when small enough, easily 
ross the endothelial lining of tumor vessels (3,4). Dvorak et al. demonstrated that not all 
essels exhibit this feature, which could explain the heterogeneous extravasation of 
y injected drugs (2). 
A
ay be improved by augmenting leakage of t
d others have previously shown that combining
ar therapy (e.g. Tumor Necrosis factor alpha
sponse, which strongly correlated with increased
v used intravital microscopy to study drug diste 
he tumor-ass
 chemotherapy 
 (TNF)) dram
 drug concentra
ribution in solid
mbination with
mes improved
v
an
en
af
A
w
pronounced. By intravital microscopy we observed a more extensive distribution of the 
liposomes when TNF was co-administered. Typically, increased extravasation of liposomes 
was observed along the tumor vessels, with a more even distribution than without TNF. 
These results indicate that more tumor vessels become permeable by TNF, leading to a 
more homogeneous distribution of the liposomes throughout the tumor, which is crucial for 
an optimal tumor response. 
 
Introduction 
Successful treatment of solid tumors with chemotherapeutics requires that adequate levels 
of anticancer agents reach the tumor cells. Localization of drugs in solid tum
th
compartment presents a major obstacle to effective delivery of agents to solid tumors (1). 
There are several reasons wh
F
th
a
p
b
d
d
T
w
c
v
systemicall
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Improvement of drug delivery by TNF 
Several studies have shown that encapsulation of anticancer agents in liposomes can reduce 
the IFP in tumors (19).  
 the present study a B16BL6 mouse tumor model has been used to investigate the 
 Stealth® liposomes of different sizes in combination with low dose TNF. 
to instructions (Molecular Probes, Eugene, OR, USA). 
systemic toxicity while retaining or even improving in vivo efficacy (5-8). Stealth® 
liposomes are sterically stabilized liposomes that contain methoxy-polyethylene glycol 
(MPEG). Because of their small size, long circulation time, and reduced interaction with 
formed elements of the blood, these liposomes tend to accumulate in tumors, presumably 
due to leakage through the often-compromised tumor vasculature (7-12). Furthermore, they 
can target the tumor with high selectivity by taking advantage of the enhanced permeability 
and retention effect (EPR) (13,14). 
In previous studies we showed that co-administration of Doxil® (Stealth® liposomal 
doxorubicin) and low-dose TNF resulted in a pronounced tumor response in both rat and 
murine tumor models. When B16BL6 melanoma-bearing mice were injected with Doxil® 
combined with TNF, drug accumulation increased 3-fold compared to liposomes alone 
(15,16). The augmented accumulation of the chemotherapeutic drug in the tumor tissue 
presumably explains the enhanced tumor regression. TNF likely increases the leakiness of 
the vasculature by increasing the gaps between the endothelial lining in the tumor, leading 
to augmented accumulation after extravasation of liposomes (17,18). Furthermore, TNF has 
been demonstrated to lower 
In
biodistribution of
Additionally we performed intravital microscopy to study tumor distribution of free and 
liposomal drugs in B16BL6 melanoma implanted in the mouse dorsal skin-fold chamber. 
Liposomes of 100 and 400 nm were used to investigate if these liposomes can cross the 
tumor vessel wall and if low dose TNF can cause an enhanced extravasation into the tumor 
tissue. 
 
Materials and methods 
Agents 
Recombinant mouse Tumor Necrosis Factor-α (TNF, specific activity 3X107 IU/mg) was 
kindly provided by Dr. G. Adolf (Bender Wien GmbH, Wien, Austria) and stored at a 
concentration of 2 mg/mL at -80°C or under liquid nitrogen. Endotoxin levels (LAL) were 
below 1 EU/mg. Pegylated liposomal doxorubicin (Doxil®) was kindly provided by Dr. 
Peter Working (ALZA Corporation, Mountain View, CA, USA). Doxil® liposomes were 
labeled with DiO according 
Doxorubicin hydrochloride (Adriblastina®) was purchased from Pharmacia (Brussels, 
Belgium). Fluorescein isothiocyanate conjugated to bovine serum albumin (FITC-BSA; 
Sigma, Zwijndrecht, the Netherlands) was dissolved in phosphate buffered saline at a 
concentration of 10 mg/ml. 
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Preparation of sterically stabilized long circulation liposomes (SL) 
For preparation of the liposomes the following chemicals were used: Partially 
Hydrogenated Egg Phosphatidyl Choline (PHEPC) was kindly provided by Lipoid GMbH 
and cholesterol (Chol) was obtained from Sigma (Zwijndrecht, the Netherlands). Distearoyl 
phosphatidylethanolamine (DSPE) is derivatized at its amino position with a MW 1900 
segment of poly-(ethyleneglycol) (PEG). PEG-DSPE was kindly provided by Dr. P. 
Working (ALZA Corporation, Mountain View, CA, USA). Gallium67 citrate was obtained 
from Nordian (Montreal, Canada) and deferoxamine mesylate (DF) from Sigma 
ter 3.5 mm) (Soniprep 150, Sanyo, 
 of 67Ga needed was diluted 1:10 in 8-hydroquinoline and incubated for 1 hour at 
2°C. 67Ga-oxine was added to the liposomes and incubated overnight at 4°C. To remove 
mes were eluted on a sephadex G-50 (Pharmacia, Uppsala, 
 column and concentrated using ultra centrifugation at 60.000 rpm for 2 hours at 
(Zwijndrecht, the Netherlands). 
A mixture of PHEPC (242.5 mg), cholesterol (64.5 mg) and PEG-DSPE (67.5 mg) in a 
molar ratio of 1.85:1:0.15, suspended in chloroform/methanol, was evaporated to dryness in 
a rotary evaporator, redissolved in tertiair buthanol and freeze-dried overnight. The dried 
lipid film was resuspended in HEPES buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) 
containing 5 mM deferoxamine mesylate (as described previously (20). The hydrated 
lipidfilm was vortexed and liposomes of approximately 100 nm were brought to specific 
size by sonification during 10 to 15 minutes at amplitude 9 using an ultrasonic disintegrator 
supplied with an exponential microprobe (diame
Leicester, UK). Liposomes of 400 nm and 800 nm were obtained by multiple extrusions 
through polycabonate membranes (Nuclepore, Pleasanton, USA) with corresponding pore 
size, followed by size purification by ultra-centrifugation. Liposome size was determined 
by dynamic light scattering (DLS, Malvern 4700 system, Malvern, UK). The total lipid 
concentration was determined according to Bartlett (21) and liposomes were labeled with 
67Ga according to Gabizon et al. (20). 1 µmol lipid was labeled with 1 µCi 67Ga. The 
amount
5
the free 67Ga-oxine the liposo
Sweden)
4°C (Beckman). The amount of lipid was determined again and the liposomes were stored 
at 4°C. 
For the preparation of RhoPE Stealth® liposomes, 400 µg rhodamine-DHPE (Molecular 
Probes, Eugene, OR, USA) was added to the mixture of PHEPC, cholesterol and PEG-
DSPE. Further preparation of 100 and 400 nm liposomes was identical as described above 
except for the addition of deferoxamine mesylate to the HEPES-buffer. After preparation, 
the amount of lipid was determined and the liposomes were stored at 4°C.  
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Animals and tumor model 
Specific pathogen-free female C57BL/6 mice were purchased from Harlan-CPB, 
(Austerlitz, the Netherlands), weighing about 20 grams, and were fed a standard laboratory 
diet ad libitum (Hope Farms Woerden, the Netherlands).  
The B16BL6 melanoma was used for the distribution studies. B16BL6 cells were 
maintained in vitro in DMEM supplemented with 10% FCS. Tumor was induced in donor 
mice by injection of 500.000 cells subcutaneously in the flank. For this purpose and 
experiments described below mice were anesthetized by subcutaneous injection of 150 µl 
of a 1:1 (v:v) mixture of Ketamine (Alfasan, Woerden, the Netherlands) and Xylazine 
ice was sandwiched between two frames, fixed with two light metal bolds and 
xperimental procedure of analysis of tumor distribution of liposomal drugs using intra-
ital microscopy 
he experiments started 10-14 days after implantation of the window chamber. The mice 
ere anesthetized and injected via the tail vein with 4.5 mg/kg Doxorubicin, 4.5 mg/kg 
(Bayer AG, Leverkusen, Germany). At a tumor size of 10 mm tumor tissue was dissected 
under sterile conditions, cut in small pieces in sterile physiologic solution, and directly used 
for implantation in the window chamber or subcutaneously for the biodistribution study as 
described below. 
All animal studies were done in accordance with protocols approved by the committee on 
Animal Research of the Erasmus MC, Rotterdam, the Netherlands. 
 
Experimental procedure of tissue biodistribution of sterically stabilized liposomes 
Experiments started at a tumor diameter of 10 ± 1 mm. At least 3 mice per group were 
injected via the tail vein with 67Ga-labeled liposomes (48 µmol/kg) with or without TNF (1 
µg/mouse). Mice were sacrificed 12 or 24 hours after liposome injection. Before sacrifice, 
blood was taken from the heart under anesthesia. Tumor, liver, spleen, lung, hart and 
kidney were collected, weighed, and counted in a Beckmann 8000 gamma counter. 
 
Preparation of window chambers and tumor implantation. 
The preparation of the dorsal skin-fold chamber is an adaptation from previously described 
procedures (22-24). Briefly, mice were anesthetized and hair was removed from the back of 
the animal. At one side of the skin-flap the window was outlined and a 12 mm diameter 
flap of skin was dissected away, leaving the fascia and opposing skin. The skin-fold on the 
back of m
sutures. A small piece of tumor (0.1 mm3) was transplanted in the fascia using a micro-
surgical microscope. On both sides the windows were closed with a 12 mm diameter 
microscopic cover glass of 0.13-0.16 mm thick. The mice were housed in an incubation 
room with an ambient temperature of 32°C and a humidity of 50%.  
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Doxil® DiO or 48 µmol/kg lipid 100 or 400 nm RhoPE liposomes (equals 4.5 mg/kg 
or vasculature were made with a 
 filter (Albumin-FITC) and 543 nm laser and 560-615 nm band pass filter 
n vitro uptake of (liposomal) drugs in B16BL6 cells 
 seeded 
after co-administration 
ith low-dose TNF compared to liposomes alone (p<0.02), and a 5.5-fold increase after 24 
ake of liposomes compared to liposomes alone (at 12 hours (p<0.02) and 
Doxil®) with or without 1 µg TNF/mouse. For intravital microscopy the mice were 
anesthetized and fixed to a heated microscopic stage. Injection of FITC-BSA allows 
visualization of functional vessels. Observations of the tum
Leica DM-RXA fluorescence microscope with the fluorescence filters for GFP (excitation 
450-490 nm and emission 515 nm, long pass filter) and Rhodamine (excitation 515-560 nm 
and emission 590 nm, long pass filter). Images of the tumor were acquired using a Sony 
3CCD DXC950 digital color video camera connected to a PC. Image acquisition and image 
analysis was performed with Research Assistant 3.0 for Windows 98 (RVC Visual 
Computing, Inc., Hilversum, the Netherlands).  
For intravital confocal microscopy the mice were fixed to a Zeiss LSM 510 META 
confocal microscope with a heated stage. Scans were made with a 488 argon laser and 500-
550 nm band pass
(Rhodamine). 
 
I
A circular cover glass was placed in a sterilized cell culture ring. B16BL6 cells were
and grown till confluency. The cells were washed and Doxil® or doxorubicin was added at 
a concentration of 5 µg/ml. The ring was placed under the Zeiss LSM 510 META confocal 
microscope equipped with an incubation chamber, which is maintained at 37°C with 
controlled CO2-flow. Every 5 minutes scans were made using the 543 nm laser and 560-615 
nm band pass filter (Rhodamine). 
 
Statistical analysis 
Results were evaluated for statistical significance with the Mann Whitney U test. P-values 
below 0.05 were considered statistically significant. Calculations were performed on a 
personal computer using GraphPad Prism v3.0 and SPSS v11.0 for Windows 2000. 
 
Results 
Tumor distribution of sterically stabilized liposomes (67Ga-labeled) 
Liposomes of 100, 400 or 800 nm with or without low-dose TNF were injected i.v. into 
mice bearing subcutaneous B16BL6 tumor (Figure 1A). The results show a 6.3-fold 
increased accumulation of 100 nm liposomes in the tumor 12 hours 
w
hours (p<0.02). Co-administration of TNF and 400 nm liposomes resulted in a 5.1 and 9.1-
fold enhanced upt
24 hours (p<0.01), respectively). Twelve hours after treatment, TNF did not cause an 
increased uptake of 800 nm liposomes, but after 24 hours we saw a 12.6-fold increase in 
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comparison with liposomes without TNF (p<0.02). Importantly, after 12 hours the uptake 
of 400 and 800 nm liposomes is significantly reduced compared to the 100 nm liposomes 
when co-administered with TNF. The same result was seen after 24 hours. There were no 
significant differences between 400 and 800 nm. These results indicate the beneficial 
properties of 100 nm liposomes as compared to the larger liposomes, even in the presence 
of TNF. 
In conclusion, TNF is able to enhance the uptake of liposomes of 100, 400 and 800 nm and 
small liposomes of 100 nm localized in the tumor in a larger amount than 400 and 800 nm 
liposomes. 
tumor  
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Tissue distribution of sterically stabilized liposomes 
Besides the tumor distribution of liposomes, also tissue distribution was investigated. In the 
spleen, TNF did not significantly increase uptake of all three liposome sizes, although a 
trend towards an increased uptake was visible (Figure 1B). Without TNF, uptake of the 
larger liposomes by the spleen was comparable to uptake of the 100 nm liposomes. When 
liposomes were co-administered with TNF, an increased uptake of the 800 nm liposomes 
Liposome levels seemed elevated in liver tissue when TNF was add ncreased 
uptake was not significant for the 800 nm liposomes at both time nts and 400 nm 
liposomes 12 hours after injection (Figure 1C). For the 100 nm liposomes a clear increased 
liposome accumulation, when combined with TNF, was detected 12 and 24 hours after 
administration (p<0.01 and p<0.03, respectively) and for the 400 nm liposomes an 
increased accumulation after 24 hours was found (p<0.02). For the liver, injection of large 
liposomes did not result in an increased uptake of these liposomes compared to 100 nm 
liposomes. 
In other organs like kidney, TNF caused an augmented accumu tion of liposomes, 
especially of the 100 and 800 nm liposomes 24 hours after injection. When co-administered 
with TNF, more 800 than 400 nm liposomes were taken up by the kidn , but less than 100 
nm liposomes (data not shown). 
Unexpectedly, levels of 100 nm liposomes in the blood circulation 24 rs after injection 
were increased when combined with TNF (p<0.03), although this was not significant after 
12 hours. TNF did not have a significant effect on the amount  large liposomes 
circulating in the blood. Less liposomes of 400 and 800 nm were circulating in the blood 
compared to 100 nm 12 hours after injection, but no differences were seen after 24 hours. 
In lung and hart tissue, TNF caused an increased uptake of all three liposomes sizes 24 
hours after injection. TNF enhanced the uptake of 100 nm liposomes ore than 800 nm or 
400 nm liposomes (data not shown). 
 
Intratumoral distribution of liposomal drugs 
Clearly, addition of a tolerable dose of TNF to systemic injection of Stealth® liposomes 
resulted in augmented accumulation of these liposomes, varying from 100 to 800 nm, in the 
tumor. However, insight in the intratumoral localiz
we studied the effect of TNF on the intratumoral d
use of intravital microscopy.  
 
 
 
was detected compared to the 100 nm (after 12 and 24 hours)(p<0.04) and the 400 nm 
liposomes (only after 24 hours)(p<0.04). 
ed, but the i
 poi
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ey
 hou
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m
ation of the liposomes is lacking. Here 
istribution of liposomal drugs with the 
142 
Improvement of drug delivery by TNF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Extravasation and intratumoral distribution of 100 nm RhoPE liposomes in B16BL6 tumor. Injection
of liposomes with PBS (PBS) or combined with 1 µg/mouse TNF (TNF). Limited extravasation of the
dy after 12 h (D-F). FITC-BSA was used to visualize the tumor-associate
liposomes was observed at 12 h when no TNF was added (A-C), while most of the liposomes remained in
blood vessels after 24 h (G-I). Addition of TNF to liposomal treatment resulted in massive and homogeneous
extravasation of the liposomes alrea d
vasculature, showing extravasation of this blood marker at 24 h after injection of liposomes combined with
TNF indicating prolonged vascular leakage (J-L). At higher magnification strong extravasation is observed
from functional vessels at 24 h (M-O). Bar: 500 µm (A-F), 200 µm (G-L), and 50 µm (M-O). 143 
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In the 10 days after the tumor was implanted in the mouse window, it has grown 
pproximately to a size of 4-5 mm and established its own blood supply. Unlike the normal 
lood vessels around the tumor, the newly formed vessels are not well organized. In the 
xperiments FITC-BSA was injected to visualize functional blood vessels. In general it can 
e concluded that blood vessels in the periphery of the tumor were more functional than the 
essels in the center of the tumor. 
e first investigated RhoPE liposomes with a size of 100 nm. Although tumor 
icrovessels are hyperpermeable, their permeability is very heterogeneous. In large parts of 
e tumor no fluorescence was detected, as shown in figures 2A-C. Most liposomes in the 
mor accumulated in blood vessels at 24 hours (Figures 2G-I). Even 48 hours after 
jection most of the liposomes were still present in the blood vessels and did not 
xtravasate into the tumor interstitium. Addition of TNF resulted in an abundant 
ccumulation of liposomes in the tumor interstitium (Figure 2D-F). Only in few areas 
posomes were trapped inside non-functional blood vessels. Importantly, liposomes 
xtravasated more homogeneously throughout the tumor when TNF was co-administered. 
he TNF-induced permeability of the tumor vessels maintained for at least 24 h, resulting 
 extravasation of Albumine-FITC at that time-point at the same spot as liposomes leaked 
ut (Figures 2J-L). At higher magnification we observed that Albumine-FITC positive 
essels were quite permeable for 100 nm liposomes (Figures 2M-O). This suggests that 
posomes extravasated from blood vessels that were functional. It can be concluded that 
e addition of TNF caused an increased extravasation of 100 nm RhoPE liposomes into the 
mor interstitium in a more homogeneous way. Strikingly, less liposomes were trapped 
side blood vessels when TNF was co-administered. These results indicate that 
dministration of TNF results most likely in an increase in the number of leaky vessels.  
revious studies show that tumor vessels exhibit gaps between the endothelial cells with a 
ut off of approximately 400 nm (25). To investigate if TNF has a comparable effect on the 
tratumoral distribution of larger liposomes, RhoPE liposomes of 400 nm were injected 
to tumor-bearing mice. Clearly, more liposomes were trapped inside blood vessels 
ompared to 100 nm liposomes (Figure 3). Strikingly, most of the vessels that contain 
posomes were non-functional and accumulation in these blood vessels was very 
heterogeneous. Addition of TNF to the liposome treatment enhanced the extravasation of 
l  
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i e examined the 
tumor distribution of free doxorubicin and the long circulating liposomal form Doxil®  
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iposomes only slightly, mostly at the periphery of the tumor, while in the central part of the
umor liposomes appeared preferentially trapped in vessels (Figure 3). These result
ndicate a diminished usefulness of the 400 nm liposomes as compared to liposomes of 100 
m for the treatment of solid tumors, also in the presence of TNF. 
t is known from previous studies that total drug uptake of free doxorubicin in tumor tissue 
s rather low compared to liposomal doxorubicin (16). In the present study w
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Figure 3. Diminished extra-
vasation of 400 nm liposomes. 
resulted predominantly in 
accumu-lation in tumor vessels, 
and remained trapped for long 
periods: 24 h (A-C) and 36 h (D-
Injection of 400 nm liposomes 
F). FITC-BSA was administered 
12 h after FITC-BSA injection 
liposomes were co-administered 
these vessels, even at the well-
FITC-BSA extravasated predominantly at the tumor periphery. Bar: 200 µm (A-C), 500 µm (D-F and J-L), and 
B16BL6 tumor (A). Only in the periphery of the tumor (dotted line), which exhibits a high degree of 
ulated in low concentration in 
®
treatment with Doxil  alone. 
to visualize the functional tumor 
vessels. Clearly rapid extra-
vasation of FITC-BSA was seen 
shortly after injection (A-C) and 
(D-F), indicating that the tumor 
vessels are predominantly 
permeable for relatively small 
substances. When 400 nm 
with 1 µg/ mouse TNF accu-
mulation in tumor vessels was 
still observed (G-I). Detailed 
examination showed stasis in 
vascularized periphery. At 36 h 
(J-L) co-administration of TNF 
augmented the accumulation of 
400 nm liposomes (*), although only at the outer rim of the tumor (dotted line) and in a rather heterogeneous way. 
100 µm (G-I). 
Figure 4.Tumor accumulation and intratumoral distribution of free doxorubicin in B16BL6 melanoma. After 
systemic injection of free doxorubicin either without or with TNF resulted in minimal drug accumulation on the 
vascularization (+) some accumulation of doxorubicin (*) was observed. In the more central areas of the tumor no 
extravasation of doxorubicin was observed. Bar, 200 µm. While doxorubicin accum
the B16BL6 tumor, either with or without TNF (B), Doxil® accumulation was 2.3-fold (without TNF) and 6.2-fold 
higher (with TNF) then free doxorubicin. Addition of TNF increased Doxil  accumulation 2.7-fold compared to 
®
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(Stealth® liposomal doxor
localization of the liposom
doxorubicin, which is red fluor
or without TNF, hardly a
doxorubicin extravasated p
vascularized. As observed
heterogeneous extravasatio
when injected alone (dat
extravasation of Doxil® (Fi
tumor tissue, abundant ext
predominantly at the rim o
doxorubicin to the nucleus of
only detected in the cytopla
that presumably most Doxil® l
the cytoplasm. 
 
In vitro uptake of (liposoma
When B16BL6 cells were e
cytoplasm was observed w
released doxorubicin to the
This in comparison with tr
directly by the nucleus within minutes after incubation (Figure 6 lower panel). Uptake by 
cells as wel
ubicin). Doxil® is labeled with DiO to distinguish between 
e (green fluorescence of the membrane-associated DiO) and 
escent. When free doxorubicin was administered, either with 
ny drug was detectable in the tumor (Figures 4A-D). Free 
referentially at the outer rim of the tumor, which is highly 
 with the rhodamine-labeled liposomes, limited, focal and 
n of Doxil® was observed especially at the tumor periphery 
a not shown). Addition of TNF dramatically enhanced the 
gure 5A-V). Although liposomes did not penetrate far into the 
ravasation could be observed already at 12 h after injection, 
f the tumor (Figures 5A-D). At later time-points transport of 
 tumor cells could be detected, while the lipid marker was 
sm or interstitial space (Figures 5M-V). These results indicate 
iposomes are taken up intact by the cells and broken down in 
l) drugs in tumor cells 
xposed to Doxil® in vitro, accumulation of this drug in the 
ithin a few minutes (Figure 6). Intracellular transport of the 
 nucleus was observed within 2 hours (Figure 6 upper panel). 
eatment with doxorubicin where the free drug was taken up 
l as intracellular transport of doxorubicin was not affected by TNF (data not 
shown). 
 
Discussion 
Here we demonstrate that administration of long circulating liposomes together with TNF 
results in a dramatically augmented accumulation of these liposomes in tumor tissue. 
Especially liposomes of 100 nm effectively home to the tumor. More precisely, intra-
tumoral distribution studies reveal that administration of TNF results in an increased and 
more homogeneous distribution of the co-injected liposomes. The results indicate that TNF 
after systemic injection. Particles or cells are cleared by the immune system (26).  
rendered more vessels permeable. 
For a systemically injected drug to reach the tumor cell a number of hurdles have to be 
taken (1). Firstly, the blood volume of a solid tumor is rather low compared to the total 
blood volume and massive dilution of the injected drug in the bloodstream occurs. As 
systemic toxicity limits the dose of chemotherapeutic agents, and because of the quick 
clearance by liver and kidney, only low levels are present at any given moment in the tumor 
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Figure 5 
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Figure 5. Intratumoral distribution of Doxil® in B16BL6 melanoma. The effect of TNF on the extravasation and 
tratumoral distribution of doxorubicin (red) released from the Doxil® liposomes (green) was studied by intravital 
microscopy. Strong and homogenous extravasation of liposomes was observed 12 and 24 h after injection (arrow, 
essels and arrow head, extravasated Doxil®)(A-H). Especially at the periphery of the tumor (dotted line) the 
travasation was most abundant (I-L). At later time-points nuclear localization of doxorubicin (red) could be 
bserved (arrow), distant from the tumor vessel (*) while the lipid marker (green) remained in the cytoplasm (M-
). Already at 36 h after injection of Doxil® combined with TNF nuclear localization of doxorubicin in cells 
(arrow) close to the tumor vessels (*) could be observed (Q-S). While concurrently doxorubicin containing 
posomes (yellow in merge) could be observed in the cytoplasm of tumor cells (arrow)(T-V). Bar 100 µm (A-P) 
d 25 µm (Q-V). 
igure 6. In vitro uptake of Doxil® and doxorubicin in B16BL6 melanoma cells. Cells were plated in a sterilized 
cell culture ring and grown till confluency. The cells were incubated with 5 µg/ml Doxil® (upper panel) or 5 µg/ml 
oxorubicin (lower panel) and every 5 minutes scans were made using the 543 nm laser and 560-615 nm band 
ass filter (Rhodamine) of the Zeiss LSM 510 META confocal microscope. The original light intensities in the 
periments were maintained during the experiment and were the same for both Doxil® and doxorubicin treatment. 
he experiments were repeated 3 times and representative time series are shown. 
 
oreover, perfusion of the tumor is heterogeneous, meaning that the drug reaches only well 
ascularized parts of the tumor, whereas hypoxic and necrotic parts are not targeted (27-
9). Secondly, for a drug to reach the tumor cells the drug has to leave the circulation and 
ross the endothelial lining. Normally the endothelial lining is a closed barrier, but blood 
essels supplying tumors appear permeable to macromolecules and particles, with a 
etermined cut off of 400 nm (25). However, not all tumor vessels exhibit this feature. 
vorak et al. demonstrated that the leaky vessels are predominantly mature veins and 
venules lined by a continuous endothelium (2,30). Strikingly, immature interface vessels 
and tumor penetrating vessels do not leak macromolecules. Small molecules on the other 
hand extravasate from all tumor vessels. Thirdly, after extravasation, the anti-tumor agents 
embark on a third barrier, the tumor interstitium. Abundant matrix regularly present in solid 
tumors hinders traverse of the agent. High interstitial pressure works against the 
ccumulation of macromolecules and particles. The accumulation of large molecules and 
s mainly convection driven, whereas small molecules distribute by diffusion (2). 
As solid tumors lack a normally functioning lymphatic system, fluid is driven out of the 
tumor at the periphery taking large molecules and particles along (31). Finally, when the 
drug reaches the tumor cell it has to cross the cell membrane, or when active at the DNA 
level, the nuclear membrane as well. 
At all levels mentioned above modifications can be made to improve efficacy of the 
therapy. An important step forwards is to define targets closer to the injected drug, i.e. the 
endothelial lining, which comprise the first cells seen by an agent after intravenous or intra-
arterial administration. Secondly, vascular manipulation can be used to help drugs, which 
act on the tumor cells, to better reach their target. Next to that tumor response would greatly 
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benefit from enhanced local drug levels, which can be accomplished by targeting the drug 
.g. with the aid of liposomes) or by limiting the dilution of the drug, and in the same time 
creasing local drug level, which can be accomplished in a so-called isolated perfusion 
etting. 
reviously, we demonstrated that addition of TNF to an isolated perfusion with melphalan 
r doxorubicin dramatically improves tumor response (32-34). Moreover, also in a systemic 
etting addition of TNF to liposomal chemotherapy improves tumor response (15,16). This 
ynergy is not, or at least not solely, due to a direct activity of TNF on the tumor cells and 
oes not result from a direct destruction of the tumor-associated vasculature. However, 
ddition of TNF, both in the perfusion setting as well as in the systemic setting, augmented 
umulation of the co-administered drug in the tumors (15,16,32-34). In other studi
bination of tumor cell directed chemotherapy and tumor vasculature 
irected therapy, is an important principle. Although it is known that TNF, but also 
hy tumor vessels, in which αvβ3 exposure is increased, are more responsive to TNF than 
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TNF also enhanced tumor accumulation of liposome-encapsulated adriamycin (35) and 
radio-antibody (36). Curnis et al. found that targeted delivery of TNF coupled to cyclic 
CNGRC peptide to tumor vessels enhances the antitumor activity of chemotherapeutic 
drugs and increased the penetration drugs in tumors (37). These findings led to the search 
for alternative agents with known vascular permeability increasing activity, such as 
histamine and IL-2. We have shown that these agents enhanced drug uptake in the tumor 
resulting in synergistic anti-tumor activity in an isolated setting (38,39) Apparently this 
dual approach, com
d
histamine and IL-2, are capable of increasing the permeability of an endothelial lining, the 
effect of TNF on tumor vessels in the tumor is largely unknown. Ruegg et al. showed that 
TNF in conjunction with IFN induced functional down-modulation of the αvβ3 integrin, 
resulting in detachment and anoikis of the endothelial cells (40). This possibly explains 
w
endothelial cells from healthy vessels, which are quiescent. Important also is which tumor 
vessels are affected by TNF and how distribution of the chemotherapeuticum in the tumor 
is altered. Here we showed that TNF improves accumulation of liposomes, i.e. liposomal 
chemotherapeutics, by making more vessels permeable. Importantly this results in a 
homogeneous drug distribution and thus a homogeneous tumor cell killing. 
In conclusion, we show that TNF improves drug accumulation in solid tumor by making 
more vessels permeable to 100 nm liposomes. As this results in a homogeneous drug 
distribution more tumor cells are exposed to the drug and a better tumor response is 
reached. Our results indicate that the dual approach with the combination of TNF and 
chemotherapy has strong potential for solid tumor therapy and necessitates the further 
development of a clinical applicable formulation. 
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Abstract  
paired drug uptake at the tumor site remains a key barrier to effective chemotherapy of 
solid tumors. Clini
asoactive agent T t 
ith Doxil® strong  
rug accumulation . 
B16BL6 tumor app , 
hile local VEGF levels are comparable in both tumor types t 
mor vascular permeability, and response to TNF, may be the  
liposomal drug delivery rather then microvessel density. 
geneous hyperpermeability to plasma proteins and other 
rculating macromolecules. Vascular permeability depends on tumor type and increases 
e from these 
normal vessels and accumulate in tumor tissue (9,10). Encapsulation of anticancer drugs 
in liposomes results in reduced systemic toxicity while retaining or improving in vivo 
ol (MPEG). They have the advantage over unmodified 
posomes that they are eliminated more slowly by the reticulo-endothelial system (RES) 
sulting in a long circulation time (9,11-13,15-17). Doxil® (Stealth® liposomal 
oxorubicin) is effective in the treatment of several tumor types (18-20). We showed in 
revious studies that co-administration of Doxil® and low-dose TNF resulted in a 
ronounced tumor response in both rat and murine tumor models. When B16BL6 
melanoma-bearing mice or soft-tissue sarcoma-bearing rats were injected with Doxil® 
ombined with TNF, a 3-fold increased drug accumulation in tumor tissue was found 
ompared to treatment with liposomes alone (18,19). The increased drug uptake correlates 
ith the synergistic antitumor response. A possible explanation for the augmented 
ccumulation is that TNF increases the leakiness of the vasculature by increasing the gaps 
etween the endothelial lining in the tumor (20,21).  
ent study we investigated whether addition of low-dose TNF to Doxil® treatment 
would lead to the same anti-tumor response and liposomal tumor distribution in tumors 
Im
cal and animal studies show strongly improved
NF is co-administered. Whilst addition of T
ly improved the anti-tumor response, which co
, in the B16BL6 model, no such effect was ob
red less vascularized than the LLC, but the ea
 tumor response when the 
NF to systemic treatmen
rrelated with the enhanced
served in the LLC model
tumor vessels were larger
. The results indicate tha
limiting factor involved in
v
w
d
w
tu
 
Introduction 
Physiological barriers hinder the effective delivery of drugs to tumors (1). Heterogeneous 
tumor perfusion and increased interstitial fluid pressure (IFP) may limit the penetration of 
drugs into tumor cells distant from blood vessels. Inadequate drug delivery leads to 
insufficient tumor cell kill and to the induction of drug resistance (1-3). It is known that 
tumor blood vessels exhibit hetero
ci
with tumor size and growth rate. It may be higher in the periphery than in the central region 
of the tumor (1,4-8). Delivery systems have been developed to exploit vascular 
permeability. Long circulating liposomal drugs preferentially extravasat
ab
efficacy (11-14). Stealth® liposomes are sterically stabilized liposomes that contain 
methoxy-polyethylene glyc
li
re
d
p
p
c
c
w
a
b
In the pres
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which differed in tumor vasculature characteristics: the B16BL6 tumor and the Lewis Lung 
A, USA). Doxil® liposomes were 
beled with DiO (Molecular Probes, Eugene, OR, USA). Doxorubicin hydrochloride 
s purchased from Pharmacia (Brussels, Belgium).  
s, and were fed a standard laboratory 
Carcinoma (LLC). 
 
Materials and methods 
Agents 
Recombinant murine tumor necrosis factor-α (specific activity 3X107 IU/mg) was kindly 
provided by Dr. G. Adolf (Bender Wien GmbH, Wien, Austria) and stored at a 
concentration of 2 mg/mL at -80°C or under liquid nitrogen. Endotoxin levels (LAL) were 
below 1 EU/mg. Pegylated liposomal doxorubicin (Doxil®) was kindly provided by Dr. 
Peter Working (ALZA Corporation, Mountain View, C
la
(Adriblastina) wa
 
Preparation of sterically stabilized long circulation RhoPE liposomes 
For preparation of the liposomes the following chemicals were used: Partially 
Hydrogenated Egg Phosphatidyl Choline (PHEPC) was kindly provided by Lipoid GMbH 
and cholesterol (Chol) was obtained from Sigma (Zwijndrecht, the Netherlands). Distearoyl 
phosphatidylethanolamine (DSPE) is derivatized at its amino position with a MW 1900 
segment of poly-(ethyleneglycol) (PEG). PEG-DSPE was kindly provided by Dr. P. 
Working (ALZA Corporation, Mountain View, CA, USA).  
A mixture of PHEPC (242.5 mg), cholesterol (64.5 mg) and PEG-DSPE (67.5 mg) in a 
molar ratio of 1.85:1:0.15 and 400 µg lissamine-rhodamine-phosphatidyl-ethanolamine 
(Rho-PE) (Molecular Probes, Eugene, OR, USA) was suspended in chloroform/methanol. 
The mixture was evaporated to dryness in a rotary evaporator, redissolved in tertiair 
buthanol and freeze-dried overnight. The dried lipid film was resuspended in HEPES buffer 
(10 mM HEPES, 150 mM NaCl, pH 7.4), as described previously (10). The hydrated lipid 
film was vortexed and liposomes of approximately 100 nm were brought to specific size by 
sonification during 10 to 15 minutes at amplitude 9 using an ultrasonic disintegrator 
supplied with an exponential microprobe (diameter 3.5 mm) (Soniprep 150, Sanyo, 
Leicester, UK). Liposome size was determined by dynamic light scattering (DLS, Malvern 
4700 system, Malvern, UK). The total lipid concentration was determined according to 
Bartlett (22) and the liposomes were stored at 4°C. 
 
Animals and tumor model 
Specific pathogen-free female C57BL/6 mice were purchased from Harlan-CPB, 
(Austerlitz, the Netherlands), weighing about 20 gram
diet ad libitum (Hope Farms Woerden, the Netherlands).  
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Small fragments (3 mm) of the B16BL6 melanoma or Lewis Lung Carcinoma (LLC) were 
implanted subcutaneously in the flank of the mice. The mice were anesthetized by 
ubcutaneous injection of 150 µl of a 1:1 (v:v) mixture of Ketamine (Alfasan, Woerden, 
ayer AG, Leverkussen, FRG). At a tumor size of 10 mm, 
sue was dissected under sterile conditions, cut in small pieces in sterile physiologic 
of 8-10 mm. The mice 
ere randomized into the following 6 groups: placebo liposomes (equivalent amounts of 
 were injected five 
f tumor diameter exceeded 15 
prepared with known concentrations of 
oxorubicin diluted in acidified isopropanol. All measurements were repeated after addition 
andard. 
tation from previously described 
procedures (24-26). Briefly, mice were anesthetized and hair was removed from the back of 
s
Netherlands) and Xylazine (B
tumor tis
solution, and directly used for implantation in the window chamber or subcutaneously for 
the efficacy study and measurements of liposomal drug accumulation as described below. 
All animal studies were done in accordance with protocols approved by the committee on 
Animal Research of the Erasmus MC, Rotterdam, the Netherlands. 
 
Treatment protocol 
Treatment was started when the tumors reached an average diameter 
w
buffer or lipids), low dose TNF, Doxil® and Doxil® plus TNF. Mice
times intravenously with an interval of 4 days between the injections; first dose of 4.5 
mg/kg Doxil® and 1.0 mg/kg for consecutive doses. TNF was given at a concentration of 1 
µg/mouse for all five doses. When mice were treated with Doxil® combined with TNF, 
these agents were injected separately, shortly after each other. Tumor growth was recorded 
by caliper measurement. Tumor size was expresses as tumor size index, i.e. the product of 
the largest perpendicular diameters. Mice were sacrificed i
mm or at the end of the experiments. 
 
Measurement of doxorubicin accumulation in tumor tissue 
The effect of TNF on Doxil® accumulation in tumors was investigated. Mice received a 
single dose of 1 mg/kg Doxil® with or without low dose TNF. Tumors were excised 24 
hours after injection and tissues were analyzed for doxorubicin and its fluorescent 
metabolites as previously described (23). Briefly, tumors were incubated in acidified 
isopropanol (0.075 N HCl in 90% isopropanol) for 24 hours at 4°C and after that the tumors 
were homogenized (PRO200 homogenizer with 10 mm generator, Pro Scientific, CT, 
USA), centrifuged for 30 min at 2500 rpm and supernatants were harvested. A Hitachi 
F4500 fluorescence spectrometer (excitation 472 nm and emission 590 nm) was used for 
measurement of the samples. A standard curve was 
d
of an internal doxorubicin st
 
Preparation of window chambers and tumor implantation. 
The preparation of the dorsal skin-fold chamber is an adap
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the animal. At one side of the skin-flap the window was outlined and a 12 mm diameter 
flap of skin was dissected away, leaving the fascia and opposing skin. The skin-fold on the 
back of mice was sandwiched between two frames, fixed with two light metal bolds and 
sutures. A small piece of tumor (0.1 mm3) was transplanted in the fascia using a micro-
surgical microscope. On both sides the windows were closed with a 12 mm diameter 
microscopic cover glass of 0.13-0.16 mm thick. The mice were housed in an incubation 
room with an ambient temperature of 32°C and a humidity of 50%.  
 
Experimental procedure of tumor distribution of (liposomal) drugs using intra-vital 
icroscopy 
ted 10-14 days after tumor implantation in the window chamber. The 
erlands).  
atoxylin (Sigma). 
he sections were examined on a Leica DM-RXA and photographed using a Sony 3CCD 
ssels per field of interest were 
m
The experiments star
mice were anesthetized and injected via the tail vein with 48 µmol/kg 100 nm RhoPE 
liposomes (equals 4.5 mg/kg Doxil®) or 4.5 mg/kg Doxil® DiO with or without 1 µg 
TNF/mouse. For intravital microscopy the mice were anesthetized and fixed to a heated 
microscopic stage. Observations of the tumor vasculature were made with a Leica DM-
RXA fluorescence microscope with the fluorescence filters for GFP (excitation 450-490 nm 
and emission 515 nm, long pass filter) and Rhodamine (excitation 515-560 nm and 
emission 590 nm, long pass filter). Images of the tumor were acquired using a Sony 3CCD 
DXC950 digital color video camera connected to a PC. Image acquisition and image 
analysis were performed with Research Assistant 3.0 for Windows 98 (RVC Visual 
Computing, Inc., Hilversum, the Neth
 
Immunohistochemistry 
Untreated tumors with a diameter or 8-10 mm were excised and immediately frozen in 
liquid nitrogen. Immunohistochemical studies were performed on acetone-fixed 5 µm 
cryostat sections. The tumor sections were fixed for 30 min with 4% formaldehyde and 
after rinsing with PBS, the endogenous peroxidase activity was blocked by incubation for 5 
minutes in methanol/3% H2O2. The slides were incubated for 1 hour with 1:50 rat-anti-
mouse-CD31 (Becton Dickinson, Alphen aan den Rijn, the Netherlands) diluted in 5% 
rabbit serum/PBS. Thereafter, sections were washed with PBS and incubated for 1 h with 
rabbit-anti-rat peroxidase-labeled antibody (DAKO, ITK Diagnostics BV, Uithoorn, the 
Netherlands) diluted 1:100 in PBS with 5% mouse serum. After rinsing with PBS, positive 
cells were revealed by immunoperoxidase reaction with DAB solution (DAB-kit, DAKO) 
and counterstained lightly with haem
T
DXC 950 camera. The number of vessels and the area of ve
measured in calibrated digital images (Research Assistant 3.0, RVC, Hilversum, the 
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Netherlands). For quantification of the microvessel density (MVD) six representative fields 
of interest (magnification 16x) per tumor and 5 or 6 animals per group were examined. 
 
In vitro cytotoxicity assay 
The mouse B16BL6 melanoma and LLC cells were both maintained in DMEM 
supplemented with 10% fetal calf serum and 0.1% penicilline-streptomycine. Media and 
supplements were obtained from Life Technologies, the Netherlands. 
he tumor cells were added in 100 µl aliquots to 96-well flat-bottomed microtiter plates 
monolayer. In vitro cytotoxicity was measured using the MTT assay. The MTT 
th curves. The experiments were repeated 
t least 3 times in duplo. 
 
T
(Costar, Cambridge, MA, USA) at a final concentration of 6x103 cells per well and allowed 
to grow as a 
assay is based on the conversion of the yellow tetrazolium salt, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) to the purple colored formazan pigment by 
mitochondrial enzymes in viable cells. Tumor cells were incubated at 37ºC in 5% CO2 for 
72 hours in the presence of various concentrations of TNF and Doxil®. The range of final 
drug concentrations was 1x10-6 - 10 µg/ml for TNF and 0.001 – 5 µg/ml Doxil®. After 72 
hours of incubation the medium was replaced with 50 µl of MTT (3 mg/ml in PBS) and 
incubated for 3 hours at 37ºC in 5% CO2. Then medium was removed and the formazan 
crystals were dissolved in 100 µl DMSO and the optical density was read at 540 nm in a 
microtiter plate reader. Tumor cell growth was calculated using the formula: cell growth = 
(test well/control) x 100 percent. The drug concentration reducing the cell growth to 50% of 
the control (IC50) was determined from the grow
a
 
VEGF ELISA 
VEGF was measured from cell-culture supernatants by ELISA (BioSource Europe, 
Nivelles, Belgium). Briefly, B16BL6 and LLC tumor cells were plated in 6-wells plates at a 
density of 1.25.105 cells/well. After 2 days, medium was replaced by 1.5 mL of fresh 
medium and the cells were incubated under normoxic and hypoxic (1% O2) conditions. 
After 48 hours supernatant was collected and spun down to remove cell debris. Cell 
numbers were counted in every well. The experiments were performed 3 times and all 
analyses and calibrations were carried out in duplicate. Protein levels were normalized to 
cell number. 
 
Statistical analysis 
Results were evaluated for statistical significance with the Mann Whitney U test. P-values 
below 0.05 were considered statistically significant. Calculations were performed on a 
personal computer using GraphPad Prism v3.0 and SPSS v11.0 for Windows 2000. 
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Results 
Addition of low-dose TNF improves anti-tumor activity of Doxil® in B16BL6 melanoma 
ut not in Lewis lung carcinoma. 
activity of Doxil® in combination with low-dose TNF, B16BL6 
or with Doxil® alone 
b
To evaluate the anti-tumor 
and LLC-bearing mice were treated at 4 days-intervals with a total of 5 injections of Doxil® 
with or without TNF. Untreated B16BL6 tumors were growing slightly faster than 
untreated LLC tumors. Treatment of B16BL6 melanoma and LLC tum
resulted in a slight tumor growth delay in both tumor types, compared to placebo treated 
animals (Figure 1). Treatment with TNF alone showed a minor but visible anti-tumor effect 
in the B16BL6 tumor but not in the LLC tumor. In the B16BL6 tumor the combination 
treatment of low dose TNF and Doxil® proved to be more effective than Doxil® alone, with 
a prolonged tumor growth delay. These results are in contrast with the LLC tumor, where 
addition of low dose TNF to Doxil® treatment did not improve the tumor response. 
2
3
5
6 B16BL6: Doxil
B16BL6: Doxil  + TNF
LLC: Doxil  + TNF
or
 s
iz
e 
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0
days after first treatment
Figure 1. Combination of TNF with Doxil® results in synergistic response of B16BL6
melanoma, but is not found in Lewis lung carcinoma. Growth curves of subcutaneous
impl
treat
4
LLC: Doxil
1
 
 mg/kg for co
Tu
m
anted B16BL6 melanoma and Lewis Lung Carcinoma after systemic Doxil®
ment with or without low dose TNF. Mice were injected five times intravenously
with an interval of 4 days between the injections; first dose 4.5 mg/kg Doxil® and 1.0
nsecutive doses and 1 µg TNF per mouse for all five doses. Tumor size
 
 
 
index is plotted against time (days after first treatment) and represents the mean of at
least 5 mice per group ± SEM. 
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TNF improves Doxil® accumulation in B16BL melanoma but not in Lewis lung 
ponse of B16BL6 melanoma and the LLC tumor to the 
Lewis lung carcin a addition of 
t
ation of 
doxorubicin in B16BL6 melanoma 
or LLC carcinoma after systemic 
treatment with Doxil® with or 
without TNF. Tumors were 
excised 24 hours after a single 
dose of 1 mg/kg Doxil® ± 1 
µg/mouse TNF. Total doxorubicin 
content was determined as 
described in materials and 
methods. The results represent the 
mean of 3-5 rats ± SD. 
 
Direct effect of Doxil® combined with TNF on tumor cells in vitro does not explain the 
improved activity towards B16BL6 melanoma. 
In vitro experiments were performed to define whether direct cytotoxicity contributed to the 
improved tumor response of Doxil® in combination with TNF of the B16BL6 tumor. 
Exposure of B16BL6 or LLC cells to Doxil® resulted in a response curve with an IC50 of 
0.07 and 0.08 µg/ml respectively (Figure 3A and B). B16BL6 cells were moderately 
sensitive to TNF, a cell viability reduction up to 24% at 10 µg/ml was observed (p<0.01). 
o-incuba 10 µg/ml, 
lthough NF, a 65% 
duced c f TNF was 
stimated e IC50 of 
oxil®, a 
 conclu cell lines were equally sensitive to Doxil . LLC cells 
ere more sensitive to TNF than B16BL6 cells and TNF did not have a synergistic effect in 
ither cell line.  
carcinoma.  
To investigate the difference in res
combination therapy of TNF and Doxil®, accumulation of Doxil® in tumor tissue was 
measured. After a single dose of 1 mg/kg Doxil® the amount of drug in tumor tissue 24 
hours after injection was 2.4 times higher in the B16BL6 tumor compared to the LLC 
tumor (Figure 2). Addition of TNF to the Doxil® treatment resulted in a 1.8-fold increased 
uptake in the B16BL6 tumor, whereas no increased uptake in the LLC tumor was found.  
 
Figure 2. In contradiction to 
om
TNF to Doxil® trea ment enhances 
drug delivery in B16BL6 
melanoma. Concen-tr
7.5
10.0
ee
fs
el
Doxil Doxil + mTNF Doxil Doxil + mTNF
0.0
2.5
5.0
      LLC   B16BL6
ug
 d
ox
/g
 w
tion of Doxil® and TNF slightly increased the IC50 value up to 0.
this increase was not significant. When LLC cells were treated with T
ell viability was detected at 10 µg/ml (p<0.01) and the IC50 value o
 at 4.7 ng/ml. Addition of TNF to Doxil® did not significantly alter th
value of 0.17 µg/ml was found.  
sion, LLC and B16BL6 ®
C
a
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B16BL6 and Lewis lung carcinoma exhibit comparable VEGF
e measured the VEGF production of the B16BL6 melanoma and LLC tumor in vitro 
BL6 melanoma cells, namely 1.38 ng 
ct
vessels and the vessels grow from outside the 
e tumor border (Figure 6a). 
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nsitivity to TNF compared to 
anoma cells. In vitro cell viability 
a) and LLC (b) cells exposed to 
ined with 0, 0.01, 0.05, 0.1, 1 or 10 
compared to untreated cells. The 
 72 hours of exposure were 
by MTT assay. The results are 
 mean ± SEM of at least three 
experiments performed in duplo. 
 production in vitro 
W
under normoxic and hypoxic conditions for 48 hours (Figure 4). The LLC tumor cells 
produced slightly more VEGF than the B16
VEGF/106 cell/24 hours and 1.08 ng VEGF/106 cell/24 hours, respectively (p=0.05). Under 
hypoxic conditions the VEGF produ ion is about 2.5-times higher than under normoxic 
conditions for both cell lines (p=0.05), although less than half of the cells survived.  
 
B16BL6 melanoma tumor vascularization is lower compared to Lewis lung carcinoma. 
Approximately 10 days after tumor implantation in the dorsal skin-fold chamber, tumors 
have grown to a size of 4-5 mm and established their own blood supply. Unlike the normal 
blood vessels around the tumor, the tumor microvessels are not well organized. There is a 
clear difference in the organization of the tumor vessels between the B16BL6 and the LLC 
tumor. The LLC tumor has many supplying 
tumor towards the tumor (Figure 5a and b). The B16BL6 tumor has few supplying vessels 
and many branches within the tumor. The vessels seem to grow from the inside of the 
tumor towards th
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Figure 4. B16BL6 melanoma and Lewis 
lung carcinoma produce equivalent levels 
of VEGF. VEGF levels in conditioned 
medium of B16BL6 melanoma and Lewis 
Lung Carinoma after 48 hours of 
incubation under normoxic (open bars) or 
2) (closed bars) conditions. 
iments were performed 3 
s and all analyses and calibrations were 
icate. VEGF levels were 
mber. The mean ± 
 † p=0.05 compared to LLC, 
ed to normoxic conditions. 
w 
from outside the tumor 
towards the tumor (a,b). 
Directly after i.v. injection 
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tumor vessels (c,d). 24 
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Figure 5. Tumor vascu-
larization and liposomal 
distribution in Lewis 
Lung Carcinoma is not 
affected by TNF. Bright 
field pictures of tumor 
vascularization. Many 
supplying vessels are 
observed, which gro
of RhoPE lip
liposomes were visibly 
circulating inside the 
hours later hardly any 
liposomes could be 
detected in the tumor 
tissue (e,f). Co-in
increased liposome acc
mulation mainly in hae-
morrhagic areas (g,h). The 
the images were main-
tained during the ex-
periments and represen-
tative pictures are shown. 
x2.5 (a), x10 (b,g,h) and 
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Quantification of the microvessel density (MVD) was p
staining of endothelial cells in frozen tumor sections (Fi
as well as the total tumor vessel area was measured. T
dividing the total vessel area by the number of vessels.
tumor was 2.1-fold higher than in the B16BL6, altho
standard deviations (Figure 7a). The total tumor vessel
than in the B16BL6 tumor, but the area per vessel was 2
in the LLC tumor, although this was not significant (F
tumor has less, but larger vessels than the LLC tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Addition of TNF to Doxil® strongly improves liposomal distribution in B16B
picture of tumor vascularization. Few supplying vessels can be observed, while the n
grow mainly inside the tumor towards the tumor border (a). Heterogeneous distribution
4 (b), 12 (c) and 24 hours (e). The liposomes accumulated inside blood vessels (e,f). Co
TNF resulted in extensive and homogeneous extravasation of RhoPE liposomes (g-i) 
(j-l), 12 hours after injection. The original light intensities in the images were maintain
and representative pictures are shown. Original magnification x2.5 (a-e, g-i), x10 (j-l) an
erformed by immunohistochemical 
gure 7a-d). The number of vessels 
he area per vessel is computed by 
 The number of vessels in the LLC 
ugh not significantly due to large 
 area was larger in the LLC tumor 
.4 times higher in the B16BL6 than 
igure 7b). In conclusion, B16BL6 
 
L6 melanoma. Bright field 
ew tumor vessels seem to 
 of RhoPE liposomes after 
-incubation with low-dose 
and Doxil® DiO liposomes 
ed during the experiments 
d x20 (f). 
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Liposomal distribution is strongly augmented and more homogeneous in B16BL6 
f TNF was co-administered liposome accumulation was observed solely in 
rrhagic areas, but most of the liposomes were still inside the blood vessels even a
 (Figure 5g and h). 
Figure 7. B16BL6 melanoma has less but larger tumor vessels compared to Lewis lung carcinoma. Microvessel 
density (MVD) of untreated B16BL6 and LLC tumors of 8-10 mm in diameter was assessed by 
immunohistochemical staining for CD31. (a) Number of vessels per field of interest, (b) area endothelium per 
vessel. Six representative fields of interest (magnification 16x) per tumor and 4-6 animals per group were 
examined. The mean ± SEM is shown. Photographs of cryostat sections of untreated tumors of 8-10 mm in 
diameter stained for CD31. (c) Lewis Lung Carcinoma, (d) B16BL6 melanoma. Representative pictures are 
 the B16BL6 tumor, the liposomal distribution was very heterogeneous and the liposomes 
ccumulated mostly inside blood vessels (Figure 6a-f). After 24 or 48 hours RhoPE 
posomes were still trapped inside these blood vessels. Already after 12 hours, co-injection 
melanoma while accumulation in Lewis lung carcinoma is not affected. 
Using the dorsal skin-fold chamber, we performed a series of experiments to examine 
liposome extravasation and content release from Stealth® liposomes in B16BL6 and LLC 
tumor tissue. To determine whether TNF could increase the permeability of the tumor 
microvasculature, we co-injected liposomes and low dose TNF.  
RhoPE liposomes of 100 nm were injected i.v. and directly after injection most of the 
liposomes were circulating inside the blood vessels (Figure 5c and d). After 24 or 48 hours, 
hardly any liposomes were detected in the LLC tumor tissue (Figure 5e and f). When low-
dose o the 
haemo fter 
36 hours
shown. Original magnification x16. 
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with low-dose TNF resulted in an augmented liposome accumulation, and distribution in 
e tumor was more homogeneous than treatment with RhoPE liposomes alone (Figure 6g-
. Extravasation occurred more often in the peripheral part of the tumor than in the central 
art. Besides RhoPE liposomes also experiments with Doxil® were performed. Doxil® was 
beled with DiO to distinguish between localization of the liposome itself and the 
oxorubicin inside. Already after 12 hours it was clear that dual treatment of TNF and 
oxil® resulted in an augmented extravasation of liposomes into the tumor tissue and 
oxorubicin released from the liposomes could be observed (Figure 6j-l). 
 conclusion, Stealth® liposomes accumulation is elevated in B16BL6 tumor compared to 
LC tumor. Moreover, co-injection of low-dose TNF resulted in augmented extravasation 
f liposomes in the B16BL6 tumor, whereas in the LLC tumor if liposomes were present 
ey were mainly trapped inside blood vessels. 
iscussion 
 the present study we show that addition of TNF to systemic Doxil® treatment resulted in 
n enhanced anti-tumor response in the B16BL6 tumor, but not in the LLC tumor. 
dditionally, an increased accumulation of Doxil® in tumor tissue was found in B16BL6 
mors systemically treated with Doxil® plus TNF compared to Doxil® alone, and no effect 
f TNF in the LLC tumor was found in relation to drug accumulation. These results were 
l molecules 
ay play a role 
n normal vessels and the 
maximum size of particles that can cross the tumor vessel wall is called the pore cutoff size. 
There is a large variance in cutoff sizes in different tumor types. Vessels of some but not all 
primary brain tumors are nearly impermeable and in other tumors cutoff pore sizes between 
100 nm and 1.2 µm are found. Vascular permeability may depend on tumor type and 
microenvironment and increases with tumor size (8,27).  
Liposomes have found useful applications in cancer therapy (11-14). Many studies 
demonstrated that long-circulating liposomes can preferentially accumulate in tumor tissue, 
th
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confirmed by intravital microscopy. First, in the B16BL6 tumor already a higher degree of 
liposome leakage was found compared to the LLC tumor. Second, unlike in the LLC tumor, 
TNF induced an augmented and more homogeneous extravasation of Stealth® liposomes 
into the B16BL6 tumor tissue.  
Transport of small drugs across the blood vessel wall involves diffusion whereas transport 
of macromolecules involves convection. Diffusion is the random motion of smal
and in highly vascularized tumors more tumor cells will be reached by the 
chemotherapeutics. Convection is mediated by the movement of fluid and m
in macromolecule drug delivery to especially peripheral tumor tissues, where a significant 
drop of the interstitial fluid pressure occurs. This pressure gradient facilitates extravasation 
of macromolecules in the periphery and causes extravasation of macromolecules into the 
tumor (2-4,7). In general, tumor vessels are more permeable tha
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due to their prolonged circulation time and by taking advantage of the enhanced 
permeability and retention effect (EPR) (9,10,17). Because the diameters of tumor vessels 
readily exceed the size of liposomes, not the size of tumor microvessels is the limiting 
factor of drug delivery to solid tumors, but the permeability of the tumors. We showed in 
previous studies that the addition of low-dose TNF to Doxil® treatment resulted in 
improved anti-tumor response in soft-tissue sarcoma-bearing rats (BN175) and B16BL6 
melanoma-bearing mice (18,19). Most likely the augmented accumulation of the liposomes 
explains the enhanced tumor response. A possible explanation for the increased drug uptake 
is that TNF increases the leakiness of the vasculature by enlarging the pore cutoff size in 
the endothelial lining of the tumor (20,21). The present study was undertaken to investigate 
whether or not addition of low-dose TNF to Doxil® treatment would have a similar effect in 
the Lewis lung carcinoma as in the B16BL6 melanoma model. We showed that the addition 
of TNF to the Doxil® treatment resulted in an improved anti-tumor response in the B16BL6 
tumor but not in the LLC tumor. Furthermore no increased tumor drug accumulation was 
found in the LLC tumor, whereas in the B16BL6 a 1.8-fold increased accumulation was 
found. A striking difference observed between the two tumor models, was the tumor 
vascular architecture. The LLC tumor has more supplying vessels than the B16BL6 tumor, 
and the vessels grow from outside the tumor towards the tumor, whereas in the B16BL6 
tumors the vessels seems to grow from the inside towards the tumor border. Although the 
B16BL6 had fewer blood vessels than the LLC tumor, the liposomal tumor accumulation 
was higher.  
Vascular endothelial growth factor (VEGF) was originally discovered because of its ability 
veins, to circulating macromolecules (28). Expression of VEGF is known to be an 
vascular permeability (32), whereas Bockhorn et al. presented a study where vascular 
permeability was not significantly altered by an anti-VEGF antibody treatment (33). In our 
study we showed that the B16BL6 melanoma is more permeable than the LLC tumor, while 
LLC produced slightly more VEGF in vitro than B16BL6. Possibly, VEGF is not 
responsible for the differences in cutoff pore size in these two tumor types. 
In vitro studies were performed to evaluate whether direct cytotoxicity also contributed to 
the improved tumor response of Doxil  plus TNF in the B16BL6 melanoma. The in vitro 
experiments showed that B16BL6 tumor cells were mode e to TNF, hile 
LLC cells were quite sensitive to TNF with an IC  of 4.7 ng/ml. Although LLC cells were 
sensitive to TNF, systemic treatment with TNF alone did not show a tumor growth delay. 
Both cell lines were equally sensitive to Doxil  and the addition of TNF did not show an 
to increase the permeability of microvessels, primarily postcapillary venules and small 
unfavorable prognostic factor in different types of tumors. Tumors with high VEGF levels 
have a higher vascular density, but have also more permeable blood vessels (29-31). Satchi-
Fainaro et al. showed that the angiogenesis inhibitor TNP-470 decreased VEGF-induced 
®
rately sensitiv w
50
®
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alteration in the IC50 value. This is in accordance with previous in vitro studies, where 
addition of TNF to Doxil® or small molecular weight drugs like doxorubicin and melphalan 
rast with the B16BL6 tumor, where a clear 
nhanced extravasation of liposomes was found into the tumor tissue, although mainly in 
of the tumor. Our results, together with the data of Parr et al. (35) and 
to systemic Doxil® treatment resulted in an enhanced anti-
;271(1):58-65. 
n tissue-isolated and subcutaneous tumors: 
solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988;133(1):95-109. 
induced no or only an additive cytotoxic effect (19,34). 
Intravital microscopy studies revealed that hardly any liposomes accumulated in LLC 
tumor tissue and no enhanced extravasation of these liposomes was found when co-
administered with low-dose TNF. This in cont
e
the periphery 
Weissig et al. (36), may be considered as an indication that subcutaneous Lewis Lung 
carcinoma is a tumor with a small vascular pore cutoff size, which is not affected by TNF. 
Possibly, the lack of permeability of the tumor vessels is linked to the lack of response to 
TNF, which is currently under investigation. Probably treatment of less permeable tumors 
like LLC may be more efficient with very small long-circulating delivery systems, such as 
PEG-based micelles (normally between 5 and 50 nm), than with the larger long-circulating 
liposomes. It is possible that TNF in combination with small PEG-based micelles will result 
in enhanced micelle uptake in the LLC tumor.  
In conclusion, addition of TNF 
tumor response and increased drug uptake in the B16BL6 tumor, but not in the LLC tumor. 
Likely, the subcutaneous Lewis Lung carcinoma is a tumor with a small vascular pore 
cutoff size. Next to that the LLC tumor vascular bed seems rather insensitive to TNF as 
increased leakiness was not observed. Apparently, not the microvessel density is the 
limiting factor of liposomal drug delivery to solid tumors, but the permeability of the tumor 
vessels and the responsiveness to TNF. 
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Abstract 
olated limb perfusion is a technique that involves canulation of the major artery and vein, 
connection to an  
plication of a t  
erfusion circuit. R r 
stemic administr f 
high-dose TNF to  
tes and this tre ent is currently one of the therapies av  
vanced bulky melanoma and sarcoma of the limbs. The anti-t  
mediated through an increased drug uptake in the tumor and damage of the tumor-
sociated vasculature. Unfortunately, not all patients respond to this therapy and other 
arious treatment options can be used in the management of locally advanced extremity 
oft tissue sarcomas (STS) or multiple in-transit melanoma metastases, like surgery, 
diotherapy, chemotherapy or eventually amputation. Treatment modalities that guarantee 
reservation of the extremity as well as good limb function have become important, 
ecause amputation does not necessarily improve the survival rate (1,2). To eradicate 
mors with chemotherapy, lethal concentration of anticancer drugs must reach the tumor 
cells. Unfortunately, inadequate drug delivery leads to regrowth of tumors and possible 
evelopment of resistant cells. Furthermore, the dose of administrated drugs is limited by 
rmal tissue tolerance (3-7). Methods for improving drug delivery are therefore of great 
clinical interest. To achieve higher intratumoral drug concentration with limited systemic 
city, an isolated limb perfusion (ILP) can be performed. Secondly, agents can be co-
dministered which favorably manipulate the tumor pathophysiology resulting in improved 
tumor response. These options will be discussed here.  
 
Isolated limb perfusion 
Isolated limb perfusion with chemotherapeutic agents was first introduced by Creech et al. 
in 1958 (8). In an ILP the circulation of a limb can be isolated from the rest of the body, 
while tissues of the isolated limb are kept viable with a perfusate, which is oxygenated by a 
bubble oxygenator. The advantage of ILP is the 15 to 25 times higher concentrations of 
chemotherapeutic agents which can be reached locally, while limiting the systemic side 
effects (9). The technique was modified in 1969 by Stehlin to include hyperthermia, which 
was expected to increase the antitumor effect of most antineoplastic agents (10). Since then, 
Is
oxygenated extracorporeal circuit, ligation 
ourniquet. Once isolation is secured, drugs 
egional drug concentrations 15-25 times higher t
ation can be achieved by ILP without systemi
m lphalan-based ILP results in impressive enhe
atm
of collateral vessels and
can be injected into the
han those reached afte
c side effects. Addition o
ancement of the response
ailable for patients with
umor effects are indirectly
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p
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ad
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agents that can further improve the response rates must be identified. The purpose of this 
article is to review existing treatment modalities and recent advances for development of 
novel therapeutic strategies using vasoactive drugs. 
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hyperthermic ILP with the alkylating cytotoxic agent melphalan (L-phenyl-alaninemustard) 
lated limb perfusion 
a (35,36). Addition of IFN had 
nly a marginal effect on the outcome (32,35,36). These studies led to the approval of TNF 
luation Agency (EMEA) in 1998 (37).  
has been used for the treatment of patients with advanced extremity melanoma. A mean 
complete remission rate of about 54% can be obtained (reviewed in (11)). Several 
chemotherapeutic agents have been used alternative to, or combined with melphalan. These 
include imidazole carboxamide, nitrogen mustard, thiotepa, fotemustine in combination 
with systemic chemosensitization (DTIC), none of which appeared to provide a better 
tumor response compared to melphalan alone (12-14). The response rates of ILP with 
cisplatin were comparable to those of melphalan, but with severe locoregional toxicity 
(15,16).  
Melphalan has also been used in the treatment of (nonresectable) extremity soft tissue 
sarcoma (STS). Because sarcomas are big in contrast to the relatively small melanomas, 
results have been quite poor. Besides melphalan, other cytotoxic drugs such as doxorubicin, 
dactinomycin and cisplatin have been used and low clinical response rates have been 
reported (17-21).  
 
TNF-based iso
Combination therapy with melphalan  
Tumor necrosis factor-α (TNF), named for its ability to cause haemorrhagic necrosis in 
subcutaneous sarcoma in mice (22), has shown anti-tumor activity in some murine and 
human tumors in vivo (23-25) and in vitro (26). The results from animal studies raised high 
expectations concerning the clinical trials. However, systemic TNF therapy proved 
ineffective with a lack of tumor response and severe side effects (hypotension and organ 
failure). The maximum tolerated dose was 10-50 times lower than the estimated effective 
dose (27-31). Importantly, such concentrations can be achieved by ILP. The application of 
TNF (plus interferon-γ (IFN)) and melphalan in ILP was pioneered by Lejeune and Lienard 
in 1988 in patients with melanoma in-transit metastases and advanced STS showing 
impressive results (32). TNF-based ILP has been reported in a European multicenter trial 
with response rates greater than 80% and limb salvage rates above 70% in advanced soft 
tissue sarcoma (33,34) and advanced extremity melanom
o
by the European Medicine Eva
 
Mechanism of TNF-based therapies 
To improve the current response rate and for the further development of combination 
therapy, it is imperative to understand the mechanism by which TNF enhances the tumor 
response so dramatically. TNF has some anti-tumor activity in certain tumors, but the 
majority of the tumor cells appear insensitive to TNF. It was speculated that the anti-tumor 
effects are indirectly mediated through damage of the tumor associated vasculature (22-25). 
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The selective destructive effects of high dose TNF in ILP have been illustrated in pre- and 
post perfusion angiographies. Angiographic studies revealed that 1 or 2 weeks after ILP all 
tumor-associated vessels had disappeared, and that normal blood vessels were still intact 
(38,39). It is important to note that in contrast to high doses of TNF (1-5 µg), low doses of 
TNF (0.01-1 ng) induce angiogenesis (40). 
To gain better insight in the working mechanism of TNF we developed TNF-based isolated 
limb perfusion models in rats, with similar results compared to the clinical setting. Directly 
after perfusion with TNF and melphalan or doxorubicin softening of the tumor tissue and 
significantly enhanced drug accumulation in tumor tissue specifically were observed (41-
plication of TNF did not seem to affect local pH, indicative that degree 
f hypoxia is not altered within the ILP time-frame. Although scattered extravazation of 
TNF ILP, accompanied by few apoptotic 
 not capable of inducing any tumor response (45). 
F 
43). Kristensen et al. showed that TNF caused a reduction in the interstitial fluid pressure 
(IFP) in human melanoma xenografts, what could lead to enhanced uptake of large 
molecules (44). In our experiments we did not see an effect of TNF on the IFP and we 
concluded that the enhanced drug uptake in the ILP setting was not due to a lowering of 
IFP. Furthermore, ap
o
erythrocytes was observed shortly after 
endothelial cells, ILP with TNF alone is
Ruegg et al. showed that inhibition of the αVβ3-mediated endothelial cell adhesion results in 
apoptosis and finally disruption of the tumor vasculature induced by TNF and IFN, but in 
this study tumor biopsies were examined 24 hours after ILP (46). More important, we 
observed an increased permeability of an endothelial layer within 30 minutes after exposure 
to TNF, which was enhanced by IFN and the presence of polymorphonuclear leukocyte 
(PMN) (45). The results indicate a subtle early effect of TNF on the tumor vasculature 
favoring augmented accumulation of the co-administered drug. 
At the histopathological level shortly after ILP the effects of TNF in a melphalan-based ILP 
starts with intratumoral endothelial cell activation followed by over-expression of adhesion 
molecules. Early PMN infiltrates were seen 2 to 3 hours after TNF-based ILP and lasted for 
at least 7 days (47). Homing of PMNs led to endothelium injury and finally coagulative and 
haemorrhagic necrosis. The tumors became infiltrated with T-lymphocytes, macrophages 
and B-lymphocytes after 1 to 3 weeks, indicating the induction of a secondary cellular and 
humoral immune response (48,49).  
 
Other combination therapies with TN
In Italy, TNF-based ILPs in combination with doxorubicin have been performed in patients 
with STS. Similar results were seen, although with significantly more regional toxicity in 
the healthy tissue (50). We also showed in our rat sarcoma ILP models that local toxicity 
was dose-limiting at sub-optimal doxorubicin concentrations (43). To decrease toxicity, the 
formulation of doxorubicin in long-circulating liposomes (Stealth® liposomal doxorubicin, 
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Doxil®) can be used. Another advantage is that Doxil® liposomes have a prolonged 
circulation time and that tumor accumulation is augmented (51-53). However, when Doxil® 
was used in the rat ILP model, minimal antitumor activity was found and its activity was 
not enhanced by TNF. No augmented accumulation of Doxil® was found compared to 
doxorubicin and the short circulation time during ILP is like inadequate for the circulation 
ction of the local NO level 
isadvantages of TNF-based ILP 
rd treatment for patients with multiple in transit 
time advantage of Doxil® to have an effect on the distribution (54). This is in contrast with a 
study of Di Filippo et al., where a favorable response with Doxil® was demonstrated (55). 
While, transport of small drugs, like doxorubicin, across the blood vessel wall involves 
diffusion, transport of macromolecules, like liposomes, involves convection. In tumor 
tissue the IFP is elevated and inhibits extravazation of marcomolecules (56,57). However, 
we showed that the elevated IFP in tumors is even more enhanced due to the ILP procedure 
and therefore probably resulting in less accumulation of Doxil® in tumor tissue (45). 
It is well known that TNF enhances the activity of actinomycin D (58,59) and therefore the 
combination of TNF and actinomycin D is evaluated in our rat soft-tissue sarcoma model. 
We showed that this combination therapy led to a synergistic anti-tumor response, but is 
accompanied with dramatic local toxicity and should therefore not be explored in a clinical 
setting (60). 
Some studies showed that administration of TNF resulted in a reduced blood flow, whereas 
others saw no effect of TNF on tumor blood flow (61-63). Initial reduction of tumor blood 
flow limits the delivery of any further external agent. However, if antivascular events are 
generated within the tumor tissue, the rate of drug removal is impaired while leaving more 
drug entrapped in the tumor.  
High levels of NO results in vasodilatation, a higher blood flow and could therefore have an 
beneficial effect on drug delivery (64). On the other side redu
impairs blood flow as well as subsequent washout. Moreover, tumor cells may suffer from 
the lack of oxygen and nutrient delivery. De Wilt et al. demonstrated a much better tumor 
response when the NO inhibitor L-NAME was added to the synergistic combination of 
melphalan and TNF (response rate increased up to 100%) (65). To obtain further inside into 
the mechanism underlying the effect of TNF on tumor blood flow, more research has to be 
performed. 
 
D
Currently, TNF-based ILP is the standa
melanoma metastases and non-resectable extremity sarcomas. TNF is approved and 
registered in Europe and clinical trials are ongoing in the United States. An important 
disadvantage is the costs involved in TNF-based ILP. 
Despite the good tumor responses found in patients treated by ILP with TNF plus 
melphalan, still about 20% of the patients do not respond to this treatment therapy. Other 
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agents that can further improve the response rates must be identified. Furthermore, TNF-
based ILP is a considerable surgical procedure with a risk of regional and systemic 
complications. Accurate and real-time monitoring of systemic leakage is needed with the 
aim of avoiding severe systemic TNF mediated toxicity. Regional toxicity can cause long-
term impaired extremity function, and the risk of a shock-like syndrome is considerable if 
>10% leakage of TNF to the systemic circulation during ILP occurs (36,66).  
 
Vasoactive drugs in combination with isolated limb perfusion 
As we observed that TNF mainly improves drug accumulation in tumor tissue which results 
from an enhanced permeability of the tumor-associated vasculature, other agents were 
sought and tested which are know for their vasoactive behavior. 
 
Interleukin-2 
In different animal models interleukin-2 (IL-2), as a single agent, has been shown to have 
antitumor activity (67,68). Clinical studies have been carried out mainly in patients with 
renal cell cancer and melanomas. High doses and multiple dosing are needed, which is 
associated with serious systemic toxicity with hypotension, massive vascular leakage 
ay as TNF.  
nse. Furthermore, a redistribution of macrophages was seen and increased 
vels of TNF mRNA were found in tumors treated with IL-2 plus melphalan (73). These 
 important role for macrophages in the IL-2-based 
lanoma and the novel combination of 
syndrome and multiple organ failure leading to death (69-72). Response rates and survival 
benefits of current systemic treatments are disappointing. We hypothesized that IL-2 could 
be a good candidate to be used in an isolated limb perfusion. IL-2 is known not to have 
direct antitumor activity, but we speculated that IL-2 could well impact on the tumor 
pathophysiology in a similar w
We demonstrated for the first time that ILP with the combination of IL-2 and melphalan in 
the BN175 tumor resulted in a strong synergistic tumor response. The tumor response (PR 
and CR combined) of 67% was much higher than the tumor response of melphalan alone 
(17%), while progressive disease was seen in all animals treated with IL-2 alone. We 
showed that IL-2 caused a 3.7-fold augmented accumulation of melphalan specifically in 
tumor tissue, which correlated closely with the enhanced tumor responses. This increase 
could very well explain the improved efficacy, as ILP with IL-2 alone did not induce any 
tumor respo
le
observations indicate a potentially
perfusion, as activated macrophages produce several cytokines (like TNF) and free radicals 
which can have a cytotoxic effect on tumor cells (74-77). 
More research has to be done to investigate whether IL-2-based ILP gives comparable 
results in other tumor types, like osteosarcoma and me
IL-2 and melphalan should be explored in a clinical ILP setting. IL-2 is already used in a 
systemic clinical setting and is a potentially safer drug than TNF and therefore a useful 
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alternative for ILP with TNF. Importantly, the lack of toxicity of IL-2 warrants its use in 
loco-regional therapy of organs such as the liver in which the application of TNF is strongly 
impaired. 
 
Histamine 
Another vasoactive drug we tested is histamine. The interest in histamine as a potential 
nti-neoplastic agent originated in the late 1970s from mouse studies in which passive 
lly induced 
rgely unknown, but it is 
uggested that both histamine receptor 1 and 2 (H1-R and H2-R) are involved (81-83).  
ausing edema in fine vessels by increasing the flow of lymph and lymph 
ddition of histamine led to a two-fold increased 
neration of ROS were inhibited. 
a
induction of local anaphylaxis reduced the size of established, chemica
fibrosarcomas (78). Antitumor effects have also been seen in Leydig cell sarcoma (79), 
chemically induced gut tumor (80), colorectal carcinoma (81) and melanoma (82). The 
mechanisms for the anti-tumoral effects of histamine are la
s
Histamine is c
proteins into the extracellular space and also by promoting the formation of gaps between 
endothelial cells (84). Therefore, it is suggested that the same mechanism that causes edema 
in fine vessels could potentially be used to increase drug concentration in tumor tissues.  
We showed the synergistic effect of histamine plus melphalan in ILP for the treatment of 
rat soft-tissue sarcoma. Tumor regression was seen in 66% of the animals treated with 
histamine and melphalan compared to 17% after treatment with histamine or melphalan 
alone. No systemic toxicity was observed in rats treated with histamine and melphalan. 
Histamine showed to have a direct cytotoxic effect on both tumor cells and tumor-
associated vasculature. Very importantly, a
melphalan uptake in tumor tissue, whereas a reduced melphalan concentration in muscle 
tissue was found. After ILP with histamine and melphalan, most of the tumor vessels were 
severely damaged and massive haemorrhage was observed (85).  
In conclusion, histamine plus melphalan in ILP seems to be a promising alternative to TNF 
and should be further evaluated in preclinical tumor models and eventually in a clinical 
setting for both limb as well as organs. 
 
IL-2 + histamine 
One of the proposed limitations of IL-2-based therapy involves inactivation of peritumoral 
and intratumoral cytotoxic T and NK cells. Reactive oxygen species (ROS) generated by 
monocytes/macrophages (MO) may inhibit cytotoxic activity within the tumor. Cytokine-
based immunotherapy could be more effective if the ge
Histamine is a potent inhibitor of ROS formation through interaction with the H2-R receptor 
on phagocytic cells. Experimental data indicate that histamine and IL-2 act synergistically 
to activate NK cell cytotoxicity (86,87). Inhibition of tumor growth and angiogenesis in 
malignant glioma is found after systemic treatment with IL-2 and histamine (88). Use of 
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histamine as an adjuvant to IL-2 is associated with a statistically significant prolongation of 
survival compared to IL-2 alone in metastatic melanoma patients with liver involvement 
(89).  
We have shown that the synergy between histamine and IL-2 seen in the systemic treatment 
ional setting, with a 30% decrease in the tumor response rate, as compared 
on 
 drug uptake in the 
 7.  Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol. 1998;8(3):164-175. 
is lost in the reg
to each drug alone plus melphalan. Tumor accumulation of melphalan after ILP with the 
triple combination of histamine, IL-2 and melphalan is very similar to the levels obtained 
after ILP with histamine or IL-2 plus melphalan. However, less haemorrhagic necrosis was 
found after the triple therapy compared to ILP with histamine plus melphalan (90). 
In conclusion, the combination of histamine and IL-2 in the melphalan-based ILP setting 
diminished the tumor response compared to melphalan ILP with either drug alone and 
should not be further explored in a clinical setting. 
 
Conclusions 
Isolated limb perfusion is an important treatment option in the management of locally 
advanced extremity soft tissue sarcoma and in-transit melanoma metastases. The additi
of TNF to the melphalan-based ILP greatly improved the response rates. The majority of 
the anti-tumor effects are indirectly mediated through damage of the tumor-associated 
vasculature leading to haemorrhagic necrosis. Importantly, addition of TNF to the perfusate 
results in an increased drug uptake in the tumor. Despite the good tumor responses, still 
about 20% of the patients do not respond to this treatment therapy. We recently showed the 
importance of vasoactive drugs in combination with melphalan in an isolated limb 
perfusion setting. ILP with histamine or IL-2 in combination with melphalan showed 
similar response rates compared to TNF plus melphalan. In both treatment modalities an 
effect on the tumor-associated vasculature is found leading to increased
tumor. These findings emphasize the importance of altering the tumor pathophysiology that 
leads to improved tumor drug uptake and the potential that this approach has to improve 
efficacy of various standard agents. 
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Introduction  
uccessful treatment of solid tumors with chemotherapeutics requires that adequate levels 
of anticancer age
elivery of drugs t  
ents. Inadequat  
evelopment of re f 
anticancer agents , 
assive dilution o rs. 2) Most anticancer drugs are also toxic  
erefore the dose of administrated drugs is limited by no ) 
Heterogeneous tumor perfusion of the tumor, arterio-venous shunting and necrotic and 
ypoxic areas, as well as a high interstitial fluid pressure (IFP) may limit the penetration of 
 delivery to improve 
erapy, namely site-specific delivery and site-specific triggering. By incorporating an 
ctive and site-specific release mechanism into liposomes release and therapeutic efficacy 
of the carried drug may be dramatically increased. This review concentrates on the use of 
site-specific targeting. 
Stealth®) Liposomes 
iposomes were discovered in 1965 (8) and soon after that their potential as vehicles for the 
elivery of cytotoxic drugs to tumors was explored (9-11). However, the use of these so-
alled conventional liposomes was limited due to rapid recognition and removal from the 
rculation by the mononuclear phagocyte system (MPS) represented by the primary organs 
er, spleen and lung. In the late eighties, liposome surface coating with polyethylene 
ycol (PEG), a synthetic hydrophilic polymer, was introduced. The PEG headgroup serves 
 a barrier preventing interactions with plasma opsonins as a result of the concentration of 
ghly hydrated groups that sterically inhibit hydrophobic and electrostatic interactions of a 
riety of blood components with the liposome surface. These PEG-coated liposomes are 
referred to as sterically stabilized or Stealth® liposomes (12-14). Stealth® liposomes have a 
long circulation time because of their small size and reduced interaction with formed 
elements of the blood. Selective targeting of liposomes to tumor tissue is believed to be 
achieved through the so-called EPR (enhanced permeability and retention) effect. Normally 
the endothelial lining is a closed barrier, but it is known that tumor blood vessels exhibit 
heterogeneous hyperpermeability to plasma proteins and other circulating macromolecules. 
Within the tumor several vascular permeability factors are produced, including vascular 
endothelial growth factor (VEGF) and TNF. Vascular permeability depends on tumor type, 
increases with tumor size and rate and is higher in the periphery compared to the central 
S
nts reach the tumor cells. Physiological bar
o tumors and are frequently responsible for fai
e drug delivery could lead to regrowth 
sistance cells. It is quite difficult to achieve a
a the tumor site because: 1) After the drugt 
ccu
riers hinder the effective 
lure of initially promising
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drugs into the tumor and prevent drugs in reaching tumor cells distant from blood vessels 
(1-7). Methods for improving drug delivery and penetration in tumor tissues are therefore 
of great clinical interest. There are two general directions within drug
th
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region of the tumor. Furthermore, poor lymphatic drainage leads to long-term retention of 
lls or other possible targets. The efficacy of liposomes as a drug 
elivery system could be increased dramatically if it were possible to selectively deliver 
ar tumor sites. The next generation of liposomes features direct 
liposomes in tumor tissue (15-20). 
The use of Stealth® liposomes as drug carriers for chemotherapeutic agents offers a 
potential means of manipulating drug distribution to improve antitumor efficacy and reduce 
toxicity. A well known liposomal formulation is Doxil® (Stealth® liposomal doxorubicin). 
Doxil® is approved in the United States and Europe for the treatment of AIDS-associated 
Kaposi’s sarcoma (21) and ovarian cancer (22) and is also effective in the treatment of 
advanced or metastatic soft tissue sarcoma (23) and metastatic breast cancer (24). Also 
other anticancer drugs encapsulated in sterically stabilized liposomes have been tested in 
preclinical and clinical studies, like SPI-077 (Stealth® liposomal cisplatin) and vincristine 
(25-27). Despite advances with prolonged circulation and liposome accumulation in the 
tumor, antitumor efficacy of these formulations is still not sufficient. 
 
Tumor cell targeting of liposomes 
Liposomal drug delivery is based on ‘passive’ targeting to tumor tissue. It’s the natural fate 
of long circulating particles (such as Stealth® liposomes) to extravasate at site with 
increased capilary leakage. However, these carriers do not directly target tumor cells, tumor 
vascular endothelial ce
d
their contents to the particul
molecular targeting of cancer cells via antibody-mediated or other ligand-mediated 
interactions. 
 
Immunoliposomes 
Immunoliposomes are developed to combine monoclonal antibody technology with the 
pharmacokinetic and drug delivery advantages of long circulating liposomes and represent 
a novel strategy for tumor-targeted drug delivery. The antibody can be coupled either to the 
lipid head group or PEG distal end. 
The HER-2 oncogene (also named neu or c-erbB-2) is a readily accessible transmembrane 
tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. 
HER-2 is overexpressed in 20-30% of breast and ovarian cancers and overexpression is 
associated with poor prognosis. Overexpression also occurs frequently in other carcinomas 
like lung, gastric and oral cancers. Immunoliposomes containing Fab’ or scFv fragments 
against Her-2 were used to deliver doxorubicin, resulting in potent and selective antitumor 
activity in a number of animal models (28,29). The efficacy of immunoliposomes 
containing doxorubicin was superior compared with free drug, non-targeted liposomal 
doxorubicin or non-targeted liposomal doxorubicin plus free anti-Her-2 Mab . 
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Immunoliposomes can also be used for targeting antigens. The human antibody GAH binds 
to cell surface antigens expressed in human gastric, colorectal and mammary cancer tissues, 
igand-directed liposomes 
thways can be exploited for specific targeting of 
ocytosis (36,37). Several studies showed that folate receptor targeted 
posomes are effective for in vitro and in vivo delivery of anticancer drugs and have 
n in the treatment of folate receptor positive solid tumors (36-40). 
rugs to various types of cancer in vivo. Several studies 
 
while normal tissues such as liver, lung or uterine do not show any significant reactivity 
with GAH. MCC-465 is an immunoliposome-encapsulated doxorubicin tagged with PEG 
and the F(ab’)2 fragment of the human antibody GAH. The immunoliposome accumulates 
in tumor tissue by utilizing the EPR effect, binds to the cancer cell surface, and is 
internalised by GAH-antigen interaction (30). MCC-465 showed strong antitumor activity 
against gastrointestinal cancers (30,31). 
Nam et al. reported that doxorubicin encapsulated in anti-G(M3) immunoliposomes was 
able to reduce in vivo tumor growth and metastasis of B16BL6 mouse melanoma cells more 
greatly than non-targeted drugs (32). 
 
L
Receptor-mediated endocytosis pa
liposomes and intracellular delivery of liposome contents (33). Liposomes conjugated to a 
ligand, that is directed to an over-expressed receptor in tumor cells and that normally 
undergoes endocytosis, is a strategy than can improve selectivity and facilitate access of 
liposomes to the intracellular compartment.  
Folic acid is a well-studied targeting ligand and cell surface receptors for this vitamin are 
overexpressed in many human tumors (34,35). Macromolecules coupled to folic acid are 
successfully recognized by folate receptors and internalized into cells via folate receptor 
mediated end
li
potential applicatio
Transferrin receptor-mediated endocytosis is a normal physiological process by which 
transferrin delivers iron to the cells. The transferrin receptor concentration on tumor cells is 
much higher than on normal cells. The glycoprotein transferrin has been employed as a 
targeting ligand to direct liposomal d
reported that transferrin-conjugation to PEG-liposome is useful for intracellular uptake in 
tumor cells in vitro and in vivo (41-43). 
 
Vascular targeting of liposomes 
Vascular targeting has become a focus of interest, since cells of the vasculture are the first 
to be encountered by systemically injected drugs or drug carriers. Especially, targeting for 
tumor angiogenic vessels seems promising for cancer treatment since these vessels express 
several proteins that are absent or barely detectable in established blood vessels, including 
integrins and receptors for certain angiogenic growth factors (44,45).  
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Figure 1. Schematic representation of different liposome types. Stealth® liposomes are conventional liposomes 
coated with polyethyleneglycol (PEG). Antibodies or ligands can be coupled to the lipid head group or PEG distal 
end.  
 
Integrin targeting 
Targeting of small peptides towards integrins was investigated by phage display library 
selection of peptides targeting to tumor blood vessels. The peptide sequence showing 
efficient binding to the αvβ3 and αvβ5-integrin receptor was the Arg-Gly-Asp (RGD) 
tripeptide (46). By coupling cyclic RGD-peptides to the distal end of Stealth® liposomes a 
superior anti-tumor activity in a murine C26 colon carcinoma model was found when 
compared to non-targeted Stealth® liposomes (47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Intravital 
microscopy image of loca-
lization of RhoPE liposomes 
couples with RAD or RGD 
peptides. Pictures are taken 
45 minutes after in-jection. 
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Maeda et al. suggested that Ala–Pro–Arg–Pro–Gly (APRPG) is a useful probe for targeting 
to angiogenic vessels, although the target molecule of APRPG is unknown. They showed 
that adriamycin-encapsulated liposomes modified with APRPG-PEG were more effective 
than adriamycin-encapsulated liposomes modified with PEG alone in Colon 26 carcinoma-
bearing mice. This difference was achieved in spite of quite similar accumulation of both 
types of liposomes in the tumor (48). 
Pastorino and coworkers reported anti-angiogenic chemotherapy by use of NGR peptide-
modified long-circulating liposomes encapsulating doxorubicin targeting aminopeptidase 
N. They showed not only drastic therapeutic efficacy against tumor-bearing mice, but also 
ted liposomal anti-cancer drug (49). 
ndoglin (CD105) is a component of the transforming growth factor β receptor complex 
 of endoglin were detected in the vasculature of different tumors (50-52). 
h MT1-MMP targeted peptide were able to induce tumor growth 
 angiogenic endothelial cells (54). 
NF-based liposomal therapy 
 many studies is shown that addition of high-dose TNF to a melphalan-based isolated 
mb perfusion (ILP) results in excellent antitumor effects against melanoma (55), large soft 
ssue sarcomas (56,57) and various other tumors in the clinical setting (58-60). We have 
reviously shown that the basis for the synergy is, on one hand a significant enhancement 
f tumor selective melphalan uptake and on the other hand destruction of tumor vasculature 
1-64). Unfortunately, the systemic application of high-dose TNF is hampered by severe 
city, suggesting that only low dosages can be applied (65,66).  
he first systemic treatments we performed with low-dose TNF were in the highly 
ascularized rat soft tissue sarcoma BN175. We showed that co-administration of Doxil® 
nd low-dose TNF resulted in a pronounced tumor response and augmented accumulation 
f the chemotherapeutic drug in tumor tissue (67). In addition, combination therapy of 
oxil® and low-dose TNF seems attractive for the treatment of the intermediate 
coma (68). However, when Doxil® was used in the ILP, minimal 
ound in both tumor models and its activity was not enhanced by 
 Doxil® was not augmented compared to doxorubicin. We 
pronounced destruction of the tumor vasculature by use of the angiogenic endothelial cell-
targe
E
and elevated levels
In vitro studies showed increased binding and internalization of the anti-endoglin liposomes 
(ILA5) and the endothelial cell-specific immunoliposomes may be useful in cancer therapy 
(53). 
Another vascular target is membrane type-1 matrix metalloproteinase (MT1-MMP). MT1-
MMP is expressed specifically on angiogenic endothelium as well on tumor cells, and 
liposomes modified wit
suppression by damaging
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hypothesized that the short circulation time during ILP is likely inadequate for the 
g-to-lipid ratio. For SPI-077, the drug-to-lipid ratio is 
h TNF a pronounced tumor response was found 
without TNF (1 µg/mouse) in 
The tumo e excised 12 
least 3 mice are shown ± SE. 
 
circulation time advantage of Doxil® to have an effect on the distribution (69). 
Also another cytotoxic agent encapsulated in pegylated liposomes was tested, SPI-077. 
Addition of TNF to a SPI-077 treatment resulted in a better tumor growth delay in the 
BN175 sarcoma than treatment with SPI-077 alone and a more prolonged antitumor activity 
was detected, but no such effect was seen in the rat osteosarcoma (70). A major difference 
between Doxil® and SPI-077 is the dru
14 µg/mg, compared with 125 µg/mg for Doxil®. Therefore, each Doxil® liposome delivers 
approximately nine times more drug than a SPI-077 liposome, which will have an 
important effect on activity (26). 
In murine tumor models similar results were seen. When B16BL6 melanoma-bearing mice 
were injected with Doxil® combined wit
(71). A more than 5-fold increased tumor drug uptake was found when liposomes of 100 
nm were combined with TNF (Figure 3). TNF was also able to enhance the uptake of larger 
liposomes of 400 and 800 nm, although liposomes of 100 nm were localized in the tumor in 
a larger amount than 400 and 800 nm liposomes (72). 
  
Figure 3. Accumulation of 
67Ga-labeled liposomes of 
100 nm (48 µmol/kg) with or 
B16BL6 mouse melanoma. 
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However, insight in the intratumoral localization of the liposomes is lacking. Therefore we 
studied the effect of TNF on the intratumoral distribution of liposomal drugs with the use of 
intravital microscopy. Addition of TNF resulted in an abundant accumulation of liposomes 
in the tumor interstitium and the liposomes extravasated more homogeneously throughout 
the tumor. Less liposomes were trapped inside blood vessels when TNF was co-
administered and these results indicate that TNF likely increases the leakiness of the 
vasculature by increasing the gaps between the endothelial lining in the tumor, leading to 
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augmented accumulation after extravasation of liposomes (72-74). In figure 4, increased 
extravasation of liposomes nearby blood vessels is shown in the B16BL6 melanoma (72) 
sociated with improved tumor uptake (79). 
 DiO in tumor vasculature en B16BL6 melanoma 
een: DiO, red: doxorubicin. 
 
 
 
 
 
 
 
 
Figure 5. Intravital microscopy image of 
locali-zation of Doxil® DiO in tumor 
vasculature of BN175 soft-tissue sarcoma 4 
days after injection of liposomes and 15 
µg/kg TNF. Green: DiO, red: doxorubicin. 
 
and similar effects were seen in the rat soft tissue sarcoma BN175 (Figure 5).  
In other studies TNF also caused an augmented tumor accumulation of liposome-
encapsulated adriamycin (75) and radio-antibody (76). Curnis et al. found that targeted 
delivery of TNF coupled to cyclic CNGRC peptide to tumor vessels enhances the antitumor 
activity of chemotherapeutic drugs and increased the penetration drugs in tumors (77). 
Kristensen et al. showed that TNF caused a reduction in the IFP in human melanoma 
xenografts, what could lead to enhanced uptake of large molecules (78). Also other 
compounds that reduce IFP are as
Figure 4. Intravital microscopy image of localization of Doxil®
omes and 1 µg/mouse TNF. Gr24 hours after injection of lipos
In general, tumor vessels are more permeable than normal vessels and the maximum size of 
particles that can cross the tumor vessel wall is called the pore cut-off size. Vascular 
permeability may depend on tumor type and microenvironment and increases with tumor 
size. It is believed that not the microvessel density is the limiting factor of macromolecule 
drug delivery to solid tumors, but the permeability of the tumor vessels (20,80). In our 
experiments we saw clear differences between two mouse tumor models, B16BL6 and 
Lewis Lung Carcinoma (LLC). In the B16BL6 tumor already a higher degree of liposome 
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leakage was found compared to the LLC tumor and TNF did not induce an augmented 
accumulation or extravasation of liposomes in the LLC tumor. A striking difference 
observed between the two tumor models was the tumor vascular architecture. The B16BL6 
Conclusions 
It is well known that the use of Stealth® liposomes as drug carriers for chemotherapeutic 
agents improve antitumor efficacy and reduce toxicity. The pegylated liposomes are long 
circulating and accumulate significantly in tumors due to a leaky vasculature. Several 
attempts are made to further improve drug targeting. Molecular targeting of cancer cells via 
antibody-mediated or other ligand-mediated liposomes have shown increased efficacy. 
umor interstitium. 
Liposomes can be coupled to small peptides that target integrins or endothelial cell 
markers. We have shown in several experiments that ad ition of TNF to different liposomal 
formulation in diverse tumor models improved the antitumor activity and caused enhanced 
tumor drug accumulation. These experiments have l o new perspectives in systemic 
treatment of solid tumors. 
 
References 
 1.  Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58-65. 
 2.  Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identificatio
solid tumors that are leaky to circulating macromolecules. A
 3.  Jain RK. Delivery of molecular and cellular medicine to so
3):149-168. 
 4.  Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery 
2003;20(9):1337-1350. 
 5.  Yuan F. Transvascular drug delivery in solid tumors. Semin 
 6.  Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in 
tumors. Neoplasia. 1999;1(3):197-207. 
had fewer blood vessels and produced also slightly less VEGF than LLC (81). In general, 
tumors with high VEGF levels have a higher vascular density, but have also more 
permeable blood vessels (82-84). Our results, together with the data of Parr et al. (85) and 
Weissig et al. (86), may be considered as an indication that subcutaneous Lewis Lung 
carcinoma is a tumor with a small vascular pore cut-off size. Possibly, VEGF is not 
responsible for the differences in cut-off pore size in these two tumor types.  
 
Besides targeting tumor cells, also the tumor vasculature can be targeted since injected 
drugs first meet blood vessels before they extravasate into the t
d
ed t
n and characterization of the blood vessels of 
m J Pathol. 1988;133(1):95-109. 
lid tumors. Adv Drug Deliv Rev. 2001;46(1-
and transport to solid tumors. Pharm Res. 
Radiat Oncol. 1998;8(3):164-175. 
 7.  Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous 
perfusion and lymphatics. Microvasc Res. 1990;40(2):246-263. 
 8.  Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen 
phospholipids. J Mol Biol. 1965;13(1):238-252. 
 9.  Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J 
Med. 1976;295(14):765-770. 
 10.  Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J 
Med. 1976;295(13):704-710. 
 11.  Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier potential of liposomes in cancer 
chemotherapy. Lancet. 1974;1(7870):1313-1316. 
 12.  Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;380(6574):561-562. 
193 
Chapter 12 
 13.  Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in 
pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460-
11464. 
 14.  Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol. 2001;28(4 Suppl 
12):32-40. 
 15.  Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and 
enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85(18):6949-6953. 
 16.  Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various 
factors, mechanisms involved and its implications. Int Immunopharmacol. 2003;3(3):319-328. 
 17.  Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular 
permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 
 18.  Gabizon AA. Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. 
J Drug Target. 2002;10(7):535-538. 
 19.  Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular e
1993;53(16):3765-70. 
ndothelial growth 
factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029-1039. 
onsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor 
oenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-12. 
 25.  Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of 
ncer Res. 2002;8(4):1172-1181. 
 et al. Tumor targeting using anti-her2 immunoliposomes. J Control 
Release. 2001;74(1-3):95-113. 
 S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K. Efficacy of immunoliposomes on 
dels in a cell-surface-antigen-density-dependent manner. Br J Cancer. 2003;%20;89(8):1545-
3
 xenografts. 
 32.  im HS, Ahn WS, Park YS. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: 
 33.  rnalizing antibodies are necessary for improved therapeutic efficacy of antibody-
3
2):193-198. 
3
3
3
3. 
 in tumor-bearing mice. Clin Cancer Res. 2003;9(17):6551-6559. 
s. 2003;20(3):417-422. 
 20.  Hobbs SK, M
type and micr
 21.  Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, 
bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized 
phase III clinical trial. J Clin Oncol. 1998;16(7):2445-2451. 
 22.  Stebbing J, Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat 
Rev. 2002;28(2):121-125. 
 23.  Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin 
(DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a 
study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870-877. 
 24.  O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial 
of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line 
treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-449. 
vincristine encapsulated in sterically stabilized liposomes. Int J Cancer. 1995;62(2):199-204. 
 26.  Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-
077) in patients with inoperable head and neck cancer. Ann Oncol. 2001;12(4):493-496. 
 27.  Meerum TJ, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal 
encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol. 2002;49(3):201-210. 
 28.  Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to 
targeted delivery. Clin Ca
 29.  Park JW, Kirpotin DB, Hong K,
 30.  Hosokawa
cancer mo
1551. 
 1.  Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal 
doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer
Cancer Sci. 2004;95(7):608-613. 
Nam SM, K
targeting to B16BL6, HRT-18 cancer cells. Oncol Res. 1999;11(1):9-16. 
Sapra P, Allen TM. Inte
targeted liposomal drugs. Cancer Res. 2002;62(24):7190-7194. 
 4.  Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding 
protein in ovarian cancers. Int J Cancer. 1997;74(
 5.  Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant 
cell lines and tissues. Cancer Res. 1992;52(12):3396-3401. 
 6.  Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41(2):147-
162. 
 7.  Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug 
Deliv Rev. 2002;54(5):675-69
 38.  Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted 
polyethylene-glycol liposomes
 39.  Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB 
oral carcinoma murine xenograft model. Pharm Re
194 
General discussion: liposomal therapy 
 40.  Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with 
phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56(8):1177-1192. 
Ishida O 41.  , Maruyama K, Tanahashi H, et al. Liposomes bearing polyethyleneglycol-coupled transferrin 
 42.  A, Yu X, Bellamkonda RV. Targeted drug delivery to C6 glioma by transferrin-coupled 
 43.   cisplatin-encapsulated 
 45.  ular sites. Drug Discov Today. 2002;7(22):1138-1143. 
9):377-380. 
004;100(1):41-52. 
 50.  D105): a target for anti-angiogenetic cancer 
 51.  Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature 
 52.  
 
n. World J Surg. 
 56.  umor necrosis 
53-2665. 
 in 186 patients with locally advanced soft tissue extremity sarcomas. The 
 58.  
lan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol. 1999;25(5):509-514. 
 60.  AM, et al. Hyperthermic isolated limb perfusion with tumor necrosis 
ical, immunohistochemical and electron 
 62.  ijn EA, Eggermont AM. Tumour necrosis 
and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol. 
 64.  ggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha 
with intracellular targeting property to the solid tumors in vivo. Pharm Res. 2001;18(7):1042-1048. 
Eavarone D
liposomes. J Biomed Mater Res. 2000;51(1):10-14. 
Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of
transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 
2002;99(1):130-137. 
 44.  Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin 
Invest. 1999;29(9):802-809. 
Ruoslahti E. Drug targeting to specific vasc
 46.  Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a 
mouse model. Science. 1998;279(534
 47.  Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted 
liposomal doxorubicin. J Control Release. 2003;91(1-2):115-122. 
 48.  Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N. Anti-neovascular therapy by use of 
tumor neovasculature-targeted long-circulating liposome. J Control Release. 2
 49.  Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor 
vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63(21):7400-7409. 
Fonsatti E, Altomonte M, Arslan P, Maio M. Endoglin (C
therapy. Curr Drug Targets. 2003;4(4):291-296. 
Wikstrom P, Lissbrant IF, 
blood vessels and is a marker for survival in prostate cancer. Prostate. 2002;51(4):268-275. 
Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in 
human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995;1(12):1623-1634.
 53.  Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. Targeting of immunoliposomes to endothelial 
cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta. 
2004;1663(1-2):158-166. 
 54.  Kondo M, Asai T, Katanasaka Y, et al. Anti-neovascular therapy by liposomal drug targeted to membrane 
type-1 matrix metalloproteinase. Int J Cancer. 1903;108(2):301-306. 
 55.  Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose 
rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusio
1992;16(2):234-240. 
Eggermont AM, Schraffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose t
factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue 
sarcomas: a multicenter trial. J Clin Oncol. 1996;14(10):26
 57.  Eggermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor 
and melphalan for limb salvage
cumulative multicenter European experience. Ann Surg. 1996;224(6):756-764. 
Bickels J, Manusama ER, Gutman M, et al. Isolated limb perfusion with tumour necrosis factor-alpha and 
melpha
 59.  Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a 
model system for new strategies. Lancet Oncol. 2003;4(7):429-437. 
Olieman AF, Lienard D, Eggermont 
factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the 
extremities: a multicenter study. Arch Surg. 1999;134(3):303-307. 
 61.  Nooijen PT, Manusama ER, Eggermont AM, et al. Synergistic effects of TNF-alpha and melphalan in an 
isolated limb perfusion model of rat sarcoma: a histopatholog
microscopical study. Br J Cancer. 1996;74(12):1908-1915. 
de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bru
factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer. 
2000;82(5):1000-1003. 
 63.  Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF 
alpha 
1996;22(2):152-157. 
van Der Veen AH, de Wilt JH, E
augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat 
sarcoma models and enhances anti-tumour effects. Br J Cancer. 2000;82(4):973-980. 
 65.  Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. 
Science. 1986;234(4775):470-474. 
195 
Chapter 12 
 66.  Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 
24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst. 1988;80(13):1039-
 67.  -dose 
:829-37. 
a-bearing rats. Anticancer Drugs. 2005;16(6):667-74. 
b perfusion in sarcoma-bearing rats. Br J Cancer. 2004;90(9):1830-1832. 
lpha in 
ubicin (Doxil) correlates with 
 72.  n TL. In 
yers by a mechanism involving regulatory G proteins. J 
 74.  ular matrix in 
00. 
ility. Int J Cancer. 1993;53(5):829-
 77.  
lteration. J Clin Invest. 2002;110(4):475-482. 
 79.  terstitial fluid pressure specifically 
 80.  
 82.  teosarcoma correlates with vascular 
 83.  
 Ther. 1997;280(3):1319-1327. 
 
1044. 
ten Hagen TL, van Der Veen AH, Nooijen PT, van Tiel ST, Seynhaeve AL, Eggermont AM. Low
tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft 
tissue sarcoma-bearing rats. Int J Cancer. 2000;87(6)
 68.  Hoving S, Seynhaeve AL, van Tiel ST, Eggermont AM, ten Hagen TL. Addition of low-dose tumor 
necrosis factor-α to systemic treatment with Stealth liposomal doxorubicin (Doxil) improved anti-tumor 
activity in osteosarcom
 69.  ten Hagen TL, Hoving S, Ambagtsheer G, van Tiel ST, Eggermont AM. Lack of efficacy of Doxil in 
TNF-alpha-based isolated lim
 70.  Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor necrosis factor-a
combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats. 
Anticancer Res. 2005;25(2A):743-750. 
 71.  Brouckaert P, Takahashi N, van Tiel ST, et al. Tumor necrosis factor-alpha augmented tumor response in 
B16BL6 melanoma-bearing mice treated with stealth liposomal doxor
altered Doxil pharmacokinetics. Int J Cancer. 2004;109(3):442-448. 
Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, Eggermont AM, ten Hage
vivo evaluation of drug delivery improvement by tumor vascular manipulation with TNF: an intravital 
microscopy study. Submitted.  
 73.  Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumor necrosis factor/cachectin 
increases permeability of endothelial cell monola
Exp Med. 1989;169(6):1977-1991. 
Partridge CA, Horvath CJ, Del Vecchio PJ, Phillips PG, Malik AB. Influence of extracell
tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol. 1992;263(6 Pt 1):L627-
L633. 
 75.  Suzuki S, Ohta S, Takashio K, Nitanai H, Hashimoto Y. Augmentation for intratumoral accumulation and 
anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. Int J 
Cancer. 1990;46(6):1095-11
 76.  Folli S, Pelegrin A, Chalandon Y, et al. Tumor-necrosis factor can enhance radio-antibody uptake in 
human colon carcinoma xenografts by increasing vascular permeab
836. 
Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular 
targeting and barrier a
 78.  Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha 
treatment of three human melanoma xenografts. Br J Cancer. 1996;74(4):533-6. 
Salnikov AV, Iversen VV, Koisti M, et al. Lowering of tumor in
augments efficacy of chemotherapy. Faseb J. 2003;17(12):1756-1758. 
Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size 
dependence and cutoff size. Cancer Res. 1995;55(17):3752-3756. 
 81.  Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, Eggermont AM, ten Hagen TL. 
Intrinsic and TNF-induced vascular hyperpermeability of B16BL6 melanoma versus Lewis lung 
carcinoma determines tumor response. Submitted. 
Hoang BH, Dyke JP, Koutcher JA, et al. VEGF expression in os
permeability by dynamic MRI. Clin Orthop Relat Res. 2004;(426):32-38. 
Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5 
Suppl 1:37-44.:37-44. 
 84.  Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial 
growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 
1998;79(2):144-146. 
 85.  Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin 
in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene 
glycol). J Pharmacol Exp
 86.  Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and 
liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res. 1998;15(10):1552-1556. 
196 
  
 
 
 
Summary and conclusions 
 
Sam
 
 
      Chapter 
 
envatting en conclusies 13 
Chapter 13 
Summary 
dequate drug uptake at the tumor site remains a crucial problem in solid tumor therapy. 
Physiological barr  
sponsible for fai  
e body result in r 
erfusion and incr s 
into the tumor.  
olated limb perf on is an important treatment option in th
vanced extremity soft tissue sarcoma and in-transit melanom  
of TNF to the melphalan-based ILP greatly improved the response rates. Despite the good 
mor responses, still about 20% of the patients do not respond to this treatment therapy. 
terest. 
an reduce systemic toxicity while 
taining or even improving in vivo efficacy. In previous studies we showed that co-
d low-dose TNF resulted in 
The aim of this thesis was to further improve local and systemic chemotherapy by changing 
the pathophysiology of solid tumors in different animal models. We tried to gain more 
insight in the mechanism of TNF in both ILP and systemic liposomal treatment. The 
enhanced tumor uptake of different cytotoxic agents due to addition of TNF to ILP 
prompted us to investigate a number of vasoactive drugs for similar effects. In this thesis 
the use of IL-2 and/or histamine in melphalan-based ILP was explored.  
 
In chapter 1 an overview is given of the history and application of TNF, IL-2 and 
histamine in cancer treatment. Previous work with ILP and systemic treatment with 
liposomes is described and the aim of the thesis is explained.  
In chapter 2 the synergistic antitumor activity of the combination of IL-2 and melphalan in 
ILP in soft-tissue sarcoma-bearing rats is shown, which is without any local or systemic 
toxicity. IL-2 significantly enhanced melphalan uptake in tumor tissue. Although scattered 
extravasation of erythrocytes was detected in the IL-2 plus melphalan treated animals, no 
signs of tumor vascular damage were seen. Clear differences were seen in the localization 
of macrophages and additionally increased levels op TNF mRNA in tumor tissue were 
found, indicating a potentially important role for macrophages in the IL-2-based ILP. The 
results in this study indicate that the novel combination of IL-2 and melphalan in ILP may 
be an alternative for ILP with TNF and melphalan. 
In chapter 3 another vasoactive drug was tested in our preclinical soft-tissue sarcoma 
model. A synergistic antitumor effect was found when histamine and melphalan were 
combined in the ILP. In comparison with TNF and IL-2, histamine alone did cause some 
A
iers hinder the effective delivery of drugs to 
lure of initially promising agents. Metabolism
 low drug concentrations at the tumor site 
eased interstitial fluid pressure (IFP) may limi
usi
tumors and are frequently
 and clearance of drugs in
and heterogeneous tumo
t the penetration of drug
e management of locally 
a metastases. The addition
re
th
p
Is
ad
tu
New treatment modalities are therefore of great clinical in
ncapsulation of anticancer agents in Stealth® liposomes cE
re
administration of Doxil® (Stealth® liposomal doxorubicin) an
enhanced tumor response in rat and murine tumor models. 
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tumor regression as was seen with treatment with melphalan alone. The strong effect of 
tial synergistic effects of IL-2 and histamine in the systemic setting, the 
re discussed. The TNF-induced 
d drug 
ccumulation in tumor tissue was low. The application of Doxil® in an isolated setting is not 
a-bearing rats are reported. 
se melanoma is studied in chapter 9 by 
histamine-based ILP with melphalan was explained by direct cytotoxicity to both tumor 
cells and tumor-associated vasculature and an indirect effect through histamine-mediated 
increased melphalan concentration in the tumor. Therefore, the combination of histamine 
and melphalan in ILP seems to be a promising alternative to TNF and should be evaluated 
in the clinical setting in both limb and organ perfusions. 
Based on the poten
combination of these drugs in the melphalan-based ILP was evaluated (chapter 4). A 30% 
decrease in response rate was found compared to each drug alone plus melphalan, although 
there was a similar melphalan accumulation in the tumor. In the different pharmacokinetic 
scenarios the combination of the two drugs lead to a down regulation of their action and 
consequently to the lost in efficacy. 
Addition of high-dose TNF to melphalan-based ILP enhances anti-tumor effects 
impressively, but the mechanism of action of TNF is still under debate. In chapter 5 effects 
of TNF on the tumor microenvironment and on secondary immunological events during 
and shortly after ILP in soft-tissue sarcoma-bearing rats a
augmentation of drug accumulation was the key explanation for the observed synergistic 
anti-tumor response, whereas it was too early for an immune response related to TNF to be 
detected. The augmented accumulation of melphalan was not due to an altered IFP, but 
most likely results from an increased permeability of the tumor vasculature. 
In chapter 6 the use of Doxil® in the ILP setting was explored. Doxil® had minimal 
antitumor activity, its activity was not enhanced by the addition of TNF an
a
a useful alternative for doxorubicin or melphalan. 
In chapter 7 the effects of systemic treatment with low-dose TNF in combination with 
liposomal cisplatin (SPI-077) in soft-tissue or osteosarcom
Depending on the type of tumor, the addition of TNF to SPI-077 resulted in a better tumor 
growth delay with a prolonged antitumor effect and in combination with the reduced 
toxicity of SPI-077, this combination may be preferable to cisplatin. 
The efficacy of Doxil® in combination with low-dose TNF in the intermediate vascularized 
osteosarcoma ROS-1 is reported in chapter 8. Not only in highly vascularized tumors TNF 
enhanced the systemic Doxil® treatment, but also in less vascularized tumors, although no 
increased drug uptake was found. Presumably the improved response when TNF was added 
resulted from a direct activity of this cytokine on the ROS-1 cells. 
Drug delivery and distribution in the B16BL6 mou
intravital microscopy. A more homogeneous tumor distribution and increased extravasation 
of liposomes along tumor vessels was found when liposomal therapy was combined with 
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low-dose TNF, which is crucial for an optimal tumor response. The results indicated that 
more tumor vessels become more permeable by TNF. 
Whilst addition of TNF to systemic treatment with Doxil® enhanced drug accumulation and 
strongly improved the anti-tumor response in the B16BL6 model, no such effect was 
observed in the LLC model (chapter 10). B16BL6 tumor appeared less vascularized than 
the LLC, but the tumor vessels were larger, while local VEGF levels were comparable in 
se of liposomes in cancer treatment. Different ways of 
xicity and in combination with TNF may 
he limiting factor for 
both tumor types. The results of this study suggest that not the tumor microvessel density 
but the tumor vascular permeability, and response to TNF, may be the limiting factor 
involved in liposomal drug delivery. 
The purpose of chapter 11 is to review existing ILP treatment modalities and recent 
advances for development of novel therapeutic strategies using vasoactive drugs. 
Chapter 12 is an overview of the u
site-specific targeting to tumors are described. 
 
Conclusions 
- ILP with IL-2 in combination with melphalan results in synergistic antitumor activity. 
- Addition of histamine to melphalan-based ILP improves the tumor response 
dramatically. 
- Combination of IL-2 and histamine leads to diminished efficacy in melphalan-based 
ILP. 
- TNF-induced augmented drug uptake in ILP is the key explanation for the observed 
anti-tumor response.  
- Application of Doxil® in ILP is not a useful alternative for doxorubicin. 
- Encapsulation of cisplatin results in reduced to
be preferable to free cisplatin. 
- TNF not only improves systemic Doxil® treatment in highly vascularized tumors, but 
also in intermediate vascularized tumors. 
- Increased number of tumor vessels become more permeable by TNF. 
- Tumor vascular permeability and not microvessel density is t
liposomal drug delivery. 
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Samenvatting 
Een van de essentiële problemen bij de behandeling van solide tumoren is een onvoldoende 
P) is een belangrijke klinische toepassing bij de 
 resulteert 
 en nieuwe therapieën zijn daarom van groot 
linisch belang. 
chemotherapeutica in Stealth® liposomen kan leiden tot een verminderde 
f 
Do somaal doxorubicine) en een lage dosis TNF leidt tot een verbeterde 
On k beschreven in dit proefschrift is gericht op de verbetering van lokale en 
st
sol nderzocht in verschillende dier modellen. We hebben geprobeerd 
als systemische 
o
doo leid tot het onderzoeken van andere vasoactieve stoffen 
his  met melfalan getest. 
his ing van kanker. Eerder gepubliceerde onderzoeken over 
eïsoleerde extremiteitsperfusies en het gebruik van liposomen bij systemische 
behandelingen zijn beschreven. Het doel van de in dit proefschrift beschreven studies wordt 
uiteengezet. 
In hoofdstuk 2 wordt beschreven dat de combinatie therapie van IL-2 en melfalan in 
geïsoleerde extremiteitsperfusies leidde tot een synergistische antitumorale werking bij rat 
weke delen sarcomen, zonder dat er lokale of systemische toxiciteit optreedt. IL-2 zorgde 
voor een verhoogde opname van melfalan in het tumor weefsel. Verspreide uittreding van 
rode bloedcellen werd waargenomen bij de dieren die zijn behandeld met de combinatie 
opname van chemotherapeutica in het tumorweefsel. Fysiologische barrières verhinderen 
de effectieve opname van geneesmiddelen in de tumor en zijn dikwijls verantwoordelijk 
voor het falen van oorspronkelijk veelbelovende therapieën. Metabolisme en eliminatie van 
chemotherapeutica zorgen voor een lage concentratie van de chemotherapeutica in het 
tumorweefsel. Door de heterogene perfusie en de verhoogde interstitiële vloeistof druk 
(IFP) in de tumor penetreren chemotherapeutica niet ver in het tumorweefsel. 
Geïsoleerde extremiteitsperfusie (IL
behandeling van lokaal vergevorderde weke delen sarcomen en in transit melanoma 
metastasen. Toevoeging van tumor necrose factor-α (TNF) aan ILP met melfalan
in een sterk verbeterde tumor respons. Ondanks de goede tumor respons, reageert 20% van 
de patiënten niet op deze behandelingsmethode
k
Inkapseling van 
systemische toxiciteit terwijl de in vivo werkzaamheid van het geneesmiddel gelijk blijft o
zelfs verbetert. In eerdere studies hebben wij laten zien dat de combinatie therapie van 
xil® (Stealth® lipo
tumor response in rat en muis tumor modellen. 
derzoe
sy emische chemotherapieën door middel van verandering van de pathofysiologie van 
ide tumoren. Dit werd o
een beter inzicht te krijgen in het mechanisme van TNF in zowel ILP 
lip somale behandeling. De verhoogde opname van chemotherapeutica in tumorweefsel 
r toevoeging van TNF heeft ge
die mogelijk een zelfde effect hebben. In dit proefschrift is het gebruik van IL-2 en/of 
tamine in geïsoleerde extremiteitsperfusies
 
Hoofdstuk 1 is een overzicht van de geschiedenis en het gebruik van TNF, IL-2 en 
tamine bij de behandel
g
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therapie IL-2 en melfalan, maar er was geen schade zichtbaar aan de tumor vaatwand. 
elen sarcoom 
e van melfalan in het tumorweefsel door histamine. De combinatie 
hoofdstuk 4). Echter een afname van 30% 
 voor de synergistische 
ntitumor respons. Op dit tijdstip is het te vroeg om een immuun response gerelateerd aan 
hter minimale antitumor activiteit en toevoeging van TNF had geen effect op 
Echter, duidelijke verschillen in de verdeling van macrofagen in het tumorweefsel werden 
gezien en tevens werd een verhoogde expressie van TNF mRNA in het tumorweefsel 
gedetecteerd. Dit zou een mogelijk belangrijke rol voor macrofagen kunnen betekenen bij 
de perfusie met IL-2. De resultaten van deze studie geven aan dat de nieuwe combinatie 
van IL-2 en melfalan in geïsoleerde perfusies een goed alternatief kan zijn voor TNF en 
melfalan. 
In hoofdstuk 3 is een andere vasoactieve stof getest in ons preklinisch weke d
model. De combinatie therapie van histamine en melfalan in ILP zorgde voor een 
synergistische antitumor activiteit. In vergelijking met TNF en IL-2, resulteerde perfusie 
met histamine in tumor regressie zoals ook werd gezien met melfalan alleen. Het effect van 
ILP met histamine en melfalan kan worden verklaard door de directe cytotoxiciteit op 
zowel tumor cellen als de tumor vasculatuur en door een indirect effect, namelijk de 
verhoogde opnam
therapie van histamine en melfalan is mogelijk een goed alternatief voor TNF en zal 
daarom verder getest moeten worden in de klinische setting in zowel extremiteit als orgaan 
perfusies.  
Aangezien IL-2 en histamine voor een synergistisch effect zorgen in de systemische setting, 
is deze combinatie getest in ILP met melfalan (
in de tumor respons is gevonden in vergelijking met IL-2 of histamine plus melfalan. De 
opname van melfalan in de tumor is echter wel gelijk gebleven. Door verschillende 
werkingsmechanismen van de twee stoffen is een goede tumor respons verloren gegaan. 
Toevoeging van hoge dosis TNF aan ILP met melfalan resulteert in een goede antitumorale 
werking, maar het precieze mechanisme is nog niet geheel bekend. In hoofdstuk 5 zijn de 
effecten van TNF op het lokale tumor micromilieu en de secundaire immunologische 
gevolgen tijdens en kort na perfusie onderzocht. De door TNF geïnduceerde verhoogde 
melfalan opname in tumorweefsel was de belangrijkste verklaring
a
TNF te detecteren. De verhoogde tumorale opname van melfalan is niet het gevolg van een 
verandering in IFP, maar hoogst waarschijnlijk door een verhoogde permeabiliteit van de 
tumor vasculatuur. 
Hoofdstuk 6 presenteert het gebruik van Doxil® in de geïsoleerde extremiteitsperfusie. 
Doxil® had ec
de opname van doxorubicine in tumorweefsel en de antitumorale werking werd ook niet 
verbeterd. Het gebruik van Doxil® in ILP is geen goed alternatief voor doxorubicine. 
De effecten van lage dosis TNF in combinatie met liposomaal cisplatin (SPI-077) in ratten 
met weke delen sarcomen of osteosarcomen zijn beschreven in hoofdstuk 7. Afhankelijk 
van het type tumor, zorgde de toevoeging van TNF aan SPI-077 voor een groei vertraging 
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van de tumor met een langdurig effect. Aangezien inkapseling van cisplatin tevens leidde 
tot een verminderde toxiciteit, is de combinatie van SPI-077 en TNF verkiesbaar boven 
cisplatin. 
In eerdere studies is aangetoond dat TNF zorgt voor een verbetering van de behandeling 
met Doxil® in goed gevasculariseerde tumoren. In hoofdstuk 8 is deze combinatie therapie 
getest in een minder goed gevasculariseerde rat osteosarcoom. Wederom werd een 
verbetering van de tumor response gevonden, alhoewel geen verhoogde opname van 
oeging van TNF aan de systemische behandeling met Doxil® zorgt voor een 
or 
it van 
doxorubicine in de tumor is gedetecteerd. Vermoedelijk is de verbetering van de tumor 
response toe te schrijven aan een direct effect van TNF op de tumorcellen. 
De opname en distributie van (liposomale ) chemotherapeutica in het muis melanoom 
model is onderzocht met behulp van intravitaal microscopie (hoofdstuk 9). Wanneer 
liposomale therapie werd gecombineerd met een lage dosis TNF, werd een meer homogene 
tumor verdeling en een betere penetratie van liposomen in het tumorweefsel gevonden. De 
verhoogde en verbeterde opname van chemotherapeutica in de tumoren is cruciaal voor een 
optimale tumor response. De resultaten in deze studie laten zien dat meer bloedvaten in de 
tumor permeabel worden door TNF. 
Terwijl toev
verhoogde tumorale opname van doxorubicine en de antitumor activiteit sterk is verbeterd 
in het B16BL6 muis melanoom model, werden deze effecten niet waargenomen in de 
Lewis Long Carcinoom (LLC) (hoofdstuk 10). B16BL6 is een minder goed 
gevasculariseerde tumor dan LLC, maar de bloedvaten zijn groter en de lokale productie 
van VEGF is vergelijkbaar. In deze studie wordt gesuggereerd dat niet de mate van tum
vascularisatie, maar de permeabiliteit van de vasculatuur de beperkende factor is bij de 
opname van liposomen. 
In hoofdstuk 11 wordt een overzicht gegeven van bestaande ILP behandelmethoden en 
nieuwe ontwikkelingen door het gebruik van vasoactieve stoffen. 
In hoofdstuk 12 wordt het gebruik van liposomen bij de behandeling van kanker 
beschreven. Diverse mogelijkheden om de opname van liposomen specifiek in 
tumorweefsel te verbeteren worden uiteengezet.  
 
Conclusies 
-  Geïsoleerde extremiteitsperfusie met IL-2 en melfalan resulteert in een synergistische 
antitumor activiteit. 
- Toevoeging van histamine aan ILP met melfalan verbetert de tumor respons drastisch. 
- De combinatie van IL-2 en histamine leidt tot een verminderde antitumor activite
geïsoleerde extremiteitsperfusies met melfalan. 
- De door TNF verhoogde intratumorale concentratie van chemotherapeutica is 
waarschijnlijk de belangrijkste verklaring voor de anti-tumor activiteit.  
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- Het gebruik van Doxil® in geïsoleerde extremiteitsperfusies is geen goed alternatief 
voor doxorubicine. 
- Liposomale inkapseling van cisplatin resulteert in een verminderde toxiciteit en in 
combinatie met TNF kan dit de voorkeur geven boven cisplatin. 
- TNF zorgt niet alleen voor een verbetering van de systemische Doxil® behandeling in 
goed gevasculariseerde tumoren, maar ook in minder gevasculariseerde tumoren. 
- TNF zorgt voor een toename in het aantal permeabele bloedvaten in tumorweefsel. 
- De permeabiliteit van het tumorvaatbed en niet de mate van vascularisatie is de 
beperkende factor voor opname van liposomen in tumorweefsel. 
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